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 A complementary chemical proteomics approach to the activity-based 
profiling strategy is described herein. Trifunctional probes, comprising of an affinity 
binding unit, a photolabile group and a fluorescent reporter tag, were designed for the 
affinity-based profiling of metalloproteases and aspartic proteases. Through a 
repertoire of labeling experiments, the ability of the probes to selectively and 
specifically capture the desired enzymes with minimal interference and background 
was adequately demonstrated, laying the framework for the use of affinity-based 
concept in large-scale proteomic profiling experiments. 
 
 An analogous strategy akin to the dynamic combinatorial chemistry concept is 
also reported. A series of azide- and alkyne-bearing cores were prepared. Using 
recombinant HIV-1 protease as a host, the sequestering of the precursors in the active 
site of the enzyme resulted in the catalysis of the click chemistry ligation reaction due 
to proximity effects. The preliminary results obtained at this stage sets the 








 Advances in genomics over the past few years have opened up a whole new 
perspective for the life sciences arena, particularly with the completion of the Human 
Genome Project [1]. With the complete sequencing of the estimated 30,000 genes in 
the genome, a wealth of information is expected to be gleaned from the genetic 
blueprint, sparking far-ranging implications and applications in the field of molecular 
and cell biology. However, proteins, the eventual product of genetic expression, not 
genes, are the ultimate factors responsible for most biological processes occurring in 
the cellular machinery and the term “proteome” was coined to describe the complete 
set of PROTeins expressed by the genOME [2]. Proteomics - the study of the 
proteome – thus aims to identify, characterize and assign biological functions to all 
the expressed proteins. 
 
 The challenges and hurdles in proteomics are unprecedented. Proteins, unlike 
the ubiquitous double helical DNA, present a far more complex façade. Studies have 
shown that there is a poor correlation between the number of genes and proteins [3]. 
Proteins are subjected to a variety of post DNA/RNA processes, including expression 
level control, compartmentalization, as well as, post-translational and post-
transcriptional modifications such as phosphorylation and glycosylation [4]. A 
conservative estimate of the number of structurally and functionally diverse proteins 
expressed in the human genome places the figure in the range of 100,000 to 
1,000,000, far exceeding the number of estimated genes [1].  
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To accomplish the Herculean effort of proteomics studies, major research 
activities in the post-genomic era focus on the development of high-throughput 
methods which are capable of large-scale analysis of proteins, including their 
expression levels, functions, localizations and interaction networks [5-7]. The 
traditional approach towards proteomics has been focused on the use of two-
dimensional gel electrophoresis (2D-GE) for large-scale protein expression analysis. 
More recently, 2D-GE, when combined with advanced mass spectrometric 
techniques, has become the state-of-the-art method for major proteomic research, 
primarily due to its ability to analyze up to a few thousand protein spots in a single 
experiment [5a].  By simultaneous analysis of the relative abundance of endogenous 
proteins present in a biological sample, 2D-GE allows the identification of important 
protein biomarkers associated with changes in the cellular/physiological state of the 
sample.  Most techniques based on 2D-GE, however, suffer from a number of serious 
technical problems: low detection sensitivity, limited dynamic range and low 
reproducibility, etc.  Furthermore, when compared with other existing protein analysis 
techniques, perhaps the major shortcoming of 2D-GE techniques is that, it gives rise 
to only information of proteins such as their identity and relative abundance.  In most 
cases, no information about the protein function and biological activity can be 
delineated from a 2D-based experiment [5b].   
 
Over the years, there has been a flourish of novel approaches towards the 
proteomics issue. Different spin-offs of 2D-GE have been developed in order to 
address some of these technicalities [5c-f].  For example, a number of fluorescence-
based protein detection methods were developed which allow highly sensitive 
detection of low-abundant proteins on a 2-D gel, and at the same time achieving broad 
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linear dynamic range [5c].  Various strategies, including ICAT, isotope-based 
metabolic labeling, DIGE, have been developed, allowing protein samples from 
different cellular states to be simultaneously separated and analyzed, thus ensuring 
quantitative comparison of the protein expression level [5d-f]. The development of 
mass spectrometric techniques has also vastly improved the sensitivity of the 
instrumentation. Of late, there has been a gradual shift of balance towards direct gel-
free MS analysis of protein mixtures, bypassing the traditional mode of 
electrophoretic separation. [5a] 
 
Asides from quantification of protein abundance level, the mapping of protein-
protein interaction in the proteome has been the subject of groundbreaking research. 
Originally designed to pull-down a single protein interaction partner, the yeast-2-
hybrid (Y2H) system has evolved into a high-throughput manner capable of mapping 
the protein interaction network of up to 5,000 yeast proteins [7e]. Another emerging 
facet of proteomics is the burgeoning field of array-based technologies, which have 
shown great promises to be the ultimate high-throughput tool for future proteomic 
research. With the protein array technology for example, it has been shown that it is 
possible to immobilize the entire protein complement of yeast (e.g. ~6000 yeast 
ORFs) onto a 2.5 x 7.5 cm glass surface, where different biological functions of all 
yeast proteins could be studies simultaneously [6d]. The protein microarray 
potentially allows for the large-scale functional and interaction studies of thousands of 
proteins to be assayed in a parallel fashion.  
 
The methods described thus far are largely reliant on technological 
advancement of instrumentation as well as molecular biology protocols with 
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negligible involvement of chemistry. However, the entry of the activity-based 
profiling strategy into the playing field vastly leveled the imbalance in proteomics [8]. 
Through the use of small molecule probes that chemically react with enzymes, 
proteins can now be profiled on the basis of function. The novelty of the strategy has 
given birth to a new aspect of proteomics – chemical proteomics, or the small 
molecule approach towards proteomics. Small molecules are typically synthetic 
organic compounds of less than 1,000 Da. Over the past decade, chemical genetics 
has seen the ad hoc systematic application of small molecules for the functional 
studies of proteins through their activation and/or inactivation [9]. The use of small 
molecules to perturb biochemical functions of biological macromolecules generates a 
plethora of data, particularly in the identification of the chemical ligands with 
potential for derivitizing into therapeutic agents.  
 
Herein, we aim to expand the scope of chemical proteomics through the 
development of two novel small molecule-based approaches towards the study of 
protein function – affinity-based profiling and the target-driven selective self-
assembly of inhibitors.  
 
1.2 Affinity-based Proteomic Profiling 
 
 In order to bridge the gap between technologies such as protein microarray 
which primarily analyze purified proteins, and 2D-GE based techniques which study 
endogenous proteins by their expression, and combine the high-throughput feature of 
2D-GE with the ability of functional-based protein studies, a chemical proteomics 
approach was recently developed which enables the activity-based profiling of 
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enzymes on the basis of their activity, rather than their levels of abundance [8]. The 
general strategy in activity-based profiling typically involves a small molecule-based, 
active site-directed probe which targets a specific class of enzymes based on their 
enzymatic activity.  The design template for activity-based probes essentially 
comprises a reactive unit, a linker unit and a reporter unit, in which the reactive unit is 
derived from a mechanism-based inhibitor of a particular enzymatic class (Fig. 1A).  
By reacting with the targeting enzymes in an activity-dependent manner, the reactive 
unit serves as a “warhead” for covalent modification, thus rendering the resulting 
probe-enzyme adducts easily distinguishable from other unmodified 
enzymes/proteins.  The reporter unit in the probe is either a fluorescence tag for 
sensitive and quantitative detection of labeled enzymes, or an affinity tag (e.g. biotin), 
which facilitates further protein enrichment/purification/identification.  A number of 
activity-based probes have thus far been reported, some of which have been 
successfully used for proteomic profilings of different enzymatic classes in complex 
proteomes [8].  For instance, fluorophosphonate/fluorophosphate derivatives have 
been developed to selectively profile serine hydrolases, including serine proteases 
[10a, b].  For cysteine proteases, different classes of chemical probes have been 
reported, including probes containing α-halo or (acyloxy)methyl ketone substituents, 
epoxy- and vinyl sulfone-derivatized peptides [10c-h].  Other known activity-based 
probes include sulfonate ester-containing probes that target a few different classes of 
enzymes [10i], as well as probes conjugated to p-hydroxymandelic acid which 
specifically label protein phosphatases [10j,k].   
 
 Herein, we describe a complimentary strategy for proteomic profiling of 
enzymes without the need of mechanism-based suicide inhibitors.  Our strategy 
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utilizes chemical probes that are made up of reversible inhibitors of enzymes (Figure 
1B): each probe has an affinity binding unit, a specificity unit and a photolabile 
group.  The affinity unit comprises a known reversible inhibitor that binds to the 
active site of the target enzyme (or a specific class of target enzymes) non-covalent 
and tightly.  We capitalize on the wealth of information available on noncovalent 
inhibitors of enzymes, thus allowing the applicability of our affinity-based strategy to 
most classes of enzymes.  The specificity unit, on the other hand, could be a specific 
peptide sequence serving as the recognition group of the target enzyme, or a simple 
linker, which confers minimum substrate specificity towards most enzymes in the 
same class.  Because the enzyme-probe interaction is solely based on affinity, an 
additional moiety, e.g. the photolabile group in our strategy, is thus required to effect 
a permanent attachment between the said molecules of interest.  The incorporation of 
a fluorescent tag eventually results in a trifunctional affinity-based probe for potential 
large-scale protein profiling experiments (Fig. 1B).  Photoaffinity labels, such as 
those containing diazirine and benzophenone, have been used to covalently modify 
molecules in a variety of biological experiments [11].  These photoactivable labels 
operate by generating reactive intermediates such as carbenes, nitrenes and ketyl 
biradicals, which result in permanent crosslinkage within the vicinity of the enzymatic 
active site [11].  The selected wavelength for UV irradiation is usually greater than 
300 nm, thus preventing potential photochemically induced damage to the enzyme.  
Overall, our affinity-based approach thus takes advantage of the reversible inhibitor 
of an enzyme which functions as the “Trojan horse” - it first ferries the photo-labeled 
affinity probe to the enzyme active site.  Upon UV irradiation, the photolabile group 
in the probe irreversibly modifies the enzyme and forms a covalent enzyme-probe 
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adduct, which renders the enzyme distinguishable from unlabeled proteins in 






















Figure 1. Schematic representation of (A) activity-based probes; (B) affinity-based 
probes. 
 
 Recently, this concept was independently reported by Hagenstein et al [12], 
whereby benzophenone-tagged isoquinolinesulfonamides were utilized in the 
functional labeling of kinases.  In this report, we demonstrate the feasibility of this 
affinity-based strategy for the large-scale proteomic profiling of aspartic and 
metalloproteases, for which activity-based probes have yet to be reported. 
 
1.3 Target-driven Selective Self-Assembly of Inhibitors 
 
 The process of drug discovery is invariably linked to the combinatorial 
synthesis of small molecule chemical ligands [13a] and high-throughput screening 
[13b,c] of the compounds with the therapeutic targets, which are typically enzymes or 
receptors. Strategies such as structure-based design [13d] and in silico chemistry 
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[13e,f] are sometimes used in conjunction to shorten the length of time taken to score 
a potential hit. Nevertheless, the road towards developing drug candidates is long and 
arduous [13g]. Combinatorial techniques such as split-pool synthesis [14a,b] generate 
millions of diverse compounds [14c] from a small pool of basic building blocks in a 
process termed the ‘one bead-one compound’ strategy. But, most of these compounds 
are eventually redundant, exhibiting little or no biochemical activity against the 
biological targets.  
 
The inception of the dynamic combinatorial chemistry approach promises to 
revolutionalize the drug discovery process [15]. Dynamic combinatorial chemistry is 
driven in whole by the interaction of the library building blocks with the target sites, 
e.g. enzymatic active sites. Reversible reactions between the basic components 
generate continuously interchanging adducts which are subjected to the target-driven 
selection and/or amplication in a self-screening process (Fig. 2A). In other words, the 
enzyme templates the self-assembly of an inhibitor with the highest binding affinity 
from a collection of precursors through eventual thermodynamic stabilization of the 
ligand. Linkages established between the building blocks typically utilize reversible 
reactions. Bond formation can be either covalent, such as a nucleophilic attack on an 
electron-deficient center (imine exchange between a primary amine and a carbonyl), 
or non-covalent, as exemplified by ligand coordination to a metal center. Recent 
examples of enzymes and chemistry used to illustrate the strategy include carbonic 
anhydrase (imines and disulfides) [16a,b] and acetylcholinesterase (AChE) (acyl 
hydrazones and thioesters) [16c,d]. 
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With its target-driven concept, the principle of dynamic combinatorial 
chemistry promises to define a whole new paradigm in small molecule screening and 
discovery. The set of constantly interchanging adducts eliminates the need for tedious 
product purification while the simultaneously amplification of the favoured enzyme-
bound substrate translates into easy identification. Yet the precise dynamic nature of 
the concept exposes its vulnerability. As all the components in the mixture are in 
constant equilibrium, the reactions have to be quenched prior to screening [15a]. Also, 
the nucleophiles and electrophiles involved are mostly incompatible with 
physiological conditions. Disulfides, for instance, are highly unstable as they are 
subjected to a constant barrage of redox reactions by endogenous thiols like GSH. As 
such, the reversible linkages in the substrate will have to be replaced by more 
permanent fixtures in the design of therapeutic agents [17].  
 
In 2002, fueled by the development of click chemistry reactions [18], such as 
the [3+2] cycloaddition between azides and alkynes, Lewis et al evolved the dynamic 
combinatorial library concept into using kinetically-driven irreversible processes in a 
complementary approach [19a] (Fig. 2B). The strategy was applied to AChE where 
the inhibitor was construed to be “clicked” together through an array of tacrine and 
phenanthridinium components decorated with the azide and alkyne moieties. The 
building blocks were localized within the active and the peripheral site; the proximity 
of binding henceforth accelerates the cycloaddition reaction. In the absence of an 
enzyme catalyst, the ligation reaction between the azide and the alkyne required 
approximately 40 years to reach 80% completion; the addition of AChE dramatically 
accelerates the bond formation within a matter of hours [19a]. .Indeed, out of a 
maximum of 98 pairs of substrates, one pair of regioselectively formed triazole-linked 
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product served as confirmation that enzymes can function as atomic-scale reaction 
vessels for the self-selective enhanced synthesis of their own inhibitors. The eventual 
inhibitor was found to be of femtomolar scale (Kd = 77 – 400 fM), rendering it one of 
the most potent noncovalent inhibitors of AChE to date. Affirmation of substrate 





Figure 2. Target-driven concept of small molecule screening. (A) Product is 
assembled through thermodynamically-driven reversible reactions; (B) product is 
assembled through kinetically-driven irreversible reactions.  
 
Although the concept of kinetically-driven target chemistry has been 
independently verified by a number of research groups [18b, 20], none of the other 
approaches possess the flexibility and biocompatibility of the azide-alkyne reaction. 
Coined by K.B. Sharpless, the term “click chemistry” describes a set of highly 
energetic or “spring-loaded” irreversible reactions with the resultant formation of 
carbon-heteroatom bonds [18]. There are a number of organic reactions that 
succinctly fall under the click chemistry umbrella, such as the Diels-Alder reaction, 
kinetically-driven carbonyl chemistry, addition to C-C multiple bonds and 
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nucleophilic ring-opening reactions. But amongst these, Huisgen’s 1,3-dipolar 
cycloaddition of alkynes and azides stands out as the premier click chemistry reaction. 
The 1,2,3-triazole-formation reaction is characterized by high yields, little or no side 
products and can be carried out under aqueous conditions. However, the most vital 
feature is that azides and alkynes are the least reactive functional groups in organic 
chemistry and are orthogonally compatible with enzymes under physiological 
conditions [21]. 
 








Scheme 1. “Click chemistry” reaction between azide and alkyne. 
 
 In recent years, another aspect of combinatorial chemistry that is gradually 
gaining relevance is the multicomponent reaction (MCR) [22], because of the 
potential implications in diversity-oriented synthesis [23]. Typically based on 
isocyanide chemistry, MCRs are domino-styled one-pot reactions where the product 
of one reaction is the substrate for the next, leading to the rapid formation of complex, 
structurally diverse skeletons. Lee et al harnessed the power of the Ugi-4 component 
reaction (U-4CR) as a key step in generating complex skeletal structures [23]. With a 
collection of basic building blocks, an overwhelming library of small molecules can 
be generated in one simple step, rivaling even the combinatorial effect of split-pool 
synthesis: if each of the 40 basic components are mixed simultaneously, the eventual 
number of products hits 404 = 2.56 million [22a]. The blurring of the dividing lines 
between MCRs and diversity-oriented synthesis pushes the frontiers of drug discovery 
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with the potential library of drug candidates available for screening purposes. 
However, the synthesis, isolation and purification of structures that yield little 
biological activity unnecessarily lengthen the screening and lead optimization 
process. More importantly, the lack of a suitable tagging/deconvolution strategy for 
MCR severely hampers its adaptation for high throughput screening, although the 
recent work of Liu and co-workers in the field of DNA-templated synthesis paves the 
way for programmable chemical synthesis [24]. 
 
 We envisaged a means by which the potential of the multicomponent reaction 
can be harnessed for wide-spread drug discovery purposes through the merger with 
the afore mentioned target-driven chemistry concept. The self-assembly strategy, 
through continuous interactions with the enzymatic active site, selectively amplifies 
the highest binding inhibitor from a mixture of substrates. Previously, the method 
outlined by Lewis et al involved the individual screening of 98 pairs of binary 
mixtures of tacrine and phenanthridium [19a]. The process is undoubtedly tedious and 
limiting. For the self-assembly strategy to truly revolutionalize the drug screening 
process, the approach has to be streamlined as a high-throughput method. We propose 
an alternative whereby multiple screenings of building blocks can be effected in one-
pot through the use of a biological target that will template the formation of the most 
potent inhibitor. In other words, the assembly of the inhibitor product and screening is 
conducted “in-house” in an approach akin to that adopted by Cheeseman et al for 
determining the most potent sulfonamide binder of carbonic anhydrase. The most 
potent inhibitor of a biological target should ideally be amplified through a series of 
ligand stabilization interactions with the active site. Herein, we set the preliminary 
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groundwork for demonstrating the feasibility of the concept through the use of a two-




              CHAPTER 2 DEVELOPING AFFINITY-BASED PROBES 
FOR PROTEOMIC PROFILING 
 
2 Developing an Affinity-based Strategy for the Proteomic Profiling of Aspartic 
and Metalloproteases 
 
Proteases are a major class of enzymes belonging to the hydrolase family, 
which target solely amide bonds in proteins or polypeptides [25]. Depending on the 
catalytic residues involved in the hydrolytic mechanism, proteases are further sub-
classified as serine, cysteine, aspartic and metalloproteases.  
 
Serine and cysteine proteases have similar catalytic cycles, whereby the 
alkoxide or thiolate ion on the catalytic amino acid side chains participates in a 
general base mechanism. The electron-rich nucleophiles attack the scissile peptide 
bond of the substrate docked in the active site, resulting in the generation of a 
tetrahedral intermediate that is covalently attached to the active site [26]. As such, 
mechanism-based inhibitors designed for the serine and cysteine proteases typically 
involve reactive groups that will eventually be irreversibly modified by the enzyme.  
 
The chemical proteomics approach of systematically labeling enzymes in a 
complex proteome mixture on the basis of catalytic activity provides a distinct means 
of functional categorization of class specific enzymes. The activity-based profiling 
strategy utilizes a small molecule probe that labels the desired class of enzymes in a 
manner that is independent of the level of natural abundance. The probe structure 
typically consists of a reactive unit, a reporter tag and a linker [8]. Selection of 
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reactive units for enzymes such as serine and cysteine proteases capitalized on the 
vast array of suicide inhibitors available through the incorporation of these reactive 
units into the probe structures [10a-h]. For instance, the epoxide- and vinyl sulfone-
based probes designated to target cysteine proteases function as electrophilic traps 
that act as electron sinks for the nucleophilic sites on the catalytic residues [10e,g]. 
The addition of a reporter tag, such as a fluorophore, would provide for convenient 
gel-based analysis of activity-based enzymatic labeling through the direct readout of 
the fluorescent intensity. The linker unit serves as a flexible chain that bridges the 
reactive ‘warhead’ and the reporter tag, thereby preventing steric perturbation in the 
active site [8]. 
 
On the other hand, aspartic and metalloproteases have markedly distinctive 
hydrolytic mechanisms mediated through the catalytic aspartic dyad and zinc (II) ion 
respectively. Hydrolysis of amide bonds does not involve direct enzymatic action on 
the substrate, but through a non-catalytic water molecule bound to the active site. The 
pKa of the water moiety is extensively lowered through hydrogen-bonding or 
coordination with a Lewis acid, which in turn, facilitates nucleophilic addition on the 
carbonyl group of the amide bond. Hence, the resultant tetrahedral intermediates 
generated in such manners will not be covalently attached to the enzyme [27]. Owing 
to a lack of known mechanism-based inhibitors that form covalent adducts with these 
enzymes, as of now, there have yet to be reports of activity-based probes capable of 
profiling aspartic proteases or metalloproteases. 
 
 The major drawback of the currently available chemical proteomics strategy is 
that only enzymes that irreversibly modify their substrates through chemical means 
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can be profiled using small molecule activity-based probes [28]. We conceive of an 
alternative complementary strategy for enzymes lacking covalent intermediates 
through an affinity-based approach. We have evolved the activity-based profiling 
concept to use affinity-binding units, as well as, to encode substrate recognition 
residues that confer active site-directing functionality. Covalent crosslinking is 
afforded via the generation of reactive intermediates from a photolabile tag. The 
simultaneous inclusion of a fluorophore would enable in-gel fluorescence analysis of 
the enzymatic labeling. 
 
Based on the affinity-based strategy discussed earlier, we disclose a novel 
chemical proteomics approach to profile the aspartic and metalloproteases, subclasses 
of the protease family which have yet to be targeted in activity-based profiling. The 
principles of probe design, the chemical syntheses as well as the enzyme labeling 
experiments are included herein. 
 
2.1 Affinity-based Proteomic Profiling of Metalloproteases 
 
2.1.1 Design of Photoactivable Affinity-based Probes for Metalloproteases 
 
Metalloproteases are a class of hydrolytic enzymes belonging in the protease 
family [25], whereby hydrolysis is mediated through a zinc-activated water molecule 
rather than through direct involvement of the catalytic residues [29]. Major 
metalloproteases, such as the matrix metalloproteinases (MMPs) [30a] and 
angiotensin-converting enzymes (ACE) [30b], have been shown to actively 
participate in a number of physiological pathways such as tissue modeling and blood 
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pressure regulation, rendering them potential pharmaceutical targets in diseases like 
arthritis [31a], Alzheimer’s disease [31b], cancer [31c] and heart disease [31d].  
Metalloproteases are distinguished by a characteristic HEXXH motif in the primary 
sequences [32]. The two histidine residues in the motif are coordinated to a catalytic 
zinc molecule, while a third Glu ligand is found some 14-26 residues C-terminal to 
the motif. A fourth ligand is provided by the water molecule, with the resultant 
generation of a tetrahedral coordination geometry. Metalloproteases typically 
hydrolyze peptide bonds via a general-base mechanism [29].  The action of the 
divalent zinc ion as a Lewis acid in addition to the H-bonding interaction between the 
coordinated Glu residue and water serve to activate the latter through lowering of its 
pKa value. The water molecule is thus activated to attack the electron-deficient 
carbonyl center of the scissile peptide bond, such that the tetrahedral intermediate 
formed is coordinated to zinc but not covalently bound to the enzyme.  Consequently, 
no mechanism-based, irreversible inhibitors of these enzymes are currently known, 
making it impossible, using existing strategies [10], to develop suitable chemical 
probes for activity-based profiling experiments.     
  
To develop chemical proteomics techniques which allow for the large-scale 
identification of novel metalloproteases present in a proteome, we searched for 
chemical functionalities which possess high affinity binding to these enzymes by 
capitalizing on the rich history of enzyme-inhibition studies.  The majority of 
metalloprotease inhibitors are substrate-based analogs that contain zinc-binding 
groups (ZBGs) (Fig. 3), which, within the active site of the enzyme, compete with 
water for the binding of the catalytically active zinc ion, thereby preventing the 
hydrolytic action from taking place [33].  Known ZBGs include formyl hydrazines, 
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sulfhydryls and aminocarboxylates, but the most potent of ZBGs are the hydroxamic 
acids [33c], which chelate zinc through their carboxyl and hydroxyl oxygens forming 
















Figure 3. Schematic representation of substrate-based inhibitors of metalloproteases. 
 
In our design, we selected Left Hand Side (LHS; unprimed) peptide-based 
hydroxamate inhibitors as the affinity binding unit (Fig. 3) [33d].  By using a 
simplistic model, we designed probes having GGX-NHOH sequences, in which X 
represents the P1 residue (see Fig. 4 for nomenclature), thus encoding the sole 
substrate recognition unit, and rendering them useful for potential broad-based 
profiling of metalloproteases which accept branched hydrophobic residues at the P1 
position.  Two glycine residues were inserted at the P2 and P3 positions to serve as a 
flexible linker that extends the ZBG away from the fluorophore/biotin and the 
photolabile groups in the probes, thus minimizing their potential perturbation when 
binding to the active site of the enzyme.  Diazirine was selected as the photolabile 
group of choice.  The C-N bond of 3-trifluoromethyl-3-phenyldiazirine cleaves 
homolytically when irradiated with near-UV light at 360 nm to yield a triplet carbene 
that inserts into any C-H bonds in the vicinity of the reactive species [11a-e]. Hence 
upon protein denaturation prior to gel-based separation, even though the hydroxamate 
is released by the zinc cation, the probe remains bound in place for subsequent 
analysis (see Fig. 5). In the recent report by Hagenstein et al., benzophenone was 
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selected as the photolabile group for protein cross-linking [12].  We therefore 
synthesized a benzophenone-tagged probe for the synchronous comparison with our 
diazirine-based probes (vide infra; see Scheme 1).  A cyanine dye, Cy3, as well as, 
biotin, was chosen as the reporter tag for easy detection and enrichment of labeled 
proteins, respectively.  The three key components were assembled together using 























Figure 4. Nomenclature of substrate residues and their corresponding binding sites. 
Pn, P2, P1, P1’, P2’, Pn’, etc. designate amino acid side chains of a peptide substrate. 
Cleavage occurs between the P1 and P1’ residues. The corresponding binding sites in 
the protease active site are designated as the Sn, S2, S1, S1’, S2’, Sn’, etc. subsites. 
 
 
Figure 5. Schematic representation of affinity-based profiling of metalloproteases (i) 
Hydroxamate zinc-binding group chelates to zinc; (ii) irradiation of the photolabile 
































carbene inserts covalently into any nearby C-H bonds in the vicinity of the active site; 
(iv) upon denaturation prior to SDS-PAGE analysis, the affinity probe is still bound to 
the enzyme even though the hydroxamate has been released by the active site. 
 
2.1.2 Chemical Synthesis of Affinity-based Probes for Metalloproteases 
 
We conceived of a solid phase strategy for the chemical synthesis of the 
tripeptidyl hydroxamates, which facilitates the preparation of a library of analogs. The 
initial steps involved the anchoring of the fluorophore Cy3 and the biotin tag onto the 
trifunctional lysine molecule.  Cy3, synthesized as previously reported [34], was 
converted to its corresponding NHS ester through DCC-mediated ester coupling [35]. 
The carboxyl-activated fluorophore, Cy3-NHS 1, was then coupled to the ε-amino 
group of Fmoc-Lys-OH in the presence of DIEA to yield Fmoc-Lys(Cy3)-OH 3. 
Fmoc-Lys(biotin)-OH 4 was prepared likewise via the intermediate D-biotin-NHS 2. 
 
Hydroxylamine hydrochloride was protected at the amino position using 
Fmoc-Cl in the presence of sodium bicarbonate to afford Fmoc-NHOH 5 as reported 
[36].   2-Chlorotrityl chloride resin was first functionalized with the hydroxylamine 
moiety in the presence of DIEA and Fmoc-NHOH, as previously reported [37].  The 
GGX tripeptidyl sequence was subsequently loaded onto the resin 6 using TBTU-
activated coupling protocols in conjunction with Fmoc chemistry, where X denotes 
the amino acid of choice for the P1 position. Fmoc-Lys(Cy3)-OH 3, which was in turn 
attached at the N-terminus of the resin-bound GGX-hydroxamate 7 using standard 
solid-phase peptide synthesis protocols.  Following Fmoc deprotection, the diazirine 
moiety was coupled to the α-amino group of lysine in the final step of the synthesis.  
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Cleavage of the substrate from the solid support using 95% TFA followed by 
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Scheme 2. Synthesis of tripeptidyl hydroxamate affinity-based probes of 
metalloproteases. (a) NHS, DCC, DMF; (b) 50% TFA/DCM; (c) Cy3-NHS 1, DIEA, 
DMF; (d) Biotin-NHS 2, DIEA, DMF; (e) Fmoc-Cl, hydroxylamine hydrochloride, 
NaHCO3, EA/water, 0 oC; (f) (i) Fmoc-NHOH 5, DIEA, DCM, 48 h; (ii) 20% 
piperidine/DCM, 30 min; (g) (i) Fmoc-amino acid, TBTU, HOBt, DIEA; (ii) 20% 
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piperidine/DMF; (h) (i) Fmoc-Lys(Cy3)-OH 3, TBTU, HOBt, DIEA; (ii) 20% 
piperidine/DMF; (iii) TFMPD, TBTU, HOBt, DIEA; (iv) 95:2.5:2.5 TFA/TIS/H2O; 
(i) (i) Fmoc-Lys(Cy3)-OH 3 or Fmoc-Lys(Biotin)-OH 4, TBTU, HOBt, DIEA; (ii) 
20% piperidine/DMF; (iii) TFMPD or 4-benzoyl benzoic acid, TBTU, HOBt, DIEA; 
(iv) 95:2.5:2.5 TFA/TIS/H2O; (j) 95:2.5:2.5 TFA/TIS/H2O. 
 
Using the described method, nine hydroxamate-based affinity probes were 
synthesized with varied P1 residues – hydrophobic (Leu 8a, Ile 8b, Val 8c, Met 8d); 
aromatic (Phe 8e); hydrophilic (Gly 8f, Thr 8g); basic (Lys 8h) and acidic (Glu 8i).  
Product yields of the HPLC-purified peptidyl hydroxamates ranged from 6-37%, as 
summarized in Table 1. Yields of the photoactive group-tagged probes were rather 
low, in particular, the hydroxamates containing Gly and Lys (8f and 8h, respectively) 
in the P1 position. The low yields were attributed to the loading of the first amino acid 
residue on to the hydroxylamine-functionalized resin 5. Past literature reports 
recommended the use of HATU/DIEA as the choice peptide coupling activating 
reagents [37]. However, due to economical reasons, TBTU/HOBt/DIEA was selected 
in lieu of the reported system, which in turn compromised the overall yield of the 
peptide hydroxamate products. 
 
The benzophenone- and biotin-containing analogs of the probe 8a, 9 and 10, 
respectively, were similarly synthesized. 9 was afforded by substituting the diazirine 
moiety with a benzophenone group while 10 was obtained by replacing the Cy3 
fluorophore with a biotin tag at the ε-amino position of Fmoc-lysine. The tripeptidyl 
hydroxamic acid, GGL-NHOH 11, was yielded following TFA-mediated cleavage of 
the GGL-hydroxamate bound resin 7, for subsequent enzyme labeling studies. 
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 Amino acid /P1 residue Yield %a
8a Leu 37 
8b Ile 22 
8c Val 16 
8d Met 27 
8e Phe 18 
8f Gly 6 
8g Thr 38 
8h Lys 8 
8i Glu 16 
 
Table 1. Summary of yields of analogs of TFMPD-Lys(Cy3)-GGX-hydroxamates 8a-
i synthesized, where X represents the amino acid in the P1 position. aYields are 
calculated based on an average 0.80 mmol/g substitution level of hydroxylamine-
functionalized resin 6. 
 
2.1.3 Affinity-based Enzyme Labeling Experiments 
 
Thermolysin (EC 3.4.24.27), a 34.6 kDa extracellular endopeptidase isolated 
from Bacillus thermoproteolyticus, was selected as the representative metalloprotease 
in our labeling experiments. Mature thermolysin is made up of 316 amino acid 
residues and consists of the characteristic HELTH motif in its sequence [32]. The N-
terminal half of the enzyme is dominated by the presence of β-sheets while α-helices 
constitute the C-terminal half. The catalytic zinc ion is located in a cleft situated 
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between the two lobes [25]. Thermolysin is the first metalloprotease for which a 
tertiary structure is elucidated through X-ray crystallographic methods [38] and it is 
the subject of a number of studies owing to its thermophilic properties [39]. 
 
The pH profile of thermolysin follows a bell-shaped curve with optimal 
catalytic activity at pH 7 [40]. The primary substrate recognition center is designated 
by the S1’ subsite which favours large, hydrophobic residues such as Ile, Phe, Leu and 
Val [40a, 41], although hydrolysis of bonds with Met, His, Tyr, Ala, Asn, Ser, Thr, 
Gly, Lys and Glu at the P1’ position has been reported [42]. The S1, S2 and S2’ 
subsites play comparatively less importance in specificity. 
 
Previously, Z-GGL-NHOH was shown to be a potent and tight-binding 
inhibitor of thermolysin, with a Ki value of 39 µM [43].  X-ray crystallographic 
studies of the enzyme-inhibitor complex suggested that, the GGL tripeptide binds 
inversely to the active site of the enzyme, with Leu fitting into the S1’ subsite and the 
hydroxamic acid forming a bidentate chelation to zinc [44].  We therefore used the 
GGL-containing probe, 8a, as a tight-binding thermolysin adduct to optimize the 
conditions of affinity-based labeling.  
 
2.1.3.1 Optimization of Conditions for Affinity-based Profiling of 
Metalloproteases 
 
To determine the optimal probe concentration needed for efficient and specific 
labeling of thermolysin, stock solutions of 8a with varying concentrations were 
prepared in DMSO.  Different labeling reactions were set up, by varying the probe 
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concentration while keeping the concentration of thermolysin constant (final 
concentrations: probe = 0-20 µM; thermolysin = 1 mg/mL). The amount of DMSO 
added in each reaction was also maintained constant throughout to avoid debilitating 
effects on the enzyme. Following incubation at room temperature in the dark for 30 
min, the reaction mixtures were irradiated with near-UV light at 360 nm for an 
additional 20 min. The reactions were quenched by boiling with 6 x SDS-loading dye, 
followed by separation on denaturing SDS-PAGE. Visualization of labeling was 
afforded by fluorescence scanning. Simultaneous labeling reactions with a series of 
control enzymes were set up. 
 
  As shown in Fig. 6, specific labeling of thermolysin was observed when the 
probe concentration was greater than 10 nM.  With increasing concentrations of the 
probe in the reaction, concurrent increases in the fluorescence intensity of the labeled 
thermolysin were observed.  No labeling was observed for any of the control 
proteases when low concentrations of the probe were used (up to 1 µM final 
concentration).  When increasing concentrations of the probe were used, however, 
non-specific labeling began to appear with control enzymes. We attributed this 
phenomenon to the fact that when large excesses of the probe were present in the 
reaction in relation to the amount of enzyme, the tripeptidyl hydroxamates are no 
longer sequestered in the active site but are found freely in the buffer solution. The 
carbenes generated upon photolysis will thus bind randomly to any protein, regardless 
of specificity and activity, giving rise to false positive results (Fig. 6). We hence 
conclude that it is essential to maintain the labeling concentration at a minimum 
which would give reasonably discernible labeling without non-specific binding. As 
such, we have determined the optimal concentration of the probe required for the 
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specific labeling of thermolysin to be ~500 nM.  This concentration was thus used for 
all subsequent labeling experiments, unless otherwise indicated.  






Figure 6. Concentration dependent affinity-based labeling. Thermolysin and 3 other 
control enzymes, papain (cysteine protease), trypsin (serine protease) and cathepsin D 
(aspartic protease) were incubated with decreasing concentrations of 8a (200, 50, 20, 
10, 5, 2, 1, 0.5, 0.1 and 0 µM respectively).  
 
We next optimized the UV irradiation time for the specific labeling of 
thermolysin.  The same thermolysin labeling reaction was set up, in which 500 nM of 
the probe 8a was used.  Following incubation in the dark for 30 min, the reaction was 
subjected to near-UV irradiation for increasing lengths of time (0 to 60 min).  As 
shown in Fig. 7, in the absence of photolysis, no labeling of thermolysin was detected, 
indicating that the in situ generation of carbenes is essential for the effecting covalent 
crosslinkage between enzyme and substrate.  With photolysis, labeling of thermolysin 
was observed. However there appears to be little effect of the period of irradiation on 
the labeling intensity since strong labeling was discernible with as little as 10 min of 
irradiation time.  We thus chose 20 min as the optimal period of UV irradiation in all 
subsequent experiments, unless otherwise indicated. 
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Figure 7. Effects of length of UV irradiation on labeling intensity. The reaction 
mixtures containing thermolysin with 8a was exposed to UV light for 0, 10, 20, 30 
and 60 min following a 30 min incubation period. 
 
2.1.3.2 Mechanistic Studies of Affinity-based Labeling of Thermolysin 
 
A number of experiments were carried out to ensure that thermolysin labeling 
by 8a is dependent on the high affinity binding of the probe towards the active site of 
the enzyme.  Firstly, competitive experiments were run, in which the labeling of 
thermolysin by 8a was performed in the presence of a competitive inhibitor, 11, 
which has the same GGL-NHOH binding unit as 8a, but devoid of both the 
fluorescent and the photolabile units.  Secondly, in our labeling strategy, since having 
a functionally active site of the enzyme is a prerequisite for the probe to bind before 
photo-labeling could occur, the extent of the enzyme labeling by a given probe could 
therefore be used to indirectly reflect the relative enzymatic activity of the enzyme, as 
well as the relative affinity of the probe against the enzyme, or both.  This was 
illustrated by running the thermolysin labeling (e.g. with 8a) reaction in the presence 
of EDTA, a well-known metalloprotease inhibitor.  Lastly, eight other probes, 
TFMPD-Lys(Cy3)-GGX-NHOH, 8b-8i, in which X represents substitutions of 
different P1 residues into the enzyme recognition sequence of the probe, were 
synthesized and tested against thermolysin, which, as an enzyme favoring 
hydrophobic P1’ residues, should confer different degrees of labeling by the probes.       
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GGL-NHOH, 11, was obtained by TFA cleavage of the GGL-hydroxamate 
bound resin 7 (Scheme 2), purified by RP-HPLC and lyophilized to afford a white 
solid.  Stock solutions of varying concentrations of 11 were made up in DMSO. 
Labeling reactions were set up such that the concentrations of the probe 8a and 
thermolysin were kept constant (500 nM and 1 mg/mL, respectively), while 
increasing amounts of 11 (from 0 up to 1 mM, final concentrations) were added in a 
manner such that the total volume of DMSO in each reaction vessel was maintained at 
equal volumes throughout. Because hydroxamates are reversible inhibitors of 
metalloproteases, the presence of 11 in the labeling reaction of thermolysin with 8a 
would set up a competitive equilibrium between the two substrates where the inhibitor 
competes with the probe for docking in the active site of the enzyme.  This was 
evident in Fig. 8, where increasing amounts of 11 coincided with a concomitant 
decrease in labeling intensity. The concentration of the competitive inhibitor in 
solution eventually reaches a saturation point such that at about 2000-fold excess, the 
labeling of thermolysin by the photoaffinity probe exhibits complete suppression. 
 
  0          5         10        20         50      100       500    1000 [Inhibitor]/µM 
 
Figure 8. Affinity-based labeling of thermolysin in the presence of a competitive 
inhibitor. Thermolysin was simultaneously incubated with 8a and increasing amounts 
of GGL-NHOH 11 (0, 5, 10, 20, 50, 100, 500 and 1000 µM, respectively) 
 
Asides from the functionally catalytic zinc ion, structural elucidation from X-
ray crystallographic studies have shown the presence of four other calcium binding 
sites [39a, 45]. It is thought that calcium plays a structural role by maintaining the 
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stability of thermolysin and prevents autolysis of the enzyme in a self-protective 
mechanism. Previous reports have demonstrated that EDTA chelates preferentially to 
the calcium ions, which causes the collapse of the three-dimensional structure of 
thermolysin. This is in turn followed by a rapid and quantitative autolytic degradation 
of the enzyme [39a]. EDTA is thus an irreversible inhibitor of thermolysin. In our 
labeling studies, we examined the effect of EDTA on the enzyme labeling reaction.  
Desalted thermolysin was simultaneously incubated with the photoaffinity probe (e.g. 
8a) and varying concentrations of EDTA (Fig. 9).  With increasing amounts of EDTA 
added to the reaction, we observed a correlated gradual decrease in fluorescence 
intensity of the labeled enzyme until the labeling was completely inhibited with 100 
µM of EDTA eventually. As with the aforementioned GGL-NHOH competitive 
labeling experiments, a large excess of the inhibitor (200-fold EDTA) was needed for 
complete inhibition of thermolysin labeling. The absence of protein labeling in the 
event of EDTA inactivation suggests that our labeling strategy is dependent on the 
activity of the enzyme, akin to the activity-based profiling strategy. It confers our 
affinity-based probes with the succinct ability to distinguish catalytically active 
enzymes from their inactive zymogen forms in complex proteome mixtures. 
 
100          50         10           0 
 [EDTA]/µM
 
Figure 9. Irreversible inactivation of thermolysin with EDTA. Desalted thermolysin 
was simultaneously incubated with 8a and decreasing concentrations of EDTA (100, 
50, 10 and 0 µM, respectively). 
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In addition to its preference for hydrophobic residues at the P1 position, 
thermolysin was previously shown to exhibit some hydrolytic activity against 
substrates with hydrophilic P1 side chains, such as Glu, Thr and Lys [42].  We 
therefore synthesized eight more probes, TFMPD-K(Cy3)-GGX-NHOH (8b-8i), 
with varied P1 residues.  Together with 8a, all nine probes were tested for their 
photoaffinity labeling against thermolysin, as well as carboxypeptidase A - another 
metalloprotease having a different substrate specificity profile.  In addition, control 
labeling experiments were also performed with a number of non-metalloproteases 
(data not shown).   
 
As shown in Fig. 10A, thermolysin exhibited intense labeling with the 
peptidyl hydroxamates containing Thr, Met, Ile and Leu at the P1 position.  Other 
probes having P1 Glu, Lys, Gly, Phe and Val residues did not appreciably label the 
enzyme, which is surprisingly inconsistent with the expected specificity of the 
enzyme. The failure of thermolysin to label the expected peptide hydroxamates may 
be due to the buffer conditions used which may not be sufficiently conducive for 
enzyme labeling. Studies have shown that the presence of small amounts (1-10 mM) 
of calcium ions in the buffer solution aids in preserving the enzyme against 
inactivation and autolytic digestion [42]. However in our experimental conditions we 
avoided the use of large excesses of ions since hydroxamates are known to chelate to 
calcium [46], resulting in a quenching effect on our enzymatic labeling. 
 
 Carboxypeptidase A (EC 3.4.17.1), a zinc metallo-exopeptidase that cleaves 
C-terminal residues from its peptide substrate, favors residues with large hydrophobic 
side chains on the imino side of the scissile peptide bond [47].  Upon incubation with 
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the nine hydroxamate probes, moderate labeling was observed for carboxypeptidase A 
with majority of the probes (Fig. 10A), indicating the enzyme has little preference for 
residues at the P1 position, which is consistent with literature reports.  
 
We next used all 9 probes to label heat-denatured thermolysin.  The enzyme 
was first boiled at 95 oC for 10 min, chilled rapidly on ice, and then treated with the 
nine probes as described above (Fig. 10B). No labeling with thermolysin was 
observed with any of the probes, further reiterating our work with irreversible EDTA 
inhibition that a functional active site in the enzyme is essential for the labeling 
strategy to work.  The destruction of three-dimensional active site translates to the 
fact that the probes are denied of affinity-binding sites in the enzyme. Consequently, 
the reactive carbenes generated will not be located in the vicinity of thermolysin and 
hence no covalent crosslinkage takes place. The absence of background labeling also 
serves as a reaffirmation of the selectivity of our hydroxamate probes for 
metalloproteases. Excess carbenes are probably rapidly quenched by the Tris.HCl 
buffer solution.  
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Figure 10. (A) Specificity profile of thermolysin and carboxypeptidase A. The 
enzymes were incubated with equal concentrations of the probes 8a-i; (B) Affinity-
based labeling of denatured thermolysin. 
 
This feature is echoed by results obtained from control experiments in which 
non-metalloproteases were used in the labeling experiments. We carried out the 
affinity-based labeling of our 9 probes on enzymes from a number of enzymatic 
classes, including those from the other protease subfamilies. There was a complete 
absence of labeling in the control enzymes, which include papain (cysteine proteases), 
trypsin (serine proteases), pepsin (aspartic proteases) and lipases (see Fig. 1, 
Appendix). Our hydroxamate probes failed to label even enzymes that contain a 
catalytically functional zinc, such as the alkaline phosphatases, further suggesting the 
specificity of the hydroxamate-containing probes solely for zinc metalloproteases. 
 
2.1.3.3 Comparison of Photolabile Group Used in Affinity-based Profiling 
 
 In the recent report by Hagenstein et al., benzophenone was chosen as the 
photoactive label [12].  We therefore synthesized a benzophenone-containing GGL-
NHOH probe, 9, for the synchronous comparison with our diazirine-based probe 8a, 
in terms of selectivity and sensitivity. The probe 9 was synthesized in an analogous 
fashion as described in Scheme 1, whereby the diazirine moiety was replaced by a 
benzophenone group. 
 
In our initial attempts, we carried out the affinity labeling with 20 µg of 
thermolysin and carboxypeptidase A, as well as, 25 other control enzymes using 500 
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nM of the benzophenone-tagged probe 9. The metalloproteases failed to be labeled by 
the probe and the problem was compounded by the fact that a number of control 
enzymes exhibited non-specific labeling under the same conditions. Subsequently, it 
was ascertained that the pure thermolysin could only be labeled adequately using 5 
µM of 9 (Fig. 11). We thus conclude that the benzophenone group contributed 
significantly to the diminished sensitivity of 9 in comparison with the diazirine-tagged 
probes 8, possibly owing to the photochemistry of the respective photoaffinity groups. 
When irradiated with near-UV light at ~360 nm, the diazirine moiety undergoes two 
homolytic C-N cleavages to yield an aryl-stabilized carbene [11a-e] while photolytic 
excitation of the benzophenone molecule causes the C=O bond of the carbonyl group 
to partially break, resulting in the formation of a triplet ketyl biradical [11f]. Studies 
have shown that since both types of reactive intermediates have lifetimes on the 
nanosecond scale [11b], it is unlikely that diffusion of the diradicals from the 
enzymatic active site occurred. Besides, the hydroxamate zinc-binding affinity unit 
and the GGL tripeptide, as well as, the Cy3 fluorophore are ubiquitous features of 
both probes; hence the inhibitory potency of 8a and 9 should, ideally, not differ much. 
We thus speculate that the high incidence of non-specific labeling may be attributed 
to the relative stability of the intermediates in the native environment. It has been 
reported that radicals generated from benzophenones are sufficiently stable in protic 
solvents [11b[. As such, excess or unbound benzophenone-tagged probes would have 










Figure 11. Affinity-based labeling of enzymes with 5 µM of benzophenone-tagged 
GGL-hydroxamate probe 9. Lanes: (M) fluorescent protein marker; (1) thermolysin; 
(2) carboxypeptidase A; (3) bromelain; (4) chymopapain; (5) papain; (6) pepsin; (7) 
bovine serum albumin; (8) alkaline phosphatase; (9) lipase; (10) lipase.  
 
 
2.1.3.4 Affinity-based Labeling of Thermolysin in Crude Yeast Extracts 
 
In order to assess the feasibility of the affinity-based approach in potential 
large-scale proteomic experiments, we next carried out the labeling of thermolysin in 
the presence of large amounts of endogenous cellular proteins. Both diazirine- and 
benzophenone-tagged probes, 8a and 9, respectively, were utilized in the subsequent 
experiments.  
 
Thermolysin-containing crude yeast extracts were prepared by spiking the 
extracts, which contain 5 mg/mL of endogenous yeast proteins, with increasing 
amounts of thermolysin (final concentrations of thermolysin: 0-10 µg/mL).  The 
resulting extracts were labeled with 8a and 9 and subsequently, the protein mixtures 
were separated by denaturing SDS-PAGE. Analysis of the labeling results was 
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obtained through both fluorescence scanning and Coomassie staining (Fig. 12). As 
can be seen in Fig. 12, both probes were able to successfully label thermolysin 
specifically in the presence of a large excess of other proteins (Fig. 12A vs. 12B).  As 
ascertained in earlier results, the diazirine-based probe 8a appeared to be a far more 
superior affinity-based probe than the benzophenone probe 9 in both its sensitivity 
and specificity. The benzophenone-tagged probe 9 was only able to label the pure 
thermolysin; in the presence of crude yeast proteins, labeling of the same amount of 
thermolysin (10 µg) was completely extinguished.  This was compared to as little as 
0.5 µg/mL of thermolysin in the same crude extract being successfully detected by 
500 nM of the diazirine probe, 8a (Lanes 1-5, Fig. 12A).  The higher specificity of the 
diazirine probe 8a over the benzophenone probe 9 was also evident when the crude 
yeast extract, without addition of any thermolysin, was labeled with both probes. No 
background labeling was observed in the lane labeled with 8a (Lane 1), whereas in 
the lane labeled with 9 (Lane 6), a high incidence of background labeling of the 
cellular yeast proteins was detected.  Finally, the presence of a sufficiently high 
concentration of EDTA was also shown to completely suppress the thermolysin 
labeling by 8a (data not shown).   
 
The quenching of thermolysin labeling in the presence of endogenous cellular 
proteins suggests that the enzymatic labeling in lane 6 may be due to non-specific 
binding of the probe 9 to the enzyme, particularly in light of the observation that 9 
exhibits infidelity labeling against non-metalloproteases. The ability of our diazirine-
tagged probe 8a to selectively and specifically capture thermolysin in the crude yeast 
proteome without external interferences from endogenous factors would potentially 
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Benzophenone 9 Benzophenone 9 Diazirine 8a  Diazirine 8a  







Figure 12. Comparison of labeling specificity of diazirine and benzophenone-based 
probes 8a and 9 respecitively, of thermolysin spiked in a crude yeast extract. (A) 
Fluorescence image; (B) Coomassie stain image. Lanes (1, 6) Crude cell lysate; (2, 7) 
Thermolysin (0.5 mg/mL); (3, 8) crude cell lysate + thermolysin (0.5 mg/mL); (4, 9) 




2.1.4 Current Work 
 
In a bid to demonstrate the versatility of our probe in labeling 
metalloproteases, we have carried out the affinity-based profiling against a broad 
spectrum of yeast metalloproteases. The results of which are described in a separate 
publication [48]. We were able to generate specific labeling profiles for the panel of 
12 metalloproteases through affinity-based tagging with the 9 peptide hydroxamate 
probes. 
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 With the favourable labeling results obtained with our diazirine probe, we 
have worked to optimize the labeling conditions to ascertain the limit of detection of 
the probe 8a for pure thermolysin [48]. Thermolysin can be distinctly labeled through 
the affinity-based method down to levels as low as 5 ng. Plots of IC50 values can be 
generated directly through the in-gel fluorescent readout of the labeling intensity. 
Competitive inhibition reactions between 8a and GGL-NHOH 11 were set up such 
that the concentrations of the latter were varied while that of the former was 
maintained constant throughout. The IC50 value of 11 was determined to be 900 µM, 
which is comparable to the value obtained through conventional microtiter plate assay 
methods (400 µM). 
 
We are also currently working to extend our affinity-based strategy towards 
large-scale proteomic profiling of metalloproteases in crude proteome mixtures. We 
have replaced the fluorescent tag on the ε-amino position of the probe 8a with a biotin 
tag. The biotinylated probe 10 is then used to pull-down metalloproteases expressed 
in either yeast or mammalian cells. Subsequent biotin-avidin affinity-based 
purification methods would result in the isolation of only the metalloproteases. Mass 
spectrometry fingerprinting of the trypsin-digested protein fragments following 2-









In conclusion, we have successfully developed an affinity-based, chemical 
proteomic approach which may be used for potential large-scale profiling of enzymes 
otherwise unattainable with current activity-based profiling approaches.  The lack of 
covalent substrates for certain classes of enzymes limits the broad-range applicability 
of activity-based proteomic profiling as a diagnostic means of enzyme functionality.  
By utilizing the non-covalent binding of easily accessible reversible inhibitors of an 
enzyme, the approach delivers a photoaffinity probe to the active site of the enzyme 
and subsequently modifies it covalently, rendering the resulting enzyme-probe 
complex detectable through denaturing gel-based methods.  We chose diazirine over 
benzophenone as the photolabile unit in our probes, as the diazirine-based probes 
were able to selectively label a small amount of the model metalloprotease from a 
crude yeast extract with high sensitivity and low background labeling.  Using a 
repertoire of hydroxamate-based probes, we have also shown that the affinity-based 
approach described herein may be used not only for the large-scale identifications of 
metalloproteases, but also to provide quick access to different labeling profiles of 
these enzymes, including their substrate “fingerprints” and inhibitory properties, etc.  
Given the significant role many metalloproteases play in a variety of diseases, our 
approach may serve as a useful tool for diagnostic therapeutics.  Studies have 
demonstrated that metalloproteases, in particular, the matrix metalloproteases, are 
secreted in tissues of patients suffering from Alzheimer’s disease and arthritis [31a,b]. 
The ability of the hydroxamate probes to profile the metalloproteases in a mixture of 
proteins from crude yeast extracts will potentially allow the development of affinity-
based proteomic profiling as a diagnostic tool for the assay and functional 
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characterization of biological disease markers. Our alternative strategy of affinity-
based profiling thus provides a promising complementary alternative to activity-based 
proteomic profiling. 
 
2.2 Affinity-based Proteomic Profiling of Aspartic Proteases 
  
 The successful implementation of our affinity-based profiling strategy towards 
metalloproteases has prompted us to develop analogous strategies for other enzymatic 
classes lacking mechanism-based suicide inhibitors. Herein, we report the affinity –
based profiling of aspartic proteases. 
 
2.2.1 Design of Photoactivable Affinity-based Probes for Aspartic Proteases 
 
 Aspartic proteases (EC 3.4.23.-) are characterized by their proteolytic 
functionality at acidic pH, with optimum activity between pH 1 and 5. [49] These 
enzymes are widely studied due to their enormous ramifications in human diseases: 
renin is implicated in hypertension, cathepsin D in breast cancer metastasis, β-
secretase in Alzheimer’s disease, plasmepsin in malaria and HIV-1 protease in AIDS 
[27b]. The HIV-1 protease, in particular, is perhaps the most widely studied protease 
in history due to its role in anti-retroviral therapy. 
 
Aspartic proteases are distinguished from the rest of the proteases by two 
aspartic acid catalytic residues in the active site and are marked by the conserved 
Asp-Thr-Gly (DTG) sequence in the primary structure [49]. Tertiary structural studies 
revealed a bilobed structure with one catalytic Asp residue in each lobe [50], one 
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protonated as a neutral residue and the other deprotonated as an aspartate. Although 
the catalytic mechanism is poorly understood, it has been generally accepted that the 
aspartic residues bind a molecule of water through extensive H-bonding [51]. The 
oxygen on water is activated, rendering it highly susceptible towards nucleophilic 
attack on a carbonyl C in a general base catalysis mechanism. The resultant 
tetrahedral intermediate generated is thus not covalently bound to the active site.  
 
In selecting affinity binding units for aspartic proteases, we focused on 
pepstatin, a naturally occurring potent reversible inhibitor of pepsin (Ki = 4.60 x 10-11 
µM), which has been widely used as a general inhibitor for the acid proteinases [52]. 
Being a hexapeptide, Ival-Val-Val-Sta-Ala-Sta, pepstatin comprises the central core 
unit, (3S,4S)-statine, which has been recognized as a transition state analog of the 
tetrahedral intermediate [53]. The latter functions as a dipeptide isostere through the 
substitution of the P1-P1’ residues in the substrate [54]. The hydroxyl group on 
statine effects tight-binding with the enzyme active site through H-bonding with the 
catalytic aspartic residues (Fig. 13), thereby replacing the nucleophilic water molecule 
[55].  We propose using a truncated analog of pepstatin, Z-Val-Val-Sta, which retains 
reasonable activity against aspartic proteases such as pepsin (Ki = 1.90 x 10-7 µM) 
[56]. Statine was retained in our probe to function as the affinity binding unit, while 
the two valine residues served as a linker and, to a lesser extent, retained some 
substrate recognition with regards to pepsin. (3R,4S)-statine was selected in lieu of its 
naturally occurring diastereomer for easy chemical synthesis, also because it was 
shown to not affect binding to pepsin by much (Ki = 3.94 x 10-5 µM) [56]. A 
photolabile group, 3-trifluorophenylmethyl diazirine, was incorporated into the probe 
structure for covalent attachment to target enzymes.  In our previous experiments, we 
have adequately demonstrated the superiority of the diazirine photolabile group over 
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the benzophenone in affinity-based proteomic profiling experiments.  Upon 
irradiation at 360 nm, the diazirine moiety undergoes homolytic C-N bond cleavage to 
generate a reactive carbene species that adds irreversibly across any C-H bonds in the 
enzyme active site [11].  The inclusion of a fluorescent tag Cy3, attached in our probe 















Figure 13. Mode of binding of statine to the catalytic Asp residues (amino acid 
numbering corresponds to cathepsin D sequence). 
 
2.2.2 Chemical Synthesis of Affinity-based Probes for Aspartic Proteases 
 
We conceived a solid phase strategy for the chemical synthesis of 21, in 
anticipation that it will be applicable in future for convenient synthesis of other 
statine-containing probes to profile other aspartic proteases. The detailed synthetic 
route is shown in Scheme 3.    
 
The 2-chlorobenzyloxy ε-amino protecting group of commercially available 
Boc-Lys(2-ClZ)-OH was unmasked through catalytic hydrogenation in the presence 
of Pd/C.  The fluorescent tag Cy3 was then anchored to Boc-lysine-OH via its 
carboxyl-activated succinimide ester,  Cy3-NHS 1, to generate 12.   
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 The intermediate Boc-leucinal 14 was afforded from reduction of Boc-Leu-
N,O-dimethylhydroxamate 13, which was in turn obtained from DCC-mediated 
coupling between Boc-leucine and N,O-dimethylhydroxyl amine hydrochloride [57].  
Boc-(3R,4S)-statine ethyl ester 15a was synthesized as reported via the aldol addition 
of the lithium enolate of ethyl acetate [58] to Boc-leucinal 14. Boc-Sta-OEt was 
afforded as a mixture of two diastereomers which are discernible through NMR 
spectrometry; the (3R,4S) diastereomer was generated as the major product in 3:1 
ratio and isolated from its naturally-occurring diastereomer by column 
chromatography.  Hydrolysis of the ethyl ester with 20% potassium carbonate 
afforded Boc-protected statine 16 [59].   
 
Construction of the statine-containing peptide was subsequently carried out on 
solid phase for easy derivatization in future studies. Merrifield resin was selected as 
the solid support owing to its compatibility with Boc chemistry. Briefly, 16 was 
neutralized to its cesium salt with Cs2CO3 at pH 7 prior to loading onto Merrifield 
resin in the presence of a catalytic amount of iodine [37]. The reaction was slowly 
agitated at 50 oC overnight. The following two valine residues were coupled to the 
statine-functionalized resin 17 using standard solid-phase peptide synthesis protocols 
using Boc chemistry.  The lysine handle containing the fluorophore, Boc-Lys(Cy3)-
OH 12, was subsequently coupled at the N-terminus of the tripeptide.  The α-amino 
Boc protecting group was removed with neat TFA, and the photolabile diazirine 
moiety attached in the last step.  The final probe 21 was obtained following TFMSA-


















































































Scheme 3. Synthesis of affinity-based probes for aspartic proteases (a) (i) H2, Pd/C 
(cat), AcOH; (ii) Cy3-NHS 1, DIEA, DMF; (b) N,O-dimethylhydroxylamine 
hydrochloride, DCC, HOBt, DIEA, DMF; (c) LAH, THF, 0 oC; (d) ethyl acetate, 
LDA, THF, -78 oC; (e) 20% K2CO3, MeOH/H2O (2:1); (f) (i) 5, 2 M Cs2CO3, 
EtOH/H2O (4:1), pH 7; (ii) KI (cat), DMF, 50 oC; (g) (i) TFA; (ii) Boc-Val-OH, 
HBTU, HOBt, DIEA, DMF; (h) (i) TFA; (ii) 12, HBTU, HOBt, DIEA, DMF; (i) (i) 





2.2.3 Affinity-based Enzyme Labeling Experiments 
 
Pepsin (EC  3.4.23.1) was selected as the working aspartic protease in our 
enzyme labeling studies, since pepstatin, upon which our affinity-based probe was 
designed, is its naturally occurring inhibitor [52]. As the principle acid protease in the 
stomach, the active pH profile for pepsin ranges from pH 1-6, with optimum catalytic 
activity at pH 3.5 [60]. Being the first enzyme to be discovered, pepsin is the subject 
of a wide number of studies in terms of activity, structural and inhibitory properties. 
In our enzymatic studies, we use pepsin isolated from the porcine species, that 
consists of a single chain of 326 residues (34.6 kDa) [61].  
 
 Structural studies have shown that the prominent feature in the pepsin 
structure is a substrate-binding cleft that is capable of accommodating eight amino 
residues, and the catalytic residues, Asp 32 and Asp 215 [62]. Although pepsin 
exhibits a broad specificity for its substrate, the major substrate recognition centers 
are defined by the S1 and S1’ subsites which are specific for hydrophobic residues in 
the corresponding P1 and P1’ subsites [63]. The remaining six substrate binding sites 
are of comparatively less importance and pepsin is known to tolerate a wide spectrum 
of amino side chain residues at those positions [63b, 64]. 
 
2.2.3.1 Optimization of Conditions for Affinity-based Profiling of Aspartic 
Proteases 
 
 Owing to the difference in character and activity profile between the acid 
proteinases and the metalloproteases, we first optimized conditions for the affinity-
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based profiling of aspartic proteases prior to carrying out further mechanistic studies 
of enzymatic labeling. 
 
In the initial stage, we sought to ascertain a working pH to carry out the 
enzyme labeling studies as pepsin is active only under acidic conditions. 2 µL of 
pepsin stock solution (10 mg/mL) was added to buffers of pH 2 and 4, respectively, 
following which the probe 21 was added and the 20 µL mixtures were incubated for 
30 min at room temperature in the dark. Subsequently, the mixtures were irradiated at 
~360 nm for 20 min. The reactions were then quenched by boiling with 6 x SDS-
loading buffer and separated on SDS-PAGE gels. The extent of the enzyme labeling 
by the probe was subsequently investigated with a fluorescence gel scanner.  As 
shown in Fig. 14, strong labeling was obtained at both pH values with no discernible 
differences in labeling intensity. However, at pH 2, the acidity of the reaction mixture 
caused a color change in the SDS-loading dye. Henceforth, we carried out all further 
labeling studies at pH 4 unless otherwise stated such as to avoid destabilizing 
conditions during SDS-PAGE. 
 
pH       2         2        4         4   
 
Figure 14. pH dependent labeling: pepsin was labeled under different pH conditions. 
 
We next varied the concentrations of the probe 21 to determine the optimal 
probe concentration required for efficient and specific labeling of aspartic proteases. 
A series of experiments were set up whereby the amount of pepsin in each reaction 
mixture was maintained at 1 mg/mL while the concentration of 21 was varied: 
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increments in the pepsin labeling intensity were registered with a concurrent increase 
in the probe concentration.  Previously in our experiments with the metalloprotease 
probes, we had shown that using unnecessarily high concentrations of affinity-based 
probes typically gives rise to non-specific labeling.  It was determined that 5 µM of 
21 in our reaction gave the maximum labeling intensity of pepsin while minimizing 
background labeling (Fig. 15).    Control experiments were run whereby non-aspartic 
proteases (1 mg/mL) were labeled under the same conditions and negligible 
nonspecific labeling was detected (see Fig. 2, Appendix).  
 
[Probe]/µM       100       50       10       5      1.25      0.5    0.025  0.01      0  
 
 
Figure 15. Concentration dependent affinity-based labeling. 20 µg of pepsin was 
incubated with decreasing amounts of probe. The optimal concentration of probe for 
affinity-based labeling of aspartic proteases was determined to be 5 µM. 
 
We next varied the period of UV irradiation whereby following a half hour 
incubation, the reaction mixtures were exposed to UV irradiation for 0, 10, 20, 30, 40 
and 60 min respectively. Following a half-hour incubation of the probe 21 and the 
enzyme in the dark, the reaction mixture was exposed to near-UV irradiation for 0, 
10, 20, 30, 40 and 60 min, respectively (Fig. 16): in the absence of photolysis, no 
labeling was detected, reaffirming our earlier observations that the generation of the 
reactive carbene species in the probe by UV photolysis is essential for our affinity-
based labeling approach.  A concomitant increase in enzyme labeling intensity noted 
when UV irradiation time was increased from 10 to 20 min, and no discernible 
difference with further increases. We concluded the optimal period of irradiation in 
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our labeling reaction was 20 min, which was used for all subsequent experiments, 
unless otherwise stated. Our results are thus experimentally consistent with those 
from our previous photoaffinity labeling studies with thermolysin.  
 
Time/min       0           10        20        30        40        60 
 
 
Figure 16. The period of UV irradiation of pepsin-probe reaction mixture was varied 
from 0 to 60 min. 
 
2.2.3.2 Mechanistic Studies on Affinity-based Labeling of Pepsin 
 
 With the optimized labeling conditions, we carried out other mechanistic 
studies to confirm that the affinity labeling of pepsin by 21 depends on the enzyme’s 
native biological activity, and therefore may be used in activity-based profiling 
experiments. 
 
  Pepstatin is a known inhibitor of pepsin, which, upon addition to our labeling 
reaction, should inhibit the activity of pepsin and consequently its labeling by 21 as 
well.  As pepstatin and 21 are both reversible inhibitors of pepsin, the addition of 
pepstatin in the reaction mixture would create a competitive equilibrium between the 
two inhibitors and the enzyme. As such, we set up experiments where the 
concentrations of pepstatin were gradually increased while keeping other parameters 
such as amounts of pepsin and probe constant. At 15 µM, a three-fold excess of 
pepstatin, the amount was sufficient to completely suppress the affinity-based labeling 
of pepsin by 21 (Fig. 17). The sequestering of pepstatin in the active site of pepsin 
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prevents the probe from affinity-based binding in the same site. Subsequently, the 
carbenes generated from the unbound probes would be quenched by the buffer 
solution and would fail to elicit covalent labeling with the enzymes. The absence of 
background labeling serves to reiterate this phenomenon. 
 
[Pepstatin]/µM     150       75      37.5      15        7.5     3.75       0 
 
Figure 17. Competitive labeling experiments: varying amounts of pepstatin were 
incubated with pepsin and probe. 
 
Functional studies relating pepsin activity with native pH conditions have 
shown that the enzyme is irreversibly inactivated under alkaline conditions [65]. 
Pepsin is an acidic bi-lobed protein with an isoelectric point below that of 1.0 [66]. 
Denaturation of the enzyme occurs through the unraveling of the N-terminal lobe at 
alkaline pH due to ionizations of the acidic residues [65]. To ascertain that the active 
site conformation is essential for affinity docking of the probe, we carried out labeling 
studies of pepsin at pH 8. Negligible labeling was detected. Coomassie staining of the 
gel revealed that proteolytic digestion or cleavage of pepsin appeared to have taken 
place, with the absence of the protein band at ~35 kDa and the simultaneous 
occurrence of fragments of lower molecular weights (Lane 2, Fig. 18). The fragments 
did not appear to be labeled by the probe 21. The loss of structural integrity of the N-
terminal lobe of pepsin translates into the collapse of the active site conformation 
since the substrate binding site is situated between the two lobes. The probe will no 
longer bind to the enzyme and hence no covalent labeling occurs and the probes 
remain unbound in solution. The correlation between the loss of functional activity 
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and the concomitant absence in enzymatic labeling thus suggests that our affinity-
based approach is in fact dependent upon the functional activity of the enzyme. 
 
     1        2  M      1       2  
 
75 kDa  
 
 
25 kDa  
 
Figure 18. Inactivation of pepsin under alkaline conditions. Left panel: fluorescence 
image; right panel: Coomassie stain image. Lanes: (M) fluorescent protein marker; (1) 
pH 4 (control); (2) pH 8. 
 
2.2.3.3 Affinity-based Labeling of Other Aspartic Proteases 
 
 We sought further confirmation of the feasibility of our affinity-based 
profiling strategy by extending the approach to the labeling of other aspartic 
proteases.  Cathepsin D (EC 3.4.23.5) and mucorpepsin (EC 3.4.23.23) were obtained 
from commercial sources.  These enzymes possess a similar catalytic mechanism as 
pepsin [25] and exhibit optimum enzymatic activity in the pH range of 3.5 to 5 [67, 
68]. They also display similar substrate specificity as pepsin, favouring hydrophobic 
residues in the P1-P1’ positions [69, 70].  Labeling studies of cathepsin D and 
mucorpepsin were carried out at pH 4 (Fig. 19): all three proteases were 
unambiguously labeled by our probe, consistent with our expectation that broad-based 
affinity probes such as 21 may serve as general reagents to profile a wide range of 
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aspartic proteases in an activity-dependent manner.  Noted also in Fig. 19 (lane 3) 
that, despite the same amounts of proteins used, the labeling of mucorpepsin was 
comparatively fainter than the other aspartic proteases, indicating that the enzyme 
may be less active catalytically.    
 
75 kDa 








Figure 19. Enzymatic labeling of aspartic proteases (arrows indicate labeled enzymes) 
– Lanes (M) fluorescent protein marker; (1) pepsin, pH 4; (2) cathepsin D, pH 4; (3) 
mucorpepsin, pH 4. 
  
2.2.3.4 Affinity-based Profiling of Aspartic Proteases in Crude Cell Extracts 
 
Having validated that our affinity-based approach was able to label aspartic 
proteases in an activity-based fashion, we next sought to determine whether it could 
be used in a proteomic experiment where the target enzymes (i.e. aspartic proteases) 
could be selectively labeled and identified in the presence of other proteins.  In order 
to do so, we spiked increasing amounts of pepsin (0 to 1.5 mg/mL) in a crude yeast 
extract containing 5 mg/mL of endogenous cellular proteins and subsequently labeled 
the extracts with our probe, 21, as earlier described (Fig. 20). Indeed, pepsin was 
unambiguously labeled from the yeast extract, with an estimated detection limit of as 
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low as 0.25 mg/mL (5% of total proteins in the extract).  The selectivity of the probe 
for pepsin lays the framework for eventual large-scale functional profiling of aspartic 
proteases in a complex proteome, where the enzymes may be captured in crude cell 
lysates by the statine-based probes without the need for extensive purification. 
 
M            1       2       3       4        5  1       2      3       4       5 
 
 75 kDa 
 
 25 kDa 
 
 
Figure 20. Labeling studies of increasing amounts of pepsin spiked in 10 µL of crude 
yeast extracts (5 mg/mL), left panel: fluorescence scanning, right panel: Coomassie 
stain – Lanes (M) fluorescent protein marker; (1) 1.5 mg/mL pepsin; (2) 1 mg/mL 




 In summary, we have successfully designed and synthesized an affinity-based 
probe which may be used for the potential proteomic profiling of aspartic proteases.  
A solid-phase synthetic strategy was developed for the convenient synthesis of this 
probe, and in future, other analogous probes.  We have established optimal conditions 
for the selective labeling of aspartic proteases over other proteins, with which the 
degree of labeling reflects the relative enzymatic activity.    Competitive inhibition 
studies, as well as pH-dependent studies, clearly demonstrated the affinity-based 
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strategy is a good complement to existing activity-based profiling approaches [10], in 
that it is also suitable to indirectly profile specific subsets of enzymatic activities.  
Equally important, we have shown that the strategy may be used to selectively label 
aspartic proteases in the presence of a large excess of other endogenous proteins, thus 
rendering it useful for future proteome profiling experiments.  Given the clinical 
importance of aspartic proteases in diseases such as malaria and AIDS [27b], it will 
become incessantly crucial to selectively profile these enzymes from a mixture of 
proteins extracted from pathological samples. The ability of the statine-based probes 
to specifically label the desired targets with negligible background promises to push 
affinity-based proteomic profiling for the development of diagnostic assay kits for the 











 The success of the affinity-based profiling strategy was demonstrated with the 
design and development of photoactivable group-tagged tripeptidyl hydroxamates and 
statine probes for metalloproteases and aspartic proteases, respectively. The key 
element of our alternative chemical proteomics strategy lies in the selection of the 
affinity-based unit of the probe. In general, enzymes belonging to the same class 
exhibit varying degrees of specificity for a given small molecule inhibitor. The 
identification of a tight-binding affinity unit for the desired enzymatic target requires 
a strategy akin to that of the drug discovery process. 
 
 The traditional medicinal chemistry approach typically involves methodically 
screening pools of available biologically-active small molecules against the target 
enzyme, although means such as structure-based methods [13d] and in silico 
chemistry [13e,f] have been gradually gaining ground. In recent years, the rapid 
development of diversity-oriented synthesis strategies has revolutionalized medicinal 
chemistry by opening up ways of generating structurally complex and diverse 
skeletons from simple building blocks. We thus aim to expedite the process of 
generating lead compounds, to accelerate the development of the affinity-based 
proteomic profiling strategy since the elemental affinity units are typically derived 
from known potent enzyme inhibitors. 
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 The report that the active site of the enzyme acetylcholinesterase (AChE) can 
be used as the in situ assembly site of its own femtomolar inhibitor from pairs of 
building blocks, promises to accelerate the small molecule screening process in drug 
discovery [19a]. False positives are anticipated to be fairly rare as the enzyme only 
sequesters the blocks with which it has highest affinity for. The rate of ligation 
between the starting components is thus enhanced through proximity effects. 
However the approach reported by Lewis et al is hampered by the tedious process of 
product screening [19a]. We envisaged a scenario whereby a biological target may be 
used to selectively amplify the self-assembly of its most potent inhibitor from a 
library of building block components in an approach similar to that of dynamic 
combinatorial chemistry [15] (Fig. 2B). In an ideal situation, the application of our 
strategy to multicomponent reactions would allow the selection of a preferred scaffold 
from a number of diverse skeletal structures through the stabilization of the chemical 
ligands with the enzyme active site. Tactically, we adopt a preliminary approach to 
verify the feasibility of our proposed strategy through its application to a two-
component reaction system. 
 
3.1.1 Target-driven Selective Self-assembly of Inhibitors  
 
 The basic prerequisites in the selection of a suitable biological system for the 
demonstration of our strategy are: (1) the enzyme should be readily available, either 
commercially or through recombinant procedures, and (2) the substrate should be  




 Earlier on, we have discussed the compatibility of the “cream of the crop” 
click chemistry reaction, the 1,3-dipolar cycloaddition between azides and acetylenes 
[71], under physiological conditions [21]. The resultant 1,2,3-triazole product displays 
similar physicochemical properties with an amide bond and exhibits comparatively 
higher stability owing to the greater number of donor sites for extensive hydrogen-
bond interaction with the active site. The development of click chemistry has 
prompted the Huisgen azide-alkyne coupling reaction to be applied to a vast number 
of biological systems. Asides from the in situ assembly of acetylcholinesterase 
inhibitors [19a], click chemistry has been adapted for high fidelity bioconjugation 
[72] and in vivo activity-based profiling of proteome mixtures [73]. Lately, one novel 
approach has seen the use of the cycloaddition reaction in the diversity-oriented 
synthesis of enzyme inhibitors in microtiter plates, followed by in situ assay without 
product isolation [74].  
 
3.1.2 HIV-1 Protease and Amprenavir 
 
 Recently, UNAIDS have reported that, as of end 2003, HIV infection rates 
have reached epidemic proportions with an estimated total of 38 million people 
infected worldwide [75]. HIV is the causative agent of AIDS, which manifests itself 
clinically through suppression of the immune system. There is, as of today, no 
definitive cure for AIDS and most patients die within 10-20 years of HIV infection. 
 
 HIV is classified as a retrovirus, which carry RNA rather than DNA as genetic 
information as [76]. The earliest therapeutic efforts against AIDS disrupts the 
retrovirus lifecycle through a class of drugs that inhibit the enzyme reverse 
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transcriptase, thereby preventing the reverse transcription of RNA into viral DNA 
[77].  A second critical phase in the HIV lifecycle is the proteolytic processing of the 
gag and gag-pol polyproteins into mature enzymes and structural proteins by the 
HIV-1 protease, essential for maturation and infectivity of the virus [78]. The HIV-1 
protease is thus rendered as the second promising enzymatic target for retroviral 
therapy. 
 
 Probably the most studied enzyme in history owing to its ramifications in the 
world health crisis, HIV-1 protease was found to have aspartic protease characteristics 
due to the signature hallmark DTG sequence encoded in the genome [79]. Subsequent 
studies revealed that the enzyme assumes a homodimeric form with a C2 symmetry, 
made up of two chains of polypeptides containing 99 amino acid residues each [80]. 
The catalytic machinery is provided by an aspartic acid from each contributing 
polypeptide chain in a feature similar to the eukaryotic aspartic proteases, and hence, 
HIV-1 protease is only functionally active as a dimer.  
 
 As an aspartic protease, the HIV-1 protease catalyzes the hydrolysis of amide 
bonds through an activated water molecule bound to the catalytically active Asp 25 
and Asp 25’ residues [77].  The aspartic acid residues function as general acid and 
base which facilitate the nucleophilic attack of water on the scissile peptide bond, 
resulting in a tetrahedral intermediate. There is a total of eight proteolytic processing 
sites in the gag and gag-pol polypeptides (summarized in table 2) with a wide range 
of amino acid side chains in the substrates [81]. Hence HIV-1 protease has no precise 
substrate specificity, though generally the enzyme favours (a) hydrophobic side 
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chains at the P1 and P1’ positions, but not β-branched at P1; (b) hydrophobic and β-
branched residues at P2 position; (c) hydrophobic or anionic residues at P2’ position. 
 
 Processing Sitesa Polyprotein Sequenceb
1 p17-p24 SQNY|PIVQ 
2 p24-p1 ARVL|AEAM 
3 (p24-p1)-p9 ATIM|MQRG 
4 p9-p6 PGNF|LQSR 
5 TF-PR SFNF|PQIT 
6 PR-RT TLNF|PISP 
7 RT-RN AETF|YVDG 
8 (RT-RN)-IN RKIL|FLDP 
 
Table 2. Summary of processing sites in the gag and gag-pol polyproteins. aMA or 
p17, matrix protein; CA or p24, capsid protein; NC or p9, nucleocapsid protein; TF, 
transmembrane protein; RT, reverse transcriptase; RN, ribonuclease; IN, integrase. b| 
denotes site of proteolytic cleavage. 
  
 Low molecular weight inhibitors for the HIV-1 protease have been designed 
based on pepstatin, a general inhibitor of aspartic proteases, which has been found to 
exhibit inhibitory properties against the retrovirus [82]. Of the isosteric transition state 
analogs derived from pepstatin, the hydroxyethylamine core displays the highest 
potency against HIV-1 protease [83]. A stereochemical feature that distinguishes the 
hydroxyethylamine moiety from other aspartic protease inhibitors is the R chirality of 
the hydroxyl-bearing carbon. At present, three out of the six HIV-1 protease inhibitors 
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in current clinical use contain the hydroxyethylamine isostere, namely Amprenavir, 
Saquinavir and Nelfinavir [77]. 
 
 More recently, nanomolar inhibitors of the HIV-1 (Human Immunodefiency 
Virus – Type 1) protease, an aspartic protease, have been identified with a microtiter 
plate screening assay protocol [74b]. The inhibitors which exhibit the highest potency 
against the enzyme are constructed from an azide core bearing the P1, P1’ and P2’ 
residues, derived from the molecular scaffold of Amprenavir, as well as, a 
corresponding aryl ring-containing alkyne moiety. Amprenavir is based on a 
hydroxyethylamine core that functions as the transition state analog of the tetrahedral 
intermediate generated during the catalytic hydrolysis of the substrate [84]. In nature, 
an enzyme selects the tightest-binding transition state, which may not necessarily 
translate into the product with the tightest fit [17]. Hence the use of transition state 
analogs potentially addresses one of the major concerns of target-driven substrate 
assembly. More importantly, the synthetic strategy for the chemical synthesis of the 
azide core, as outlined in Scheme 4, suggests that the product can be afforded readily 
from easily available starting materials such as Boc-protected amino acids, with a 
number of positions for convenient derivatization in future studies. We thus selected 
the HIV-1 protease together with its triazole-linked Amprenavir-based substrates for 
validation of our target-driven self-assembly concept. 
 
 Developed through structure-based design concepts, Amprenavir contains the 
unique N,N-disubstituted sulfonamide functionality and exhibits a high potency of Ki 
= 0.60 nM against the HIV-1 protease [84]. Consequently, the azide core analog 
derived from Amprenavir by Brik et al in their diversity-oriented microtiter plate 
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assay effects tight-binding interactions with the target enzyme [74b]. The azide core 
bears the following residues designed to fit into the corresponding enzymatic site: P1 
– Phe; P1’ – Leu; P2’ (methoxy arylsulfonamide), while the P2 position is provided by 
the aromatic ring-containing acetylene moiety.  
 
 Based on the specificity requirements of the HIV-1 protease, we propose the 
synthesis of a number of azide cores based on varying P1 positions, using a variety of 
hydrophobic amino acid residues: Phe (as originally used), Leu (γ-branched); Val (β-
branched) and Ala (unbranched). The latter two cores serve as negative controls. 
Variation at the P2 positions will be afforded from four different aryl-bearing 
compounds decorated with the acetylene moiety. 
 
3.2 Expression and Purification of Recombinant HIV-1 Protease 
  
 Owing to the biological implications of the HIV-1 protease in the lifecycle of 
the retrovirus, there have been wide numbers of studies pertaining to the large-scale 
recombinant expression of the protease in a variety of expression hosts since the 
endogenous amount of enzyme expressed in the virus is too miniscule for analysis and 
there is a danger associated with the large-scale production of the HIV virus [85]. The 
HIV-1 protease required in the validation of our strategy can thus be obtained 
conveniently through expression of the recombinant protein in E. coli. The enzyme is 
produced mostly as inclusion bodies in bacterial hosts due to its cytotoxic effect on 
the cells. The inclusion bodies are harvested and denatured prior to purification and 
subsequently, the enzyme is refolded with full recovery of catalytic activity.  
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The expression vector for HIV-1 protease, bearing the triple mutation 
Q7K/L33I/L63I for stability against autolysis, is a generous gift from Dr. John. M. 
Louis (National Institutes of Health, Bethesda, USA). The vector was transformed 
into chemically competent BL21(AI) cells, which were then plated on LB+Amp agar 
media overnight. The E. coli colonies obtained were used for subsequent expression 
studies. 
 
3.2.1 Small-scale Expression of HIV-1 Protease 
 
 Our initial approach was to ascertain the optimal conditions for the expression 
of the HIV-1 protease. Small-scale expression studies were carried out where the 
conditions varied were the temperature of incubation, the length of incubation and the 
concentration of arabinose used for induction of expression. Briefly, a single colony 
was innoculated in LB-Amp media overnight. The culture was then diluted 100-fold 
and allowed to grow to OD600 of 0.5. 16 aliquots of 1 mL of cell culture were 
prepared and different amounts of arabinose (0, 0.2, 0.6 and 1.0%) were added to 
induce the expression of the HIV-1 protease. The cultures were incubated for different 
lengths of time (4 hrs or overnight) at varying temperatures (4 oC, room temperature, 
30 oC and 37 oC). The samples were then prepared for SDS-PAGE analysis. HIV-1 
protease was visualized as a protein band in the 11 kDa range. The results of the 
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Figure 21. Optimization of conditions used for small-scale expression of HIV-1 
protease (indicated by box). (A) 37 oC, 4 h; (B) 30 oC, 4 h; (C) room temperature, 
overnight; (D) 4 oC, overnight. Lanes (1) 0% arabinose (uninduced); (2) 0.2% 
arabinose; (3) 0.6% arabinose; (4) 1.0% arabinose. 
 
At 4 oC, the growth rate of the bacterial cells was too low for any significant 
amount of HIV-1 protease to be expressed. Incubations of the cell culture for 4 h at 37 
oC and overnight at room temperature produced higher levels of expression than 
incubation at 30 oC for 4 h. In all four sets of experiments, the amount of arabinose 
added had no apparent effect. Subsequently, unless otherwise stated, induction of 
HIV-1 protease expression in E. coli hosts was carried out overnight at room 
temperature, with the addition of 0.2% arabinose. 
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3.2.2 Large-scale Expression and Purification of HIV-1 Protease 
 
 Large-scale expression of the HIV-1 protease was carried out using the 
optimal conditions determined previously. Briefly, an overnight inoculation of a 
single colony of bacteria in LB media was diluted 100-fold into 800 mL of cell 
culture. The culture was grown to OD600 of 0.5 and expression of the protein was 
induced overnight at room temperatures in the presence of 0.2% arabinose, with 
agitation at 200 rpm. 










Figure 22. Large-scale expression of HIV-1 protease (indicated by slanted arrow). 
Lanes (M) protein marker; (1) uninduced cell culture; (2) induction of protein 
expression using 0.2% arabinose. 
 
 The cells were collected as pellets by centrifugation of the culture. A lysis 
buffer was added to the pellets to break open the bacterial cell walls, with the aid of 
lysozyme to ensure complete digestion of peptidoglycans and other outer membrane 
protein contaminants. HIV-1 protease was expressed as insoluble inclusion bodies and 
extracted from the cells as a pellet by centrifugation. 
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  Purification of the HIV-1 protease was effected through gel filtration 
chromatography. The inclusion bodies were first solubilized in 50% acetic acid and 
subjected to ultra centrifugation to remove any insoluble particles. The supernatant 
containing the enzyme was then applied to a pre-packed column of Sephacryl S-100 
HR beads (MW range: 1,000 – 100,000) pre-equilibrated with elution buffer (50% 
acetic acid with 1 mM DTT). Elution was carried out for a period of 4 h whereby the 
elution buffer was continuously applied to the column at a constant flow-rate of ~0.6 
mL/min. UV absorbance at 280 nm were measured for each fraction collected and 
charted against the total volume of eluent collected (see Graph 1). Chromatography of 















Graph 1. Graph of UV absorbance at 280 nm against the volume eluted. The two 
peaks indicate protein-containing fractions. 
 
 Small amounts (~0.2 mL) from each protein-containing fraction were removed 
for SDS-PAGE analysis to determine the presence and purity of HIV-1 protease. 
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However the samples cannot be prepared directly for SDS-PAGE as the acidity of the 
solutions resulting from 50 % acetic acid caused broad smearing of the protein bands 
during gel electrophoresis. Dialysis of the samples had to be first carried out to 
remove all traces of the acidic medium. The solutions were individually injected into 
dialysis cassettes and dialyzed against deionized water.  Following which, the samples 
were lyophilized and analyzed by SDS-PAGE. Quantitation of protein expression 
level was obtained by Coomassie staining. As seen in Fig. 23, the first and higher 
peak was found to be heavily contaminated with endogenous bacterial proteins, 
containing relatively little HIV-1 protease. On the other hand, the second peak 
consisted of acceptably pure amounts of HIV-1 protease. Consequently, all fractions 
corresponding to the second elution peak were pooled and the protein refolded. 









Figure 23. SDS-PAGE analysis of eluted fractions following small-scale dialysis 
(slanted arrow depicts HIV-1 protease). Lanes (M) protein marker; (1-3) first elution 
peak; (4-5) second elution peak. 
 
 Prior to refolding, the HIV-1 protease was first dialyzed against 50 mM of 
formic acid at 4 oC to ensure complete denaturation and unfolding of the protein. The 
protein was then refolded via dialysis against a buffer that consists of 100 mM sodium 
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acetate (pH 5.0), 1 mM DTT, 1 mM EDTA and 0.05% Triton X-100. The solution 
was then dialyzed against deionized water to remove all traces of salt and lyophilized 
to yield HIV-1 protease as a fine white powder. As can be seen from Fig. 24, SDS-
PAGE analysis of the purified protein sample demonstrated the presence of a 
predominant band at 11 kDa corresponding to the HIV-1 protease, with slight 
contamination from heavier molecular weight proteins. 









Figure 24. SDS-PAGE analysis of purified protein (indicated by slanted arrow). Lanes 
(M) protein marker; (1) purified and refolded HIV-1 protease; (2) uninduced crude 
cell lysate. 
 
3.2.3 Validation of Catalytic Activity of Refolded HIV-1 Protease 
 
 Although it was reported that the renaturation of the protein from the above-
mentioned method is more than 95 % efficient, we sought to validate the activity of 




3.2.3.1 Circular Dichroism (CD) Spectrum Analysis of Renatured HIV-1 
Protease 
 
 The circular dichroism (CD) spectrum was recorded with a 100 µM solution 
of the refolded HIV-1 protease in the range 260-200 nm (Graph 2). The CD profile 
obtained, with the local minimal at 215 nm, is a reflection of a protein that 
predominantly consists of secondary β-sheet structures, corresponding with that of 





















Graph 2. Far-UV CD spectrum of refolded HIV-1 protease. 
 
3.2.3.2 Affinity-based Labeling of HIV-1 Protease 
 
 Based on our mechanistic studies carried out previously on the affinity-based 
profiling strategy, we have determined that enzymes lacking functional catalytic 
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activity cannot be labeled by the respective photolabile probes. Hence, the application 
of our statine-derived probe, TFMPD-K(Cy3)-VVSta-OH 21, to the HIV-1 protease 
would display an accurate profile of the catalytic activity of the enzyme. As before, a 
20 µL reaction containing the enzyme (1 mg/mL) and the probe (5 µM) in Tris.HCl 
buffer (50 mM, pH 5) was incubated in the dark for 30 min. The reaction was then 
subjected to 20 min photolysis at ~360 nm, and prepared for SDS-PAGE analysis. 
Fluorescence scanning allowed visualization of the strong labeling of the HIV-1 
protease by 21, as can be seen from Fig. 25 (Lane 1), reaffirming the functional 
activity of the HIV-1 protease.  pH activity profiling from previous studies have 
determined that optimal catalytic function of the HIV-1 protease lies at pH 5. We 
attempted affinity-based labeling of enzyme at alkaline pH, and found that there was 
no loss in labeling strength (Lane 2). In a further validation that labeling of HIV-1 
protease is in fact dependent upon its activity, pepstatin, a general reversible inhibitor 
of aspartic proteases, was simultaneously incubated in the presence of the probe and 
the enzyme (Lane 3). We note a decrease in labeling intensity as the pepstatin and 
probe set up a competitive reaction, thereby preventing the affinity-based probe from 
forming tight-binding interactions with the active site. 
 
 Hence with the extension of our alternative chemical proteomics strategy to 
the functional characterization of HIV-1 protease, our affinity-based profiling strategy 
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Figure 25. Affinity-based labeling of HIV-1 protease. (A) Fluorescence scanning; (B) 
Coomassie stain. Lanes (FM) fluorescent protein marker; (1) pH 5; (2) pH 8; (3) pH 




 The HIV-1 protease was obtained through recombinant expression in E. coli 
hosts as insoluble inclusion bodies, which were harvested from the cells and subjected 
to gel filtration purification. Fractions containingly relatively pure HIV-1 protease 
were pooled and refolded, allowing the yield of 12 mg/L cell culture of protein. 
Renaturation of the enzyme was effected with recovery of enzymatic activity, as per 






3.3 Chemical Synthesis of Azide and Alkyne Cores 
 
 The synthesis of the four azide and four acetylene cores were obtained as 
outlined in Schemes 4 and 5. These cores were subsequently used as in our 
preliminary investigation of the viability of using the HIV-1 protease to self-assemble 
its own inhibitor from a mixture of starting components. 
 
 The azide cores used by Brik et al in their diversity-oriented microtiter plate 
screening assay concept displayed R stereochemistry at the hydroxyl-bearing carbon 
(C2) [74b]. In our bid to develop an expedient synthesis for a library of analogs 
bearing different side chains at the P1 positions, we opt to synthesize the final azido-
containing core as a mixture of diastereomers (2RS,3S), with room for derivatization 
in further studies, rather than to carry out diastereoselective synthesis to obtain the 
(2R,3S) desired stereochemical conformation.  
 
 In our synthetic approach, the carboxylic acid functionality in the 
commercially available starting materials, Boc-protected L-amino acids, were reduced 
to aldehydes 14, via the N,O-dimethylhydroxamate intermediates 13, as described 
earlier [57]. Wittig olefination of the aldehyde was then carried out as reported [86], 
where the methyl triphenylphosphonium ylide was generated in the presence of a 
base, potassium hexamethyldisilazane (KHMDS), and added to a solution of the 
aldehyde at –78 oC. Subsequently, the reaction was heated at 40 oC overnight and the 
terminal alkenes 22 were afforded following chromatography. The olefins were 
epoxidized in the presence of MCPBA [86], with the resultant formation of both threo 
and erythreo diastereomers 23. The desired (2R,3S) diastereomers were afforded as 
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the minor products, consistent with past reports. Ring-opening of the epoxides 23 
were effected through the nucleophilic attack of isobutylamine on the less hindered 
side, to afford the secondary amines 24, substituted with a leucine-like side chain 
[87]. Diastereomeric mixtures of the sulfonamides 25 were obtained via a SN2 
substitution reaction between 24 and p-methoxy benzenesulfonyl chloride in the 
presence of triethylamine [88]. The t-butoxylcarbonyl protecting group was then 
removed with 4 M HCl/dioxane and used directly in the following step without prior 
purification. The diazo transfer reaction was accomplished using triflyl azide, TfN3 
(generated from a reaction between sodium azide and triflic anhydride in a biphasic 
mixture of DCM and water), in the presence of potassium carbonate and a catalytic 
amount of Cu2+, to afford the azide core 26 [89]. In all the steps, the (2RS,3S) 
diastereomers afforded were of similar polarity and thus, cannot be efficiently 
separated by column chromatography. Using the prescribed procedure, four azide 
cores were prepared from the respective Boc-amino acids: phenylalanine 26a, leucine 
26b, valine 26c and alanine 26d. 
 
 The alkyne cores were conveniently synthesized from a series of aromatic-ring 
bearing carboxylic acids, namely Boc-(4-amino)-methylbenzoic acid 27, Boc-Phe-
OH, isonicotinic acid and benzoic acid. DCC/HOBt mediated peptide coupling 
between the carboxylic acids and propargyl amine afforded the alkyne cores 28-31. 
 
 The diastereomeric ratios determined from the 1H NMR spectra of the 
epoxides 23, as well as, the yields of the four azide and four alkyne cores are 
summarized in Tables 3 and 4, respectively. 
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Azides Yield/% Alkynes Yield/% 
26a 8 28 32 
26b 20 29 78 
























































a: R = Phe
b: R = Leu
c: R = Val





Scheme 4. Synthetic strategy for the synthesis of the azide cores. (a) DCC, HOBt, 
N,O-dimethylhydroxylamine hydrochloride, DIEA, DMF; (b) lithium aluminium 
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hydride, THF, 0 oC; (c) methyl triphenylphosphonium bromide, KHMDS, THF, 40 
oC; (d) MCPBA, DCM; (e) isobutylamine, MeOH, 50 oC; (f) p-methoxy 
benzenesulfonyl chloride, TEA, DCM; (g) (i) 4 M HCl/dioxane; (ii) Tf2O, NaN3, 







































Scheme 5. Synthetic strategy for the synthesis of the alkyne cores. (a) di(t-
butoxylcarbonyl) carbonate, NaOH, dioxane/water (2:1); (b) propargyl amine, DCC, 
HOBt, DMF. 
 
3.4 Target-driven Selective Self-assembly of HIV-1 Protease Inhibitors 
  
 In the previous report where femtomolar acetylcholinesterase inhibitors were 
assembled in situ using the active site of the enzyme as a reaction vessel, 98 pairs of 
azides and alkynes were mixed and screened individually [19a]. In order to expedite 
the screening and assay process, we are keen to investigate the viability of using a 
biological target to amplify its most potent inhibitors from a pool of starting 
components. Successful validation of this will potentially allow strategies such as the 
multicomponent reaction, which enables the construction of a huge number of 
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complex and structurally diverse skeletons in a one-pot process, to accelerate the drug 
discovery process.  
 
 With the purified HIV-1 protease obtained from recombinant expression in E. 
coli as the biological target, and the azide and acetylene-bearing starting components, 
we sought to determine the feasibility of our concept. The HIV-1 protease is an ideal 
candidate as (1) its compatibility to the click chemistry reaction has been previously 
verified, with no debilitating effects even in high concentrations of t-butyl 
alcohol/water [74b]; (2) the Amprenavir derived cores are transition-state analogs 
which mimic the tetrahedral intermediate generated in the course of the catalytic 
hydrolytic action on the peptide substrate; (3) the product of the azide-alkyne 
coupling reaction is a nanomolar inhibitor of the HIV-1 protease owing to the tight-fit 
docking of the substrate in the corresponding enzymatic subsites. 
 
3.4.1 Devising an Experimental Set-up 
 
 Recent work pertaining to Huisgen’s 1,3-dipolar cycloaddition of azides and 
alkynes has found that the rate of reaction can be dramatically enhanced by the 
addition of the Cu(I) catalyst. By itself, the ligation reaction between the two 
functionalities takes approximately 40 years to reach 80 % completion [19a]; in the 
presence of a catalytic amount (0.25-2 mol %) of Cu(I), the 1,2,3-triazole product is 
obtained within 6-36 h [90]. A further favorable factor conferred by the copper-
catalyzed reaction is that the 1,4-disubstituted triazole is regioselectively generated in 
lieu of the 1:1 ratio of the 1,4:1,5 product (Scheme 6) [90].  
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Scheme 6. 1,4- and 1,5-disubstituted 1,2,3-triazole regioisomers. 
 
In the afore-mentioned microtiter plate screening strategy, all the azides and 
alkynes were assembled in the presence of a catalytic 3 mol % of Cu(I) such that only 
one structural isomer is selectively produced for enzymatic assay with the HIV-1 
protease [74b]. Interestingly, when acetylcholinesterase is used to template the 
cycloaddition without the influence of a catalyst, the assembly of the 1,5-disubstituted 
triazole-linked inhibitor was, instead, found to be amplified [19a]. Hence, we 
conceived of two plausible scenarios in the implementation of our concept: (1) in the 
presence of the Cu(I) catalyst, all possible products are assembled from the starting 
components, however, amplification of the most potent inhibitor will occur owing to 
stabilization of the chemical ligand with the biological target; (2) the enzyme is used 
as the sole catalyst by sequestering the starting components with the tightest fit in the 
enzymatic site, thereby enhancing the rate of azide-alkyne coupling due to proximity 
effects. 
 
At this stage, it is impossible to mix all four azide and four alkyne cores 
simultaneously, particular in view of the fact that the azides were prepared as 
diastereomeric mixtures. Potentially, a library of 4 x 4 x 2 = 32 products would be 
generated. Herein, we opted instead to set up four different experiments whereby a 
limiting amount of each azide is incubated with equimolar excesses of all four alkynes 
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in the presence of the purified HIV-1 protease. The conditions investigated are the 
length of incubation and the effect of the Cu(I) catalyst. Briefly, 1 µL of an azide core 
(10 mM, t-BuOH) and 1 µL each of the four alkyne cores (10 mM, t-BuOH) were 
dissolved in a buffer solution (2 mM Tris.HCl, pH 6.4). The HIV-1 protease (1 
mg/mL) and Cu(I), generated in situ through a disproportionation reaction between 
Cu(II) (3 mol %) and copper powder, were added where required. The reaction 
mixtures were made up to a final volume of 100 µL, such that the final concentration 
of each starting component is ~100 µM, and agitated slowly at room temperature. 
Analysis of the reactions was carried out by RP-HPLC after two days and six days. 
The details of the experimental set-up are summarized below in Table 5. 
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Reactiona
1 µL Azide 26 (10 
mM) 
4 x 1 µL Alkynes 28-31 
(10 mM)/µL 
10 µL HIV-1 protease (1 
mg/mL) 
Cu(0)/Cu(II) 
Tris (2 mM, pH 
6.4)/µL 
2 days 
X1      
      
      
      
      
+ + - - 95
X2 + + - + 95
X3 + + + + 85
X4 + + + - 85
6 days 
X5 + + + - 85
76 
Table 5. Summary of conditions used for the assembly of enzymatic inhibitors using HIV-1 protease as the target. aX denotes amino acid 
derivative of the azide core: F 26a, L 26b, V 26c and A 26d. 
 
3.4.2 RP-HPLC Analysis Results 
 
 Reverse phase-HPLC was used as the main mode of analysis. In a typical set-
up, ~25 µL of the desired solutions were separated on the C18 column, and eluted 
with solvent gradients consisting of mixtures of eluent A (0.1 % TFA/acetonitrile) 
and eluent B (0.1 % TFA/water). Prior to the experimental set up, 100 µM solutions 
of each individual component were prepared and analyzed separately to determine the 
purity and the optimal elution gradients. We obtained verification of the high purity of 
the azides 26 and the alkynes 28-31, as well as, ascertained that elution conditions of 
either 30-100 % acetonitrile or 40-100 % acetonitrile in 30 min afforded excellent 
resolution of each core without peak overlap. The diastereomeric pairs of the azides 
can also be visualized, with the more polar (2S,3S) diastereomer product constituting 
the major azide peak, albeit with poorer resolution.  These conditions were used for 
all subsequent analysis unless otherwise stated (see Appendix for HPLC traces). 
 
 Previously, Brik et al reported the formation of a nanomolar inhibitor (Ki = 4 
nM) of HIV-1 protease when the phenylalanine-derived azide core 26a was “clicked” 
together with the alkyne 28 [74b]. Hence we expect the most dramatic results with the 
F1-5 set of experiment, where the peaks corresponding 26a and 28 diminish 
significantly in the presence of the enzyme. A cursory examination of the HPLC 
traces of reactions F2 and F3, which contain catalytic amounts of Cu(I), after a two-
day incubation period, showed the consumption of all the azide, consistent with the 
limiting effect of 26a (Fig. 26). The alkynes peaks, too, exhibited diminished profiles 
with no alkyne particularly favored or disfavored under the influence of the enzyme. 
Attempts to separate the product peaks found near RT 2-3 min by the use of a more 
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polar elution gradient (0-50 % acetonitrile, 30 min) proved futile as the elution 
conditions failed to give definitive peaks, possibly due to the myriad of eight 
plausible triazoles formed as catalyzed by Cu(I). Similar phenomena were observed in 
other three sets of experiments, L2-3, V2-3 and A2-3 (see Appendix).  With HIV-1 
protease as the sole influence on the outcome of the reaction (reaction F4), 
considerable consumption of the azide occurred after a two-day period, with further 
diminishing of the azide peak after six days (reaction F5), relative to the control F1. 
We attempted the experiments with the other three azide cores 26b-26d under the 
same conditions and found a widespread depletion of the starting components after 
the six-day incubation period. It should be noted that due to the baseline drift, it is 
difficult to quantify the peaks by integration, and thus at this stage, we are able to 
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Figure 26. RP-HPLC traces of reaction mixtures (A) F1 and (B) F4, at 254 nm, 
elution conditions 30-100 % acetonitrile, 30 min. a29 can only be detected at 214 nm. 
 
 Overall, the presence of the HIV-1 protease in the reaction mixture resulted in 
the pronounced depletion of the azide cores, thereby demonstrating the ability of the 
enzyme to serve as a reaction vessel. The sequestering of the azide and acetylene 
starting components in the active site brought the respective functionalities into close 
proximity, resulting in an acceleration of the reaction rate (Fig. 27). However, the 
ability of the HIV-1 protease to assemble products from the Val-based azide core 26c 
is somewhat surprising, particularly as from previous substrate specificity studies, the 
enzyme is known to disfavor β-branched hydrophobic residues in the P1 position, 
which, in this instance, is occupied by the isopropyl valine side chain. The HIV-1 
protease typically exhibits higher selectivity for R stereochemistry at the C2 carbon, 
which is an unique feature amongst the aspartic protease family. Thus, ideally, we 
should detect the consumption of the less polar (2R,3S) diastereomer, with negligible 
effect on the more polar diastereomer, yet, in our HPLC traces, we observe depletion 










Figure 27. Schematic illustration of the target-driven selective self-assembly of 
inhibitors concept: (i) the basic building blocks decorated with azide and alkyne 
moieties were incubated in the presence of the HIV-1 protease target; (ii) the azide 
and alkyne cores with the highest binding affinity are sequestered in the active site of 
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the enzyme and proximity effects will result in the acceleration of the formation of the 
ligated 1,2,3-triazole product. 
 
 The enzyme did not appear to exude any overall dramatic effect on the 
alkynes with selective enhancement or diminishing of any alkyne. We attributed this 
to the number of substrate recognition sites encoded by the alkyne core relative to the 
azide cores.  The latter bears the P1, P1’ and P2’ residues for enzymatic interaction 
while the acetylene-decorated core only encodes the P2 residue. HIV-1 protease 
exhibits favorable binding to large hydrophobic residues at that position and since the 
alkyne cores synthesized are typically aryl rings decorated with the acetylene moiety, 
the structure activity relationship of the alkynes may not be so pronounced. 
 
In light of our experimental results, it is not possible to make any substantial 
conclusions that will prove or disprove our approach of using enzymes to template the 
selective assembly of an inhibitor from a pool of potential candidates. The 
experiments carried out above merely sets the preliminary stage for further studies to 
be done. 
 
3.5 Future Studies 
 
An immediate task at hand would be to devise a sensitive means of detecting 
minute quantities of product formed. This is crucial, especially if the strategy were to 
be applied to a more complex system involving multiple components. The HPLC 
method is a cumbersome mode of analysis and an obvious solution would be direct 
 80
analysis of the reaction mixture, effected through mass spectrometry technology, akin 
to the DIOS method employed by Lewis et al [19a]. 
 
The assembly of tight-binding, potent inhibitors of the HIV-1 protease in the 
active site will be invariably linked to the demise of enzymatic activity. The use of 
enzymatic assays, through the proteolytic cleavage of a fluorogenic substrate, would 
allow the inactivation of the protease to be tracked over time. Alternatively, reversible 
inhibitors such as pepstatin would set up a competitive reaction within the enzymatic 
subsite, henceforth preventing the sequestering of the starting components. 
 
Eventually, with a more viable means of product identification and 
quantification, and with further validation of the catalytic nature of the self-assembly 
process, all the azide- and acetylene-bearing cores can be mixed simultaneously in a 
one-pot solution with the enzyme. Our synthetic strategy facilitates the generation of 
azide analogs with room for modification at the P1, P1’ and P2’ position, as well as, 
diastereomeric mixtures with RS stereochemistry at C2, allowing potentially the 




 In summary, we have set up a manageable system and created a precedent for 
further investigations whereby an enzyme can be used to assemble its most potent 
inhibitors from a pool of precursors through its ability to sequester the building blocks 
and catalyze the reaction in situ, through proximity effects and stabilization of the 
chemical ligand. The active presence of the biological target negates the need for an 
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external catalyst such as Cu(I) which considerably complicates the situation, through 
the generation of the entire repertoire of possible products. Our strategy accelerates 
the small molecule drug discovery process, invariably linked to chemical proteomics 
owing to the enzyme-substrate relationship that is exploited in the activity-based and 
affinity-based proteomic profiling strategy. The identification of tight-binding low 
molecular weight inhibitors would facilitate the design of affinity-based probes that 
will exhibit greater specificity and selectivity towards biologically significant 
therapeutic targets. Used in conjunction with our promising strategy for profiling 
enzymes that lack mechanism-based inhibitors, we can eventually develop a platform 
for the assay of an enzyme, e.g. HIV-1 protease, either in the crude cell extract or in 
vivo, thereby placing chemical proteomics on the biotechnology world map. 
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CHAPTER 4 EXPERIMENTAL SECTION 
 
 
4.1 General Information 
 
  Starting materials and reagents were purchased commercially and used 
without further purification, unless otherwise stated.  All solvents used were of HPLC 
grade.  All moisture-sensitive reactions were performed under a positive pressure of 
nitrogen.  1H NMR spectra were recorded on a 300 MHz Bruker ACF300 or DPX300 
NMR spectrometer, using either CDCl3, CD3OD or DMSO-d6 for both the deuterium 
lock and reference.  Chemical shifts are reported as δ in units of parts per million 
(ppm) downfield from tetramethylsilane (δ 0.0) using the residual solvent signal as an 
internal standard: chloroform-d1 (δ = 7.26, singlet), methanol-d4 (δ = 3.3, quintet) and 
DMSO-d6 (δ = 2.5 quintet).  13C NMR spectra are reported as δ in units of parts per 
million (ppm) relative from solvent signal: chloroform-d1 (δ=77.0, triplet) and 
methanol-d4 (δ=49.0, singlet).  19F NMR spectra are reported as δ in units of parts per 
million (ppm) relative from the trifluoroacetic acid internal standard.  ESI mass 
spectra were acquired in the positive mode using a Finnigan/Mat TSQ7000 
spectrometer.  Analytical thin layer chromatography was performed using Macherey-
Nagel silica gel plates (0.25 mm thickness) with fluorescent indicator UV254.  
Subsequent to elution, spots were visualized by ultraviolet illumination, iodine 
staining, or by submerging in a ceric molybdate solution, KmnO4 solution, 5 % 
ninhydrin/ethanol and developing on a hot plate.  Flash chromatography was 
performed using Merck silica gel (40 µm particle size) and freshly distilled solvents.  
Analytical and preparative RP-HPLC separations were performed on Phenomex C18 
column (250 x 4.60 mm) and Phenomex C18 (250 x 21.20 mm) columns, respectively, 
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using a Waters 600E HPLC system equipped with a Waters 600 controller and a 
Waters 2487 UV detector. Eluents A (0.1 % TFA/acetonitrile) and B (0.1 % 
TFA/water) were used as the mobile phase.   
 
4.2 Developing Affinity-based Probes for Proteomic Profiling 
 
4.2.1 Chemical Synthesis of Affinity-based Probes for Metalloproteases 
 
Where Fmoc chemistry was used, solid-phase peptide synthesis was carried 
out at room temperature using the Quest™ 210 Peptide Synthesizer using standard 
synthesis protocols.  Qualitative confirmation of successful coupling or deprotection 
was determined using the Kaiser test.  Quantitative resin loading was determined 
using Fmoc cleavage procedure and UV measurements at 290 nm, and calculated 
from the following formula 
Loading,  mmol /g = Abs− Absref
1.65 × weightre sin ,  mg
 
 
Cy3-NHS (1). To a solution of Cy3 (0.44 g, 0.76 mmol) in DMF (5 mL) was added 
N-hydroxysuccinimide (106 mg, 0.92 mmol) and DCC (190 mg, 0.92 mmol).  The 
reaction mixture was stirred overnight, followed by concentration in vacuo and 
purification by flash column with 5% DCM/EtOH to afford Cy3-NHS 1 as a red solid 
(0.42 g; 83 % yield): 1H NMR (300 MHz, CDCl3) δ 8.38 (dd, J = 13.7 Hz, J = 13.2 
Hz, 1H), 7.34-7.30 (m, 4H), 7.21-7.08 (m, 6H) 4.18 (br t, 2H), 3.72 (s, 3H), 2.76 (s, 
4H), 2.69 (br t, 2H), 2.07-1.85 (m, 4H), 1.64 (s, 12H); ESI-MS cald for C33H38N3O4 
[M-I]+ 540.3, found 540.4; Rf 0.40 (DCM/EtOH 8:1). 
 84
D-Biotin-NHS (2). To a solution of D-biotin (0.24 g, 1.00 mmol) in DMF was added 
N-hydroxysuccinimide (0.14 g, 1.20 mmol) and EDC (0.23 g, 1.20 mmol).  The 
reaction was allowed to proceed overnight.  The resulting mixture was filtered and the 
residue was washed copiously with water and MeOH to afford biotin-NHS as a white 
solid (0.21 g; 62 % yield) without further purification: 1H NMR (300 MHz, CD3OD) 
δ 6.40 (br s, 1H), 6.35 (br s, 1H), 4.33-4.29 (m, 1H), 4.17-4.13 (m, 1H), 3.12-3.08 (m, 
1H), 2.86-2.81 (m, 5H) including 2.81 (s, 4H), 2.67 (t, J = 7.2 Hz, 2H), 2.61-2.59 (m, 
1H), 1.70-1.24 (m, 6H); ESI-MS cald for C14H20N3O5S [M+H]+ 342.1, found 342.1. 
 
Fmoc-Lys(Cy3)-OH (3).  To a solution of Fmoc-Lys(Boc)-OH (0.20 g, 0.43 mmol) 
in DCM (2 mL) was added TFA (2 mL).  The reaction was stirred at room 
temperature for 1 h and concentrated in vacuo.  Cy3-NHS 1 (0.34 g, 0.52 mmol) 
dissolved in DMF (1.5 mL) was added followed by DIEA (0.15 mL, 0.86 mmol), and 
the reaction mixture was stirred at room temperature for 48 h.  The resulting product 
was concentrated in vacuo and purified by flash chromatography using DCM/EtOH 
(5-50 % gradient).  Further purification by preparative HPLC (5-95 % acetonitrile 
gradient in 30 min) afforded 1 as a red solid (194 mg; 49 % yield): 1H NMR (300 
MHz, CD3OD) δ 8.46 (dd, J = 13.2 Hz, J = 13.7 Hz, 1H), 7.73 (d, J = 7.6 Hz, 2H), 
7.64-7.59 (m, 2H), 7.48-7.45 (m, 2H), 7.41-7.23 (m, 12H), 6.36 (dd, J = 13.7 Hz, J = 
13.7 Hz, 2H), 4.31-4.04 (m, 6H), 3.59 (s, 3H), 3.16 (br t, 2H), 2.25 (br t, 2H), 1.78-
1.67 (m, 18H) including 1.69 (s, 6H) and 1.67 (s, 6H), 1.50-1.38 (m, 4H); ESI-MS 
cald for C50H57N4O5 [M-I]+ 793.4, found 793.5; Rf 0.23 (DCM/EtOH 4:1). 
 
Fmoc-Lys(Biotin)-OH (4).  To a solution of Fmoc-Lys(Boc)-OH (0.24 g, 0.51 
mmol) in DCM (0.4 mL) was added TFA (0.4 mL).  The reaction was stirred at room 
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temperature for 1 h and concentrated in vacuo.  Biotin-NHS 2 (0.21 g, 0.62 mmol) 
and DIEA (0.11 mL, 0.62 mmol) dissolved in DMF (2.0 mL) were subsequently 
added, and the reaction mixture was stirred at room temperature overnight.  The 
resulting gelatinous solid formed was filtered, washed copiously with DMF and 
MeOH to afford the pure Fmoc-Lys(Biotin)-OH, 2, as a white solid (0.30 g; 97 % 
yield): 1H NMR (300 MHz, CD3OD) δ 7.89 (d, J = 7.6 Hz, 2H), 7.72 (d, J = 7.7 Hz, 
2H), 7.42 (t, J = 7.3 Hz, 2H), 7.33 (t, J = 7.3 Hz, 2H), 6.41 (br s, 1H), 6.35 (br s, 1H), 
4.31-4.22 (m, 4H), 4.13-4.09 (m, 1H), 3.91-3.84 (m, 1H), 3.10.-3.00 (m, 3H), 2.80 
(dd, J = 4.9 Hz, J = 12.2 Hz, 1H), 2.56 (d, J = 12.5 Hz, 1H), 2.03 (t, J = 7.3 Hz, 2H), 
1.61-1.29 (m, 12H);  ESI-MS cald for C31H39N4O6S [M+H]+ 595.3, found 595.2. 
 
N-(9-Fluorenylmethoxycarbonyl)hydroxylamine, Fmoc-NHOH (5). A mixture 
of sodium hydrogen carbonate (1.48 g, 17.6 mmol) in water (15 mL) and ethyl acetate 
(30 mL) was added to hydroxylamine hydrochloride (0.61 g, 8.80 mmol) and the 
biphasic mixture was cooled to 0 oC. Fmoc-Cl (2.07 g, 8.00 mmol) in ethyl acetate 
(10 mL) was added dropwise over 30 min. After addition, the reaction mixture was 
slowly warmed up to room temperature and stirred for an additional 3 h. The reaction 
mixture was separated and the organic layer was washed with saturated KHSO4 
solution (3 x 30 mL) and brine. Subsequently, the organic layer was dried over 
MgSO4 and concentrated in vacuo. The product was afforded as a white solid 
following trituration in hexane, 1.85 g (90 % yield): 1H NMR (300 MHz, CDCl3) δ 
7.77 (d, J = 7.6 Hz, 2H), 7.59 (d, J = 7.2 Hz, 2H), 7.41 (t, J = 7.2 Hz, 2H), 7.32 (t, J = 
7.0 Hz, 2H), 7.18 (br s, 1H), 5.64 (br s, 1H), 4.51 (d, J = 6.8 Hz, 2H), 4.26 (t, J = 7.0 
Hz, 1H); ESI-MS cald for C15H13NNaO3 [M+Na] 278.1, found 278.1. 
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 Synthesis of hydroxylamine-functionalized resin (6). 2-Chlorotrityl chloride resin 
(1.0 g, 1.2 mmol/g, Novabiochem) was swelled in DCM (15 mL) for 1 hour.  Fmoc-
NHOH 5 (0.61 g, 2.4 mmol) was added, followed by DIEA (0.42 mL, 2.4 mmol).  
The reaction mixture was shaken at room temperature for 48 h.  The resulting resin 
was collected by filtration and washed with DMF and DCM, followed by capping 
with DCM/MeOH/DIEA (17:2:1) (10 mL) for 30 min.  The resin (substitution level: 
0.80 mmol/g) was collected by filtration and washed with DMF, DCM and MeOH.  
Prior to deprotection, the resin was swelled in DCM (12 mL) for 1 h. Piperidine (3 
mL) was subsequently added and the mixture was shaken for 30 min.  The resin was 
collected by filtration and washed extensively with DMF, DCM and MeOH. The 
product 6 was dried in vacuo overnight. 
 
General procedure for synthesis of GGX-NHO-Resin (7).  100 mg of resin 6 was 
placed into a 5 mL reaction vessel provided with the Quest 210™ organic synthesizer.  
For the first amino acid substituion, the coupling reaction was carried out for 24 h.  
The resin was pre-swelled in DMF for 1 h.  In a separate reaction vessel, Fmoc-amino 
acid (4 eq), TBTU (4 eq) and HOBt (4 eq) were dissolved in a minimum amount of 
DMF.  DIEA (8 eq) was then added and the reaction mixture was shaken for 10 min.  
The pre-activated solution was subsequently added to the resin.  The resulting 
reaction mixture was then agitated on the synthesizer for 24 h, after which the 
reagents were drained.  The resin was washed (with DMF, DCM and MeOH 
sequentially) and dried in vacuo overnight.  Quantitative Fmoc substitution level was 
determined for the resin. Unreacted sites were capped by treating the resin with acetic 
anhydride (10 eq) and DIEA (20 eq) in DMF for 30 min if necessary.  The reagents 
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were drained and the resin was washed with DMF, DCM and DMF.  Deprotection 
was carried out using 20 % piperidine/DMF (2 x 15 min); the resin was then washed 
with DMF, DCM and DMF. Subsequent Gly, Gly couplings were carried out using 
the above procedure over 4 h durations. 
 
General procedure for synthesis of TFMPD-K(Cy3)-GGX-NHOH (8).  Fmoc-
Lys(Cy3)-OH 3 (4 eq), TBTU (4 eq) and HOBt (4 eq) were dissolved in a minimal 
amount of DMF.  DIEA (8 eq) was added and the mixture was shaken for 10 min.  
The solution was then added to the resin 7 and the reaction mixture was agitated for 4 
h, drained and washed with DMF, DCM and DMF.  Fmoc deprotection of the 
resulting resin was carried out using 20 % piperidine (in DMF; 2 x 15 min) to yield 
resin-bound H2N-K(Cy3)-GGX-NHOH.  Next, 20 mg of the resin was swelled in 
DMF for 1 h.  4-(3-Trifluoromethyl-3H-diazirin-3-yl)-benzoic acid (4 eq), TBTU (4 
eq) and HOBt (4 eq) were dissolved in a minimal amount of DMF.  DIEA (8 eq) was 
added and the mixture was shaken for 10 min.  The solution was then added to the 
resin and the reaction mixture was agitated for 4 h in the dark.  Subsequently, the 
resin was washed with DMF, DCM and MeOH.  The resulting product was cleaved 
from the solid support using a cleavage cocktail (95 % TFA, 2.5 % TIS and 2.5 % 
water; 0.5 mL total volume) for 2 h.  The filtered solution was subsequently 
concentrated in vacuo and purified by RP-HPLC to afford the final pure product.  
 
 Using the above described protocol, the following compounds were prepared: 
 
TFMPD-K(Cy3)-GGL-NHOH (8a).  The compound was afforded as a red solid (6 
mg; 37 % yield): 1H NMR (300 MHz, CD3OD) δ 8.58 (dd, J = 13.7 Hz, J = 12.8 Hz, 
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1H), 7.95 (d, J = 8.0 Hz, 2H), 7.54-7.23 (m, 10H), 4.43-4.34 (m, 2H), 4.12 (br t, J = 
6.8 Hz, 2H), 3.88-3.86 (m, 4H), 3.67 (s, 3H), 3.17 (m, 2H), 2.25 (br t, J = 6.6 Hz, 2H), 
1.93-1.25 (m, 25H) including 1.76 (s, 6H) and1.75 (s, 6H), 0.92 (d, J = 5.2 Hz, 3H), 
0.87 (d, J = 5.6 Hz, 3H); 19F NMR (282 MHz, CD3OD) δ -0.92; ESI-MS cald for 
C54H68F3N10O7 [M-I]+ 1025.5, found 1025.4 
 
TFMPD-K(Cy3)-GGI-NHOH (8b).  The compound was afforded as a red solid (4 
mg; 22 % yield): 1H NMR (300 MHz, CD3OD) δ 8.46 (dd, J = 13.3 Hz, 13.6 Hz, 1H) 
), 7.88 (d, J = 8.4 Hz, 2H), 7.45 (d, J = 7.3 Hz, 2H), 7.39-7.33 (m, 2H), 7.28-7.19 (m, 
6H), 6.35 (d, J = 13.6 Hz, 2H), 4.38-4.33 (m, 1H), 4.08-4.00 (m, 3H), 3.87-3.73 (m, 
4H), 3.59 (s, 3H), 3.10 (t, J = 6.4 Hz, 2H), 2.17 (t, J = 6.6 Hz, 2H), 1.95-0.99 (m, 
25H) including 1.68 (s, 6H) and 1.67 (s, 6H); 19F NMR (282 MHz, CD3OD) δ -0.95; 
ESI-MS cald for C54H68F3N10O7+ [M-I]+ 1025.5, found 1025.5. 
 
TFMPD-K(Cy3)-GGV-NHOH (8c).  The compound was afforded as a red solid (3 
mg; 16 % yield): 1H NMR (300 MHz, CD3OD) δ 8.46 (dd, J = 13.2 Hz, J = 13.6 Hz, 
1H), 7.88 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 7.3 Hz, 2H), 7.40-7.33 (m, 2H), 7.29-7.19 
(m, 6H), 6.35 (d, J = 13.6 Hz, 2H), 4.35 -4.30 (m, 1H), 4.19-4.13 (m, 1H), 4.06 (t, J = 
7.0 Hz, 2H), 3.84-3.81 (m, 4H), 3.60 (s, 3H), 3.10 (t, J = 5.6 Hz, 2H), 2.17 (t, J = 6.4 
Hz, 2H), 1.91-1.17 (m, 23H) including 1.68 (s, 6H) and 1.68 (s, 6H), 0.93-0.82 (m, 
6H); 19F NMR (282 MHz, CD3OD) δ -1.11; ESI-MS cald for C53H66F3N10O7+ [M-I]+ 
1011.5, found 1011.4. 
 
TFMPD-K(Cy3)-GGM-NHOH (8d).  The compound was afforded as a red solid (5 
mg; 27 % yield): 1H NMR (300 MHz, CD3OD) δ 8.54 (dd, J = 13.6 Hz, J = 13.2 Hz, 
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1H), 7.97 (d, J = 8.4 Hz, 2H), 7.54 (d, J = 7.3 Hz, 2H), 7.48-7.42 (m, 2H), 7.37-7.28 
(m, 6H), 6.44 (d, J = 13.6 Hz, 2H), 4.46-4.42 (m, 2H), 4.14 (t, J = 7.0 Hz, 2H), 3.90-
3.87 (m, 4H), 3.68 (s, 3H), 2.56-2.41 (m, 2H), 2.26 (t, J = 6.6 Hz, 2H), 2.05-1.29 (m, 
27H) including 2.05 (s, 3H), 1.77 (s, 6H), 1.76 (s, 6H); 19F NMR (282 MHz, CD3OD) 
δ -1.05; ESI-MS cald for C53H66F3N10O7S+ [M-I]+ 1043.5, found 1043.4. 
 
TFMPD-K(Cy3)-GGF-NHOH (8e).  The compound was afforded as a red solid (3 
mg; 18 % yield): 1H NMR (300 MHz, CD3OD) δ 8.53 (dd, J = 13.2 Hz, J = 13.3 Hz, 
1H), 7.96-7.89 (m, 2H), 7.72-7.60 (m, 1H), 7.53-7.19 (m, 14H), 6.41 (d, J = 13.3 Hz, 
2H), 4.54-4.42 (m, 1H), 4.22-4.10 (m, 5H), 3.86-3.80 (m, 2H), 3.66 (s, 3H), 3.13 (br t, 
J = 5.6 Hz, 2H), 2.24 (br t, J = 6.6 Hz, 2H), 1.78-1.29 (m, 24H) including 1.75 (s, 6H) 
and 1.74 (s, 6H); 19F NMR (282 MHz, CD3OD) δ -0.78; ESI-MS cald for 
C57H66F3N10O7 [M-I]+ 1059.5, found 1059.3. 
 
TFMPD-K(Cy3)-GGG-NHOH (8f).  The compound was afforded as a red solid (1 
mg; 6 % yield): 1H NMR (300 MHz, CD3OD) δ 8.57 (dd, J = 13.6 Hz, J = 13.2 Hz, 
1H), 7.98 (d, J = 8.4 Hz, 2H), 7.56 (d, J = 7.3 Hz, 2H), 7.50-7.44 (m, 2H), 7.39-7.30 
(m, 6H), 6.46 (d, J = 13.6 Hz, 2H), 4.49-4.45 (m, 1H), 4.16 (t, J = 6.6 Hz, 2H), 3.96-
3.82 (m, 6H), 3.70 (s, 3H), 3.21 (t, J = 6.5 Hz, 2H), 2.28 (t, J = 6.6 Hz, 2H), 2.06-1.48 
(m, 22H) including 1.79 (s, 6H) and 1.78 (s, 6H); 19F NMR (282 MHz, CD3OD) δ -
1.30; ESI-MS cald for C50H60F3N10O7+ [M-I]+ 969.5, found 969.4.  
 
TFMPD-K(Cy3)-GGT-NHOH (8g).  The compound was afforded as a red solid (7 
mg; 38 % yield): 1H NMR (300 MHz, CD3OD) δ 8.46 (dd, J = 13.6 Hz, J = 13.2 Hz, 
1H), 7.88 (d, J = 8.7 Hz, 2H), 7.46 (d, J = 7.3 Hz, 2H), 7.40-7.33 (m, 2H), 7.29-7.20 
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(m, 6H), 6.35 (d, J = 13.6 Hz, 2H), 4.38-4.34 (m, 1H), 4.16-4.13 (m, 2H), 4.08-4.04 
(m, 2H), 3.86-3.80 (m, 3H), 3.60 (s, 3H), 3.16-2.99 (m, 3H), 2.17 (t, J = 6.4 Hz, 2H), 
1.68-1.21 (m, 22H) including 1.68 (s, 6H) and 1.67 (s, 6H), 1.07 (d, J = 6.27 Hz, 3H); 
19F NMR (282 MHz, CD3OD) δ -1.08; ESI-MS cald for C52H64F3N10O8+ [M-I]+ 
1013.5, found 1013.4. 
 
TFMPD-K(Cy3)-GGK-NHOH (8h).  The compound was afforded as a red solid (2 
mg; 11 % yield): 1H NMR (300 MHz, CD3OD) δ 8.55 (dd, J = 13.6 Hz, J = 13.6 Hz, 
1H) ), 7.97 (d, J = 8.4 Hz, 2H), 7.54 (d, J = 7.3 Hz, 2H), 7.48-7.41 (m, 2H), 7.37 (m, 
6H), 6.43 (d, J = 13.6 Hz, 2H), 4.44-4.30 (m, 2H), 4.14 (t, J = 6.8 Hz, 2H), 3.97-3.80 
(m, 4H), 3.68 (s, 3H), 3.18 (t, J = 6.8 Hz, 2H), 2.92 (t, J = 7.5 Hz, 2H), 2.26 (t, J = 6.6 
Hz, 2H), 1.77-1.29 including 1.77 (s, 6H) and 1.76 (s, 6H); 19F NMR (282 MHz, 
CD3OD) δ -1.24; ESI-MS cald for C54H69F3N11O7+ [M-I]+ 1040.5, found 1040.4. 
 
TFMPD-K(Cy3)-GGE-NHOH (8i).  The compound was afforded as a red solid (3 
mg; 16 % yield): 1H NMR (300 MHz, CD3OD) δ 8.54 (dd, J = 13.6 Hz, J = 13.2 Hz, 
1H), 7.97 (d, J = 8.4 Hz, 2H), 7.54 (d, J = 7.3 Hz, 2H), 7.48-7.42 (m, 2H), 7.37-7.28 
(m, 6H), 6.43 (d, J = 13.2 Hz, 2H), 4.48-4.43 (m, 1H), 4.35=4.31 (m, 1H), 4.14 (t, J = 
6.8 Hz, 2H), 3.89 (m, 4H), 3.68 (s, 3H), 3.19 (t, J = 6.6 Hz, 2H), 2.40-2.35 (m, 2H), 
2.26 (t, J = 6.5 Hz, 2H), 2.16-1.30 (m, 24H) including 1.77 (s, 6H) and 1,76 (s, 6H); 
19F NMR (282 MHz, CD3OD) δ -0.95; ESI-MS cald for ESI-MS cald for 
C53H64F3N10O9+ [M-I]+ 1041.5, found 1041.3.   
 
BP-K(Cy3)-GGL-NHOH (9).  Fmoc-Lys(Cy3)-OH 3 (4 eq), TBTU (4 eq) and HOBt 
(4 eq) were dissolved in a minimal amount of DMF.  DIEA (8 eq) was added and the 
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mixture was shaken for 10 min.  The solution was then added to the resin 7a in the 
reaction vessel and the reaction mixture was agitated for 4 h.  Subsequently, the 
reagents were drained and the resin was washed with DMF, DCM and DMF.  Fmoc 
deprotection was performed using 20 % piperidine (in DMF; 2 x 15 min) to yield the 
resin-bound H2N-K(Cy3)-GGL-NHOH.  Next, 20 mg of the resin was swelled in 
DMF for 1 h.  4-Benzoyl-benzoic acid (4 eq), TBTU (4 eq) and HOBt (4 eq) were 
dissolved in a minimal amount of DMF.  DIEA (8 eq) was added and the mixture was 
shaken for 10 min.  The solution was then added to the resin and the reaction mixture 
was agitated for 4 h in the dark.  The resulting resin was washed with DMF, DCM 
and MeOH.  The product was cleaved from the resin using a cleavage cocktail (95 % 
TFA, 2.5 % TIS and 2.5 % water; 0.5 mL total volume) for 2 h.  The filtered solution 
was subsequently concentrated in vacuo and purified with RP-HPLC to afford the 
final product, 6, as a red solid (2.5 mg; 14 % yield): 1H NMR (300 MHz, CD3OD) δ 
8.52 (dd, J = 13.7 Hz, J = 13.2 Hz, 1H), 8.01 (d, J = 8.4 Hz, 2H), 7.83-7.74 (m, 4H), 
7.67-7.62 (m, 1H), 7.54-7.49 (m, 4H), 7.47-7.40 (m, 2H), 7.35-7.26 (m, 4H), 6.41 (dd, 
J = 13.3 Hz, 13.3 Hz, 2H), 4.52-4.46 (m, 1H), 4.37-4.32 (m, 1H), 4.11 (t, J = 6.8 Hz, 
2H), 3.91-3.89 (m, 4H), 3.20 (t, J = 6.4 Hz, 2H), 2.25 (t, J = 6.6 Hz, 2H), 1.98-1.45 
(m, 25H) including 1.75 (s, 6H) and 1.74 (s, 6H), 0.90 (dd, J = 6.0 Hz, J = 6.0 Hz, 
6H); ESI-MS cald for ESI-MS cald for C59H73N8O8+ [M-I]+ 1021.6, found 1021.6.   
 
TFMPD-Lys(Biotin)-GGL-NHOH (10).  The H2N-GGL-hydroxamate-
functionalized resin (20 mg) was pre-swelled in DMF for 1 h.  Separately, Fmoc-
K(Biotin)-OH 2 (4 eq), TBTU (4 eq) and HOBt (4 eq) were dissolved in a minimal 
amount of DMF.  DIEA (8 eq) was subsequently added and the mixture was shaken 
for 10 min, which was then added to the resin. The resulting mixture was agitated for 
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4 h.  The resin was washed with DMF, DCM and DMF.  Fmoc deprotection was 
performed using 20% piperidine (in DMF; 0.5 mL) for 30 min, after which the resin 
was washed with DMF, DCM and DMF.  A preactivated solution of 4-(3-
trifluoromethyl-3H-diazirin-3-yl)-benzoic acid (4 eq), TBTU (4 eq), HOBt (4 eq) and 
DIEA (8 eq) was subsequently added.  The solution was agitated for 4 h, drained and 
the resulting resin was washed copiously with DMF, DCM and MeOH before drying 
in vacuo overnight.  The resin-bound product was cleaved using a cleavage cocktail 
(95 % TFA, 2.5 % TIS and 2.5 % water; 0.5 mL total volume) for 2 h.  The filtered 
solution was subsequently concentrated in vacuo and purified with RP-HPLC to 
afford the desired product as a white solid (2.0 mg; 15 % yield): 1H NMR (300 MHz, 
CD3OD) δ 7.98 ( d, J = 8.4 Hz, 2H), 7.35 (d, J = 8.4 Hz, 2H), 4.50-4.42 (m, 2H), 
4.37-4.26 (m, 2H), 3.97-3.83 (m, 4H), 3.34 (m, 1H), 2.91 (dd, J = 5.0 Hz, J = 12.7 Hz, 
1H), 2.71-2.62 (m, 1H), 2.17 (t, J = 7.1, 2H), 2.02-1.38 (m, 15H), 0.93 (d, J = 5.9 Hz, 
3H), 0.89 (d, J = 6.3 Hz, 3H); 19F NMR (282 MHz, CD3OD) δ –1.27; ESI-MS cald for 
C35H50F3N10O8S [M+H]+ 827.3, found 827.3. 
 
GGL-NHOH (11).  100 mg of resin-bound GGL-NHOH 7a was cleaved off using a 
cleavage cocktail of TFA/TIS/water (95:2.5:2.5).  The solution was triturated in cold 
ether, and the resulting precipitate was collected, washed repeatedly with cold ether, 
lyophilized and purified by RP-HPLC to afford 11 as a white solid, (10 mg; 48 % 






4.2.2 Affinity-based Labeling Studies of Metalloproteases 
 
Unless otherwise stated, all enzymes used for labeling studies were purchased 
from commercial suppliers.  Stock solutions of enzymes were prepared in final 
concentrations of 5-10 mg/mL (in H2O) and stored at -20 oC.  Desalted stock solutions 
were prepared, if necessary, by passing the above enzyme solutions through a NAP5 
desalting column (Amersham, USA) prior to use.  Stock solutions of the probes were 
prepared in DMSO and stored at -20 oC until use.  UV photolysis experiments were 
carried out using a handheld UV lamp (UVP, USA) at ~360 nm.  Fluorescence 
imaging was performed using a Typhoon™ 9200 fluorescence gel scanner 
(Amersham, USA) at ex = 532 nm and analyzed with the ImageQuant™ software 
(Amersham, USA). 
 
General procedure for photoaffinity labeling studies.  Unless otherwise stated, 2 µL 
of an enzyme stock solution (5-10 mg/mL) was diluted with 17.8 µL of Tris.HCl 
buffer (50 mM, pH 8).  0.2 µL of the probe stock solution (50 µM in DMSO) was 
added and the reaction was incubated at room temperature in the dark for 30 min.  
Subsequently, the reaction mixture was irradiated with the handheld UV lamp under 
the long-range UV channel for 20 min.  The reaction was quenched by addition of 4 
µL of 6 x SDS loading buffer followed by boiling at 95 oC for 10 min.  The sample 
was then analyzed on a 12% denaturing SDS-PAGE gel followed by visualization 
with the Typhoon fluorescence gel scanner. 
 
Concentration-dependent labeling studies.  2 µL of thermolysin stock solution (10 
mg/mL) were diluted with 17.8 µL of Tris.HCl buffer (50 mM, pH 8).  0.2 µL of the 
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probe  8a (2 mM, 500, 200, 100, 50, 20, 10, 5, 2, 1 and 0 µM in DMSO) was added.  
The samples were then treated as described above. 
 
Labeling experiments with variable irradiation time.  2 µL of the thermolysin stock 
solution (10 mg/mL) were diluted with 17.8 µL of Tris.HCl buffer (50 mM, pH 8).  
0.2 µL of probe 8a (50 µM) was added and the reactions were incubated at room 
temperature in the dark for 30 min.  The reaction mixtures were then irradiated for 0, 
10, 20, 30 and 60 min with UV light, quenched and analyzed by SDS-PAGE as 
described above. 
 
Heat-denaturing experiments.  2 µL of thermolysin solution (10 mg/mL) was diluted 
with 17.8 µL of Tris.HCl buffer (50 mM, pH 8).  The solution was heated at 95 oC for 
10 min and allowed to cool down to room temperature.  0.2 µL of the probes 8a-i  (50 
µM in DMSO) was added and the reaction was incubated at room temperature in the 
dark for 30 min, irradiated under UV for 20 min and analyzed as described above. 
 
Competitive inhibition studies with GGL-NHOH 11.  2 µL of thermolysin solution (10 
mg/mL) was diluted with Tris buffer (50 mM, pH 8).  The desired amounts of GGL-
NHOH 11 (10 mM, DMSO) were added to create solutions with increasing 
concentrations of 0, 5, 10, 20, 50, 100, 500 and 1000 µM. 0.2 µL of the probe 8a (500 
M in DMSO) was then added and the reactions were incubated at room temperature 




EDTA inhibition studies.  2 µL of the desalted thermolysin stock solution (5 mg/mL) 
was diluted with 15.6 µL of Tris.HCl buffer (50 mM, pH 8).  2 µL of an EDTA stock 
solution (50, 25, 10, 5, 1, 0.5 and 0.1 mM in water, pH 8) and 0.2 µL of the probe 8a 
(50 M in DMSO) were added simultaneously.  The reaction was incubated at room 
temperature in the dark for 30 min, irradiated under UV for 20 min and analyzed as 
described above.  
 
Enzyme labeling studies using benzophenone-tagged probe 9. 2 µL of enzyme stock 
solution (10 mg/mL) were diluted with 17.8 µL of Tris.HCl buffer (50 mM, pH 8).  
0.2 µL of the probe 9 (500 µM, DMSO) was added.  The samples were then treated as 
described above. 
 
Labeling of thermolysin spiked in crude cell extracts. Thermolysin-containing crude 
yeast extracts were prepared by spiking the extracts, which contain 5 mg/mL total 
proteins, with different amounts of thermolysin (final concentrations of thermolysin: 
0-10 g/mL).  The resulting extracts were labeled with 8a (50 µM, DMSO) and 9 
(500 µM, DMSO) and treated as described above. 
 
4.3 Developing Affinity-based Probes for Aspartic Proteases 
 
4.3.1 Chemical Synthesis of Affinity-based Probes for Aspartic Protease 
 
Solid-phase peptide synthesis was carried out at room temperature using Boc 
synthesis protocols.  Qualitative confirmation of successful coupling or deprotection 
was determined using the Kaiser test. 
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 Boc-Lys(Cy3)-OH (12). To a solution of Boc-Lys(2-ClZ)-OH (100 mg, 0.24 mmol) 
in AcOH (1 mL) was suspended Pd/C (5 mg, 5 % w/w). Hydrogen gas was bubbled 
continuously through the mixture. The reaction was stirred at room temperature 
overnight. The mixture was then filtered and concentrated in vacuo to afford Boc-
Lys-OH, which was used in the subsequent step without further purification. To a 
solution of Boc-Lys-OH in DMF (2 mL) was added Cy3-NHS 1 (193 mg, 0.29 mmol) 
and DIEA (42 µL, 0.29 mmol). The reaction mixture was stirred at room temperature 
overnight, following which the solvent was removed in vacuo. The product was 
purified by flash chromatography using EtOH/DCM (5-25 % gradient) to afford 12 as 
a red solid (13.8 mg, 7 % yield): 1H NMR (300 MHz, CD3OD) δ 8.54 (dd, J = 13.3 
Hz, J = 13.7 Hz, 1H), 7.53 (d, J = 7.6 Hz, 2H), 7.47-7.44 (m, 2H), 7.36-7.28 (m, 4H), 
6.43 (d, J = 13.2 Hz, 2H), 4.16 (t, J = 6.8 Hz, 2H), 4.04-3.97 (m, 1H), 3.68 (s, 3H), 
3.16 (t, J = 6.6 Hz, 2H), 2.27 (t, J = 6.6 Hz, 2H), 1.93-1.41 (m, 31 H) including 1.76 
(s, 12H) and 1.41 (s, 9H); ESI-MS cald for C40H55N4O5 [M-I]+ 671.4, found 671.3.     
 
Boc-Leu-N,O-dimethylhydroxamate (13b). To a solution of Boc-Leu-OH (2.49 g, 
10.00 mmol) in DMF (30 mL) was added DCC (2.27 g, 11.00 mmol) and HOBt (1.68 
g, 11.00 mmol). The reaction was allowed to proceed at room temperature for 30 min, 
following which the solution was filtered to remove DCU. Subsequently, N,O-
dimethyl hydroxylamine hydrochloride (1.17 g, 12.00 mmol) and DIEA (2.01 mL, 
12.00 mmol) were added and the reaction was stirred overnight. The solvent was 
removed in vacuo and the reaction mixture was redissolved in ethyl acetate. The 
organic layer was washed with sat. NaHCO3, 0.5 M HCl and brine, dried over MgSO4 
and concentrated in vacuo. Purification by flash chromatography using hexane/ethyl 
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acetate 2:1 afforded 13b as colorless oil, 2.18 g (80 % yield): 1H NMR (300 MHz, 
CDCl3) δ 5.09 (br d, J = 8.8 Hz, 1H), 4.71 (m, 1H), 3.79 (s, 3H), 3.20 (s, 3H), 1.77-
1.64 (m, 3H), 1.43 (s, 9H), 0.96 (d, J = 6.4 Hz, 3H), 0.93 (d, J = 7.2 Hz, 3H); 13C 
NMR (300 MHz, CDCl3) δ 173.8, 155.6, 79.3, 61.4, 48.9, 41.9, 32.1, 28.2, 24.6, 23.2, 
21.4; ESI-MS cald for C13H26N2NaO4 [M+Na]+ 297.1, found 297.0; Rf 0.54 
(hexane/ethyl acetate 1:1). 
 
Boc-Leu-H (14b). To a solution of 13b (2.18 g, 7.93 mmol) in THF (25 mL) cooled 
to 0 oC was added lithium aluminium hydride (0.45 g, 11.09 mmol) slowed under a 
positive pressure of nitrogen. The reaction was stirred on ice for 15 min, following 
which the reaction was quenched by the addition of 5 % KHSO4 solution (2.15 g, 
15.86 mmol). The mixture was allowed to warm up to room temperature. The 
aqueous layer was extracted with ethyl acetate (2 x 150 mL). The combined organic 
extracts were washed with 0.5 M HCl, sat. NaHCO3 and brine, dried and concentrated 
in vacuo. Purification by flash chromatography using hexane/ethyl acetate 3:1 
afforded 14b as a colorless oil, 1.37 g (80 % yield): 1H NMR (300 MHz, CDCl3) δ 
9.58 (br s, 1H), 4.91 (br s, 1H), 4.24 (m, 1H), 1.81-1.71 (m, 2H), 1.45 (s, 9H), 1.43-
1.33 (m, 1H), 0.97 (d, J = 6.4 Hz, 3H), 0.96 (d, J = 6.4 Hz, 3H); 13C NMR (75 MHz, 
CDCl3) δ 200.2, 155.4, 79.9, 58.3, 38.1, 28.2, 24.6, 23.0, 21.8; ESI-MS cald for 
C11H21NNaO3 [M+Na]+ 238.1, found 238.1; Rf 0.86 (hexane/ethyl acetate 1:1). 
 
Boc-(3RS,4S)-Sta-OEt (15). To THF (7.5 mL) in a flame-dried rbf cooled to –78 oC 
was added ethyl acetate (1.04 mL, 10.51 mmol) and 2.0 M LDA solution (5.26 mL, 
10.51 mmol) under nitrogen. The reaction was stirred at –78 oC for 15 min. Boc-
leucinal 14b (1.13 g, 5.26 mmol) in THF (5 mL) was transferred to the reaction 
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mixture by cannula and the reaction was stirred for a further 10 min at –78 oC before 
0.5 M HCl was added to quenched the reaction. The reaction mixture was slowly 
warmed up to room temperature and acidified to pH 2-3 with 0.5 M HCl, then 
extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were washed 
with brine, dried over MgSO4 and concentrated in vacuo. Purification by flash 
chromatography with hexane/ethyl acetate (8:1 to 1:1) afforded 15 as a mixture of 
diastereomers, 1.25 g (78 % yield).  
 
Boc-(3R,4S)-Sta-OEt (15a). The compound was isolated as a colorless oil, 0.92 g (58 
%) yield: 1H NMR (300 MHz, CDCl3) δ 4.60 (br d, J = 8.9 Hz, 1H), 4.15 (q, J = 7.2 
Hz, 2H), 3.97 (m, 1H), 3.65 (m, 1H), 3.47 (m, 1H), 2.46-2.43 (m, 2H), 1.68-1.23 (m, 
15H) including 1.42 (s, 9H) and 1.25 (t, J = 7.2 Hz, 3H), 0.92 (d, J = 6.8 Hz, 3H), 
0.89 (d, 6.8 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ172.7, 156.0, 79.4, 71.3, 60.7, 
52.7, 38.8, 38.0, 28.2, 24.6, 23.5, 21.4, 14.0; ESI-MS cald for C15H29NNaO5 [M+Na]+ 
326.2, found 326.0; Rf 0.20 (hexane/ethyl acetate 4:1).  
 
Boc-(3S,4S)-Sta-OEt (15b). The compound was isolated as a colorless oil, 0.33 g (20 
% yield): 1H NMR (300 MHz, CDCl3) δ 4.80 (br d, J = 9.2 Hz, 1H), 4.21 (q, J = 7.1 
Hz, 2H), 3.98 (br s, 1H), 3.59-3.54 (m, 1H), 3.48 (m, 1H), 2.49-2.46 (m, 2H), 1.64-
1.20 (m, 15H) inclusive of 1.40 (s, 9H) and 1.22 (t, J = 7.2 Hz, 3H), 0.88 (d, J = 6.4 
Hz, 6H); 13C NMR (75 MHz, CDCl3) δ 173.2, 155.9, 79.0, 69.6, 60.6, 51.9, 41.6, 
38.7, 28.2, 24.6, 22.9, 22.1, 14.0; ESI-MS cald for C15H29NNaO5 [M+Na]+ 326.2, 
found 326.0; Rf 0.24 (hexane/ethyl acetate 4:1).  
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Boc-(3R,4S)-Sta-OH (16). To a solution of 15a (0.92 g, 3.03 mmol) in 
methanol/water (2:1, 30 mL) was added 20% K2CO3 solution (0.84 g, 6.06 mmol). 
The reaction mixture was stirred at room temperature overnight. The aqueous layer 
was extracted once with ether. After which the aqueous phase was acidified to pH 2-3 
and extracted with ether (2 x 50 mL). The combined organic extracts were washed 
with brine, dried over MgSO4 and concentrated in vacuo to afford 16 as a white solid, 
0.45 g (54 % yield): 1H NMR (300 MHz, CDCl3) δ 4.62 (m, 1H), 4.00 (m, 1H), 3.72 
(m, 1H), 2.50 (br d, J = 5.6 Hz, 2H), 1.69-1.45 (m, 12 H) including 1.45 (s, 9H); ESI-
MS cald for C13H25NNaO5 [M+Na]+ 298.2, found 298.1. 
 
Loading of 1st amino acid residue. To a solution of Boc-(3R,4S)-Sta-OH 16 (0.45 g, 
1.63 mmol) in a mixture of EtOH (3.26 mL, 2 mL/mmol) and H2O (0.82 mL, 0.5 
mL/mmol) was added a solution of 2 M Cs2CO3 until pH 7.0. The solvents were then 
removed in vacuo. Repeated cycles of adding 1,4-dioxane and concentrating in vacuo 
afforded the dried neutral cesium salt of statine.  
 
 Merrifield resin (1.7 g, 0.80 mmol/g, Novabiochem) was preswelled in DCM 
for 1 h. The solvent was drained and the resin was washed with DMF. The cesium salt 
obtained as above (1.20 eq) was dissolved in DMF and added to the resin. A catalytic 
amount of KI (0.1 eq) was added and the reaction was agitated gently at 50 oC. The 
resin was collected by filtration and washed extensively with DMF (3 x), DMF/H2O 
(1:1) (3 x), DMF (3 x), DCM (3 x) and MeOH (3 x), and dried overnight to afford the 
statine-functionalized resin 17.  
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General procedure for synthesis of Boc-Lys(Cy3)-Val-Val-Sta-functionalized 
resin (19). Amino acid couplings were carried out stepwise from the C-terminus to 
the N-terminus using HBTU/HOBt/DIEA synthesis protocols. Briefly, Boc-protecting 
groups were removed in the presence of neat TFA (10 mL/g resin) for 1 h. The resin 
was then collected by filtration and washed extensively with DMF, DMF/DIEA (1:1), 
DMF, DCM and MeOH, and dried in vacuo. Boc-protected amino acids (4 eq), 
HBTU (4 eq) and HOBt (4 eq) were dissolved in a minimal amount of DMF. DIEA (8 
eq) was added and the reaction mixture was agitated for 10 min. The pre-activated 
solution was then added to the deprotected resin and the reaction was allowed to 
proceed for 4 h. The resin was then collected by filtration and washed with DMF, 
DCM and MeOH, and dried in vacuo. The coupling-deprotection cycles were 
repeated using Boc-Val-OH (2 x) and Boc-Lys(Cy3)-OH 12 to afford Boc-Lys(Cy3)-
Val-Val-Sta-functionalized resin 19.  
 
TFMPD-Lys(Cy3)-Val-Val-Sta-OH (21). The Boc protecting group on 19 was 
removed using neat TFA (10 mL/g resin) for 1 h. The resin was then collected by 
filtration and washed extensively with DMF, DMF/DIEA (1:1), DMF, DCM and 
MeOH, and dried in vacuo. 4-(3-Trifluoromethyl-3H-diazirin-3-yl)-benzoic acid (4 
eq), HBTU (4 eq) and HOBt (4 eq) were dissolved in a minimal amount of DMF. 
DIEA (8 eq) was added and the reaction mixture was agitated for 10 min. The pre-
activated solution was then added to the deprotected resin and the reaction was 
allowed to proceed for 4 h. The resin was then collected by filtration and washed with 
DMF, DCM and MeOH, and dried in vacuo to afford resin-bound TFMPD-Lys(Cy3)-
Val-Val-Sta-OH 20. The final product was cleaved from the solid support using 
standard TFMSA cleavage protocol [3]. To the resin 9 in a rbf was added 
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thioanisole/EDT (2:1) 150 µL and the mixture was cooled to 0 oC. TFA (1 mL) and 
TFMSA (0.1 mL) were added and the cleavage reaction was allowed to proceed for a 
further 2 h. The filtered solution was subsequently collected and concentrated in 
vacuo. The crude mixture was subjected to RP-HPLC purification and the pure 
product 21 was afforded as a red solid (0.4 mg) : 1H NMR (300 MHz, CDCl3) δ 8.54 
(dd, J = 31.2 Hz, J = 12.5 Hz, 1H), 7.94-7.91 (m, 2H), 7.55-7.27 (m, 10H), 6.43 (d, J 
= 12.9 Hz, 2H), 4.55-4.51 (m, 1H), 4.21-4.06 (m, 3H), 3.68 (s, 3H), 3.54 (m, 2H), 
3.18 (m, 2H), 3.07 (m, 1H), 2.66 (m, 2H), 2.27 (m, 2H), 2.01-1.22 (m, 27H) including 
1.76 (s, 12H), 0.93-0.85 (m, 18H) ; 19F NMR (282 MHz, CD3OD) δ -0.76; ESI-MS 
cald for C62H83F3N9O8 [M-I]+ 1138.6, found 1138.4. 
 
4.3.2 Affinity-based Labeling Studies of Aspartic Proteases 
 
General procedure for photoaffinity labeling studies.  Unless otherwise stated, 2 µL 
of an enzyme stock solution (5-10 mg/mL) was diluted with 16 µL of Tris.HCl buffer 
(50 mM, pH 4).  2 µL of the probe stock solution 21 (50 µM in DMSO) was added 
and the reaction was incubated at room temperature in the dark for 30 min.  
Subsequently, the reaction mixture was irradiated with the handheld UV lamp under 
the long-range UV channel for 20 min.  The reaction was quenched by addition of 4 
µL of 6 x SDS loading buffer followed by heating at 95 oC for 10 min.  The sample 
was then analyzed on a 12 % denaturing SDS-PAGE gel followed by visualization 
with the Typhoon fluorescence gel scanner. 
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pH-dependent labeling studies.  2 µL of pepsin stock solution (10 mg/mL) were 
diluted with 16 µL of Tris.HCl buffer (50 mM, pH 2, 4 or 8).  2 µL of the probe 21 
(50 µM in DMSO) was added.  The samples were then treated as described above. 
 
Concentration-dependent labeling studies.  2 µL of pepsin stock solution (10 mg/mL) 
were diluted with Tris.HCl buffer (50 mM, pH 4).  Appropriate volumes of probe 
stock solutions 21 (1 mM, 50 µM and 1 µM in DMSO) were added such that probe 
concentrations of 100, 50, 10, 5, 1.25 and 0.5 µM and 25, 10 and 0 nM were 
achieved. The total reaction volumes were made up to 20 µL with Tris.HCl buffer.  
The samples were then treated as described above. 
 
Labeling experiments with variable irradiation time.  2 µL of the pepsin stock 
solution (10 mg/mL) were diluted with 16 µL of Tris.HCl buffer (50 mM, pH 4).  2 
µL of probe 21 (50 µM) was added and the reactions were incubated at room 
temperature in the dark for 30 min.  The reaction mixtures were then irradiated for 0, 
10, 20, 30, 40 and 60 min with UV light, quenched and analyzed by SDS-PAGE as 
described above. 
 
Pepstatin competitive inhibition studies.  2 µL of pepsin solution (10 mg/mL) were 
diluted with Tris buffer (50 mM, pH 4).  The desired amounts of pepstatin (1 mg/mL 
and 50 µg/mL, DMSO) were added to create solutions with increasing concentrations 
of 0, 3.75, 7.5, 15, 37.5, 75 and 150 µM. 2 µL of the probe 21 (50 M in DMSO) was 
then added and the reactions were incubated at room temperature in the dark for 30 
min, irradiated under UV for 20 min and analyzed as described above. 
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 Labeling studies of pepsin in crude yeast extracts.  10 µL of crude yeast lysate were 
diluted with Tris buffer (50 mM, pH 4).  The desired amounts of pepsin solution (10 
mg/mL) were added such that increasing amounts of 0, 5, 10, 20 and 30 µg of protein 
were attained. 2 µL of the probe 21 (50 M in DMSO) was then added and the 
reactions were incubated at room temperature in the dark for 30 min, irradiated under 
UV for 20 min and analyzed as described above. 
 
4.4 Target-driven Selective Self-Assembly of Inhibitors 
 
4.4.1 Expression and Purification of HIV-1 Protease 
 
 Plasmid pET-11a, carrying the HIV-1 protease triple mutant Q7K/L33I/L63I 
gene construct, was a generous gift from Dr John M. Louis (National Institutes of 
Health, Bethesda, Maryland, USA). 
 
4.4.1.1 Small-scale Expression of HIV-1 Protease in E. coli 
 
 The plasmid pET-11a was transformed into the E. coli hosts. The transformed 
E. coli BL21 (AI) cells were subsequently used for expression of the HIV-1 protease. 
Small-scale expression experiments were first carried to ascertain the optimal 
conditions. 
 
 A single colony from the agar plates were inoculated into 5 mL of LB + Amp 
(1 µL/mL) medium and incubated at 37 oC overnight. 200 µL of the overnight culture 
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was then inoculated into 20 mL of LB + Amp medium. The culture was incubated at 
37 oC, with agitation at 200 rpm, until an OD600 of ~ 0.5 was reached. 4 sets of 4 1 
mL aliquots of the culture were prepared in eppendorf tubes and conditions such as 
concentration of arabinose and temperature of incubation were varied to determine the 
optimal condition for expression.  In one experiment, the volumes of 20 % arabinose 
solution added to the aliquots were varied such that the addition of 0, 10, 30 and 50 
µL of stock solution gave final concentrations of 0 (uninduced), 0.2, 0.6 and 1.0 % 
arabinose respectively. The samples were then incubated at 37 oC for 5 h. Another 3 
experiments were carried out whereby each set of samples were incubated at 30 oC for 
5 h, room temperature (overnight) and 4 oC (overnight). 
 
The samples were then prepared for SDS-PAGE analysis by centrifuging at 5000 rpm 
for 5 min, after which the supernatants were discarded and the pellets resuspended in 
an appropriate volume of deionized water. 
 
4.4.1.2 Large-scale Expression of HIV-1 Protease in E. coli 
 
 A 10 mL overnight culture was prepared by inoculating a single colony of 
transformed E. coli BL21 (AI) cells into two 5 mL of LB + Amp (1 µL/mL) medium 
and incubated at 37 oC overnight. 4 mL of the culture from each tube was then 
inoculated into 2 400 mL of LB + Amp medium. The cultures were incubated at 37 
oC, with agitation at 200 rpm, until both reached an OD600 of ~0.5. 1 mL of sample 
was removed from each flask for SDS-PAGE analysis, following which expression of 
the protein was induced by the addition of 2 x 4 mL of 20 % arabinose until a final 
concentration of 0.2 %. The cultures were incubated at room temperature, overnight, 
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with agitation at 200 rpm, after which 1 mL from each flask was removed for SDS-
PAGE analysis. The bacterial cells were subsequently harvested by centrifugation at 
6,000 rpm for 20 min at 4 oC, the supernatant discarded and the pellet stored at –80 oC 
until further use. 
 
4.4.1.3 Extraction of HIV-1 Protease  
 
 The frozen harvested cells were thawed and suspended in 32 mL of cold lysis 
buffer (50 mM Tris.HCl pH 8.0, 10 mM EDTA pH 8.0, 10 mM DTT). The 
suspension was sonicated in 10 cycles of 30 s on, 1 min off  (output 5), to completely 
suspended the thawed cells. 3.2 mg of lysozyme was then added. The suspension was 
mixed thoroughly and incubated at room temperature for 20 min and sonicated again 
in 10 discontinuous rounds of 1 min on, 2 min off. The lysed cell suspension was then 
centrifuged at 18,000 rpm for 30 min at 4 oC. The supernatant was discarded and the 
pellet was resuspended in another 32 mL of cold lysis buffer and re-sonicated in 10 
cycles of 30 s on, 2 min off. The suspension was then divided into four portions and 
centrifuged at 18,000 rpm for 30 min at 4 oC. The supernatant was discarded and the 
four pellets containing HIV-1 protease as inclusion bodies were stored at –80 oC until 
further use.  
 
4.4.1.4 Purification of HIV-1 Protease  
 
 Inclusion bodies from one portion were solubilized in 6.4 mL of 50 % acetic 
acid. The cloudy suspension was clarified by centrifuging at 18,000 rpm for 30 min at 
4 oC. The pellet was discarded and 5 mM DTT was added to the supernatant. The 
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protein was then purified by gel filtration chromatography on a Pharmacia XK 16/100 
column packed with Sephacryl S-100 HR beads (Amersham, USA) and pre-
equilibrated with elution buffer (50 % acetic acid + 1 mM DTT). The flow rate was 
maintained at ~ 0.5 mL/min using a Watson-Marlow 101U peristaltic pump. Fractions 
were collected at 10 min intervals using a BioRad 2128 fraction collector. The eluted 
fractions were monitored at A280. Analysis of fractions was carried out using SDS-
PAGE. Small-scale dialysis was carried out prior to gel electrophoresis to remove 
acetic acid. 
 
4.4.1.5 Small-scale Dialysis  
 
 200 µL of each fraction to be analyzed were transferred to dialysis membranes 
(MWCO 7000). The fractions were dialyzed against deionized water at 4 oC for 6 h, 
following which the water was replaced with a fresh batch and dialysis continued for 
a further 6 h. The dialyzed fractions were recovered and lyophilized. The samples 
were then resuspended in deionized water and prepared for SDS-PAGE analysis. 
SDS-PAGE analysis of portions from the first run were carried out to ascertain 
fractions containing the pure HIV-1 protease. For subsequent runs, fractions with the 
protein were pooled based on their A280 values.  
 
4.4.1.6 Refolding of HIV-1 Protease 
 
 Fractions containing relatively pure HIV-1 protease were pooled and 
transferred to dialysis membrane (MWCO 7000). Dialysis was carried out against 50 
mM formic acid for 6 h. After which, the buffer was changed and dialysis continued 
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for another 6 h. The enzyme was then refolded by dialyzing against 100 mM sodium 
acetate pH 5, 1 mM EDTA, 1 mM DTT and 0.5% Triton X-100 for 6 h (2 times). The 
solution was finally dialyzed against deionized water for another 12 h (2 x 6 h). The 
lyophilized protein was subsequently afforded in powdered form. 
 
4.4.1.7 Preparation of Samples for SDS-PAGE Analysis 
 
 20 µL of the sample is mixed with 4 µL of 6 x SDS-loading dye and boiled at 
95 oC for 10 min. The proteins were analyzed on 15 % polyacrylamide gels. Proteins 
were visualized by staining with Coomassie blue. 
 
4.4.1.8 Circular Dichroism (CD) Spectra  
 
 A 10 µM solution of the lyophilized protein in Tris.HCl buffer (50 mM, pH 5) 
was prepared. The CD spectrum was recorded in the far-UV range, 260-190 nm, 
using a Jasco J-810 Spectropolarimeter. 
 
4.4.1.9 Affinity-based Labeling of HIV-1 Protease 
 
 2 µL of HIV-1 protease (10 mg/mL) was diluted in 16 µL of Tris. HCl buffer 
(50 mM, pH 5 or 8). 2 µL of the probe 21 (50 µM, DMSO) was added and the 
reaction was incubated at room temperature in the dark for 30 min. Photolysis using a 
handheld UV lamp at 360 nm was carried out for a further 20 min, following which 
the reaction was quenched by the addition of 4 µL of 6 x SDS loading buffer and 
boiling at 95 oC for 10 min. The sample was separated on 15 % denaturing SDS-
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PAGE gel. Enzyme labeling was visualized by fluorescence scanning and the protein 
bands were stained with Coomassie blue. 
 
Pepstatin inhibition of HIV-1 Protease. 2 µL of HIV-1 protease (10 mg/mL) was 
diluted in 15 µL of Tris. HCl buffer (50 mM, pH 5 or 8). 1 µL of pepstatin (50 
µg/mL, DMSO) and 2 µL of the probe 21 (50 µM, DMSO) were added. The sample 
was treated as above. 
 
4.4.2 Chemical synthesis of Azide Cores 
 
 
General procedure for synthesis of Boc-X-N,O-dimethylhydroxamate (13). To a 
solution of Boc-amino acid (1.0 mmol) in DMF (3 mL) was added DCC (0.27 g, 1.1 
mmol) and HOBt (0.17 g, 1.1 mmol). The reaction was stirred at room temperature 
for 30 min, and the DCU formed was removed by filtration. N,O-dimethylhydroxyl 
amine hydrochloride (0.11 g, 1.2 mmol) was added as a solid to the filtered reaction 
along with DIEA (0.19 mL, 1.2 mmol). The reaction was allowed to proceed 
overnight. The reaction mixture was concentrated in vacuo and subsequently 
dissolved in ethyl acetate (75 mL). The organic layer was extracted with saturated 
NaHCO3 (2 x 50 mL), 0.5 M HCl (2 x 50 mL) and brine (2 x 50 mL). Subsequently, 
the organic layer was dried over MgSO4 and concentrated in vacuo. The product 13 
was afforded from purification by flash chromatography using hexane/ethyl acetate as 
the eluent. 
 
Boc-Phe-N,O-dimethyl hydroxamate (13a). The compound was prepared from the 
above procedure and afforded as a colorless oil, 2.21 g (95 % yield): 1H NMR (300 
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MHz, CD3OD) δ  7.30-7.15 (m, 5H), 5.16 (br s, 1H), 4.93 (br s, 1H), 3.64 (s, 3H), 
3.15 (s, 3H), 3.04 (dd, J = 6.2 Hz, J = 13.5 Hz, 1H) 2.90-2.83 (m, 1H), 1.38 (s, 9H); 
ESI-MS cald for C16H24N2NaO4 [M+Na]+ 331.2, found 331.0; Rf 0.60 (Hexane/ethyl 
acetate 1:1) 
 
Boc-Leu-N,O-dimethyl hydroxamate (13b). Preparation of the compound was 
reported in an earlier section. 
 
Boc-Val-N,O-dimethyl hydroxamate (13c). The compound was prepared from the 
above procedure and afforded as a colorless oil, 2.39 g (92 % yield): 1H NMR (300 
MHz, CD3OD) δ 5.14-5.11 (m, 1H), 4.57 (m, 1H), 3.77 (s, 3H), 3.21 (s, 3H), 2.04-
1,93 (m, 1H), 1.43 (s, 9H), 0.93 (2d, J = 6.8 Hz, 6H); 13C NMR (75 MHz, CDCl3) δ 
172.9, 155.7, 79.3, 61.4, 54.9, 31.8, 31.2, 28.2, 19.3, 17.4; ESI-MS cald for 
C12H24N2NaO4 [M+Na]+ 283.2, found 283.1; Rf 0.63 (Hexane/ethyl acetate 1:1). 
 
Boc-Ala-N,O-dimethyl hydroxamate (13d). The compound was prepared from the 
above procedure and afforded as a white solid, 0.96 g (41 % yield): 1H NMR (300 
MHz, CD3OD) δ 5.23 (br s, 1H), 4.69-4.64 (m, 1H), 3.76 (s, 3H), 3.19 (s, 3H), 1.43 
(s, 9H), 1.30 (d, J = 6.8 Hz, 3H); ESI-MS cald for C10H20N2NaO4 [M+Na]+ 255.1, 
found 254.9; Rf 0.51 (Hexane/ethyl acetate 1:1). 
 
General procedure for the synthesis of Boc-X-H (14). To a solution of 14 (1 mmol) 
in THF (3 mL) cooled to 0 oC, was added lithium aluminium hydride (56 mg, 1.5 
mmol) slowly under a positive atmosphere of nitrogen. The reaction was allowed to 
proceed at 0 oC for 15 min, following which the reaction was quenched with 5 % 
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KHSO4 (0.27 g, 2.0 mmol) solution. The mixture was slowly warmed up to room 
temperature. The cloudy suspension was extracted with ethyl acetate (2 x 50 mL). The 
combined organic extracts were washed with 0.5 M HCl (2 x 50 ml), sat. NaHCO3 (2 
x 50 mL) and brine (2 x 50 mL). The organic layer was dried over MgSO4 and 
concentrated in vacuo. Purification by flash chromatography using hexane/ethyl 
afforded the title compound. 
 
Boc-Phe-H (14a). The compound was prepared from the above procedure and 
afforded as a yellowish solid, 1.45 g (81 % yield): 1H NMR (300 MHz, CD3OD) δ 
9.63 (s, 1H), 7.34-7.16 (m, 5H), 5.03 (br s, 1H), 4.44-4.42 (m, 1H), 3.12 (d, J = 6.4 
Hz, 2H), 1.44 (s, 9H); ESI-MS cald for C28H38N2NaO6 [2M+Na]+ 521.3, found 521.1; 
Rf 0.68 (Hexane/ethyl acetate 1:1). 
 
Boc-Leu-H (14b). Preparation of the title compound was reported in an earlier 
section. 
 
Boc-Val-H (14c). The compound was prepared from the above procedure and 
afforded as a colorless oil, 1.56 g (84 % yield): 1H NMR (300 MHz, CD3OD) δ 9.64 
(s, 1H), 5.07 (br s, 1H), 4.24 (m, 1H), 2.32-2.23 (m, 1H), 1.45 (s, 9H), 0.99 (2d, J = 
6.8 Hz, 6H); ESI-MS cald for C20H39N2O6 [2M+H]+ 403.3, found 402.9; Rf 0.68 
(Hexane/ethyl acetate 1:1). 
 
Boc-Ala-H (14d). The compound was prepared from the above procedure and 
afforded as a white solid, 0.58 g (82 % yield): 1H NMR (300 MHz, CD3OD) δ 9.52 (s, 
1H), 5.16 (br s, 1H), 4.18 (m, 1H), 1.41 (s, 9H), 1.29 (d, J = 7.2 Hz, 3H); 13C NMR 
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(75 MHz, CDCl3) δ 199.6, 155.2, 80.0, 55.4, 28.2, 14.7; ESI-MS cald for C8H16NO3 
[M+H]+ 174.1, found 173.1; Rf 0.68 (Hexane/ethyl acetate 1:1). 
 
General procedure for the synthesis of Boc-X-olefin (22). To a suspension of 
vacuum-dried methyl triphenylphosphonium bromide (0.64 g, 1.8 mmol) in THF (3 
mL) at 0 oC was added 0.5 M KHMDS (3.5 mL, 1.75 mmol) dropwise under nitrogen 
atmosphere. The reaction was stirred at 0 oC for 1 h. The aldehyde 14 (1 mmol) was 
dissolved in THF (3 mL) and cooled to –78 oC. The yellow ylide solution was then 
added to the aldehyde solution dropwise. Upon completion of addition, the reaction 
was stirred at –78 oC for a further 15 min. The mixture was slowly warmed up to 
room temperature, and was then allowed to proceed at 40 oC overnight. The reaction 
cooled down and was quenched with a few drops of MeOH and aq. Rochelle salt 
solution. The crude product was extracted with ethyl acetate (2 x 50 mL). The 
combined organic extracts were washed with water (2 x 50 mL) and brine (2 x 50 
mL). The organic layer was dried over MgSO4 and concentrated in vacuo. 
Purification by flash chromatography using hexane/ether afforded the title compound 
22. 
 
Boc-Phe-olefin (22a). The compound was prepared from the above procedure and 
afforded as a yellowish solid, 0.25 g (25 % yield): 1H NMR (300 MHz, CD3OD) δ 
7.32-7.17 (m, 5H), 5.80 (ddd, J = 5.2 Hz, J = 10.4 Hz, J = 16.9 Hz, 1H); 5.12 (d, J = 
11.6 Hz, 1H); 5.07 (dm, J = 4.8 Hz, 1H), 4.48 (br s, 1H), 4.42 (m, 1H), 2.84 (d, J = 
6.4 Hz, 2H), 1.41 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 155.1, 138.0, 137.3, 129.4, 
128.2, 126.4, 114.6, 79.3, 53.5, 41.4, 28.3; Rf 0.57 (hexane/ethyl acetate 4:1). 
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Boc-Leu-olefin (22b). The compound was prepared from the above procedure and 
afforded as a colorless oil, 1.31g (82 % yield): 1H NMR (300 MHz, CD3OD) δ 5.73 
(ddd, J = 5.9 Hz, J = 10.7 Hz, J = 17.0 Hz, 1H), 5.15 (ddd, J= 1.2 Hz, J = 1.6 Hz, J = 
15.6 Hz, 1H), 5.06 (ddd, J= 1.2 Hz, J = 1.6 Hz, J = 10.4 Hz, 1H), 1.74-1.31 (m, 12H) 
including 1.44 (s, 9H), 0.93 (d, J = 2.0 Hz, 3H), 0.91 (d, J = 2.0 Hz, 3H); 13C NMR 
(75 MHz, CDCl3) δ 155.2, 139.4, 113.9, 79.1, 51.0, 44.4, 28.3, 24.6, 22.6, 22.3; Rf 
0.67 (hexane/ethyl acetate 4:1). 
 
Boc-Val-olefin (22c). The compound was prepared from the above procedure and 
afforded as a colorless oil, 1.08 g (70 % yield): 1H NMR (300 MHz, CD3OD) δ 5.73 
(ddd, J = 5.6 Hz, J = 10.8 Hz, J = 17.0 Hz, 1H), 5.14 (dm, J = 9.7 Hz, 1H), 5.11 (m, 
1H), 4.47 (br s, 1H), 3.98 (br s, 1H), 1.83-1.74 (m, 1H), 1.45 (s, 9H), 0.89 (2d, J = 6.8 
Hz, 6H); 13C NMR (75 MHz, CDCl3) δ 155.5, 137.5, 115.0, 92.6, 57.8, 32.1, 28.3, 
18.5, 17.9; Rf 0.65 (hexane/ethyl acetate 4:1). 
 
Boc-Ala-olefin (22d). The compound was prepared from the above procedure and 
afforded as a colorless oil, 0.24 g (41 % yield): 1H NMR (300 MHz, CD3OD) δ 5.82 
(ddd, J = 5.2 Hz, J = 10.4 Hz, J = 17.3 Hz, 1H), 5.14 (dt, J = 1.2 Hz, J = 17.3 Hz, 1H), 
5.05 (dt, J = 1.2 Hz, J = 10.4 Hz, 1H), 4.41 (br s, 1H), 4.20 (br s, 1H), 1.45 (s, 9H), 
1.21 (d, J = 6.8 Hz, 3H); Rf 0.34 (hexane/ethyl acetate 4:1). 
 
General procedure for the synthesis of (2RS,3S)-Boc-X-epoxide (23). To a 
solution of the olefin 22 (1.00 mmol) in anhydrous DCM (10-20 mL) was added m-
chloroperoxybenzoic acid (0.90 g, 4.00 mmol). The reaction was stirred at room 
temperature and when the reaction was complete by TLC analysis, the mixture was 
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diluted with ether and washed sequentially with cold 10 % Na2SO3, sat. NaHCO3 and 
brine. The organic layer was dried over MgSO4 and concentrated in vacuo. 
Purification by flash chromatography using hexane/ethyl acetate afforded the title 
compound as a diastereomeric mixture. 
 
(2RS,3S)-Boc-Phe-epoxide (23a). The compound was prepared from the above 
procedure and afforded as a yellow solid, 33 mg (76 % yield), (2S,3S)/(2R,3S) 5:1: 1H 
NMR (300 MHz, CD3OD) δ 7.32-7.20 (m, 5H), 4.50 (br s, 1H), 4.09 (m, (2S,3S)) and 
3.68 (m, (2R,3S)) (total 1H), 3.02-2.73 (m, 3H), 2.68 (dd, J = 4.2 Hz, J = 4.2 Hz, 1H), 
2.59-2.56 (m, 1H), 1.38 (s, (2S,3S)) and 1.38 (s, (2R,3S)) (total 9H); ESI-MS cald for 
C15H21NNaO3 [M+Na]+ 286.1, found 286.1; Rf 0.36 (hexane/ethyl acetate 4:1). 
 
(2RS,3S)-Boc-Leu-epoxide (23b). The compound was prepared from the above 
procedure and afforded as a colorless oil, 0.17 g (74 % yield), (2S,3S)/(2R,3S) 6:1: 1H 
NMR (300 MHz, CD3OD) δ 4.27 (br s, 1H) and 3.96 (br s, 1H), 2.99-2.97 (m, 
(2S,3S)) and 2.86-2.82 (m, (2R,3S)) (total 1H) , 2.75-2.71 (m, 1H), 2.60-2.58 (m, 1H), 
1.78-1.67 (m, 1H), 1.44 (s, (2R,3S)) and 1.43 (s, (2S,3S)) (total 9H), 0.96 (d, J = 6.8 
Hz, (2S,3S)) and 0.92 (2d, J = 6.8 Hz, (2R,3S)) (total 6H); 13C NMR (75 MHz, CD-
Cl3) δ 155.6, 155.3, 79.3, 54.4, 53.8, 47.1, 46.0, 44.3, 42.2, 40.8, 29.6, 28.2, 24.6, 
24.4, 23.2, 22.9, 22.0, 21.7; ESI-MS cald for C12H23NNaO3 [M+Na]+ 252.2, found 
252.0; Rf 0.44 (hexane/ethyl acetate 4:1). 
 
(2RS,3S)-Boc-Val-epoxide (23c). The compound was prepared from the above 
procedure and afforded as a colorless oil, 0.79 g (68 % yield), (2S,3S)/(2R,3S) 16:1: 
1H NMR (300 MHz, CD3OD) δ 4.46 (br s, 1H), 3.76-3.31 (m, 1H), 3.06 (m, (2S,3S)) 
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and 2.87-2.84 (m, (2R,3S)) (total 1H), 2.76-2.73 (m, (2R,3S)) and 2.69 (td, J = 0.8 Hz, 
J = 4.8 Hz, (2S,3S)) (total 1H), 2.53 (m, 1H), 1.98-1.87 (m, 1H), 1.43 (s, 1H), 1.03-
0.98 (m, 6H); ESI-MS cald for C11H21NNaO3 [M+Na]+ 238.1, found 238.0. Rf 0.45 
(hexane/ethyl acetate 4:1). 
 
(2RS,3S)-Boc-Ala-epoxide (23d). The compound was prepared from the above 
procedure and afforded as a colorless oil, 0.14 g (55 % yield), (2S,3S)/(2R,3S) 2:1: 1H 
NMR (300 MHz, CD3OD) δ 4.37 (br s, 1H), 3.98 (br s, (2S,3S)) and 3.64 (br s, 
(2R,3S)) (total 1H), 2.99-2.96 (m, (2S,3S)) and 2.92 (m, (2R,3S)) (total 1H), 2.78-2.70 
(m, 2H), 2.60 (dd, J = 2.4 Hz, J = 4.6 Hz, 1H), 1.45 (s, (2R,3S)) and 1.43 (s, (2S,3S)) 
(total 9H), 1.26 (d, J = 7.2, (2S,3S)) and 1.15 (d, J = 6.8 Hz, (2R,3S)) (total 3H); ESI-
MS cald for C9H18NO3 [M+H]+ 188.1, found 187.9; Rf 0.30 (Hexane/ethyl acetate 
4:1). 
 
General procedure for the synthesis (2RS,3S)-Boc-X-iBuNH (24). To a solution of 
the epoxide 23 (1.00 mmol) in MeOH (10 mL) was added isobutylamine (0.99 mL, 
10.00 mmol). The reaction was stirred overnight at 50 oC, following which, the 
mixture was concentrated in vacuo. Purification by flash chromatography using ethyl 
acetate/MeOH afforded the title compound as a diastereomeric mixture. 
 
(2RS,3S)-Boc-Phe-iBuNH (24a). The compound was prepared from the above 
procedure and afforded as a yellow solid, 34 mg (84 % yield): 1H NMR (300 MHz, 
CD3OD) δ 7.31-7.16 (m, 5H), 5.01-4.98 (m, (2S,3S)) and 4.75-4.72 (m, (2R,3S)) (total 
1H), 3.81-3.49 (several m, 2H), 2.99-2.33 (several m, 8H), 1.78-1.64 (m, 1H), 1.39 (s, 
(2S,3S)) and 1.35 (s, (2R,3S)) (total 9H), 0.93 (d, J = 6.4 Hz, (2R,3S)) and 0.89 (d, J = 
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6.8 Hz, (2S,3S)) (total 6H); ESI-MS cald for C19H33N2O3 [M+H]+ 337.2, found 337.1; 
Rf 0.13 (Ethyl acetate/MeOH 8:1). 
 
(2RS,3S)-Boc-Leu-iBuNH (24b). The compound was prepared from the above 
procedure and afforded as a colorless oil, 0.17 g (75 % yield): 1H NMR (300 MHz, 
CD3OD) δ 4.76-4.72 (m, 1H), 3.72-3.51 (m, 2H), 2.88.2.44 (m, 3H), 1.85-1.20 (m, 
13H) including 1.44 (s, (2S,3S)) and 1.43 (s, (2R,3S)) (total 9H), 0.97-0.88 (m, 6H); 
ESI-MS cald for C16H35N2O3 [M+H]+ 303.2, found 303.1; Rf 0.11 (ethyl 
acetate/MeOH 8:1). 
 
(2RS,3S)-Boc-Val-iBuNH (24c). The compound was prepared from the above 
procedure and afforded as a colorless oil, 1.01 g (96 % yield): 1H NMR (300 MHz, 
CD3OD) δ 4.91-4.87 (m, 1H), 3.82-3.77 (m, (2S,3S)) and 3.46 (m, (2R,3S)) (total 1H), 
3.19-3.13 (m, (2S,3S)) and 2.74 (m, (2R,3S)) (total 1H), 2.68 (dd, J = 4.0 Hz, J = 12.0 
Hz, 1H), 2.56-2.36 (m, 2H), 1.93-1.81 (m, 1H), 1.78-1.65 (m, 1H), 1.44 (s, 9H), 0.97 
(2d, J = 6.5 Hz, 6H), 0.91 (d, J = 6.4 Hz, 6H); ESI-MS cald for C15H33N2O3 [M+H]+ 
289.2, found 289.1. Rf 0.20 (ethyl acetate/MeOH 8:1). 
 
(2RS,3S)-Boc-Ala-iBuNH (24d). The compound was prepared from the above 
procedure and afforded as a colorless oil, 0.17 g (75 % yield): 1H NMR (300 MHz, 
CD3OD) δ 4.82 (br s, 1H), 3.62-3.47 (m, 2H), 2.73-2.40 (several m, 4H), 1.98 (br s, 
2H), 1.77-1.65 (m, 1H), 1.44 (s, 9H), 1.23 (d, J = 6.8 Hz, (2S,3S)) and 1.16 (d, J = 6.4 
Hz, (2R,3S)) (total 3H), 0.92 (d, J = 6.4 Hz, (2R,3S)) and 0.91 (d, J = 6.8 Hz, (2S,3S)) 
(total 6H); ESI-MS cald for C13H29N2O3 [M+H]+ 261.2, found 261.1; Rf 0.04 (ethyl 
acetate/MeOH 8:1). 
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 General procedure for the synthesis of (2RS,3S)-Boc-X-sulfonamide (25). To a 
solution of the secondary amine 24 (1.00 mmol) in anhydrous DCM (3 mL) was 
added p-methoxy benznenesulfonyl chloride (0.27 g, 1.30 mmol) and triethylamine 
(0.17 mL, 1.20 mmol). The reaction was allowed to proceed at room temperature 
overnight, following which it was poured in sat. NaHCO3 (few mL) and extracted 
with ether (2 x 50 mL). The combined organic extracts were washed with brine, dried 
and concentrated in vacuo. Purification by flash chromatography using hexane/ethyl 
acetate afforded the title compound as diastereomeric mixtures. 
 
(2RS,3S)-Boc-Phe-sulfonamide (25a). The compound was prepared from the above 
procedure and afforded as a colorless oil, 0.20 g (73 % yield): 1H NMR (300 MHz, 
CD3OD) δ 7.72-7.65 (m, 2H), 7.31-7.18 (m, 5H), 6.98-6.93 (m, 2H), 5.01-4.98 (m, 
1H), 3.87 (s, (2R,3S)) and 3.85 (s, (2S,3S)) (total 3H), 3.80-3.61 (m, 1H), 3.55 (br s, 
1H), 3.25 (dd, J = 9.2 Hz, J = 15.3 Hz, 1H), 2.99-2.62 (m, 5H), 1.63-1.53 (m, 1H), 
1.39 (s, (2S,3S)) and 1.34 (s (2R,3S)) (total 9H), 0.88 (2d, J = 6.8 Hz, (2R,3S)) and 
0.79 (2d, J = 6.8 Hz, (2S,3S)) (total 6H); ESI-MS cald for C26H39N2O6S [M+H]+ 
507.3, found 506.9; Rf 0.21 (hexane/ethyl acetate 4:1). 
 
(2RS,3S)-Boc-Leu-sulfonamide (25b). The compound was prepared from the above 
procedure and afforded as a colorless oil, 53 mg (81 % yield): 1H NMR (300 MHz, 
CD3OD) δ 7.75-7.70 (m, 2H), 6.99-6.94 (m, 2H), 3.87 (s, (2R,3S)) and 3.86 (s, 
(2S,3S)) (total 3H), 3.79-3.75 (m, 1H), 3.61-3.50 (m, 1H), 3.27-2.95 (m, 2H), 1.91-
1.79 (m, 1H), 1.69-1.55 (m, 2H), 1.42 (s, (2S,3S)) and 1.42 (s, (2R,3S)), 0.97-0.87 (m, 
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12H); ESI-MS cald for C23H40N2NaO6S [M+Na]+ 495.3, found 495.3; Rf 0.45 
(hexane/ethyl acetate 4:1). 
 
(2RS,3S)-Boc-Val-sulfonamide (25c). The compound was prepared from the above 
procedure and afforded as a colorless oil, 1.45 g (90 % yield): 1H NMR (300 MHz, 
CD3OD) δ 7.75-7.69 (m, 2H), 6.99-6.94 (m, 2H), 4.93-4.89 (m, 1H), 4.02-3.99 (m, 
1H), 3.87 (s, (2R,3S)) and 3.86 (s, (2S,3S)) (total 3H), 3.37 (br s, 1H), 3.22 (dd, J = 
9.6 Hz, J = 15.2 Hz, 1H), 3.10-3.01 (m, 2H), 2.84-2.73 (m, 2H), 1.94-1.79 (m, 2H), 
1.43 (s, (2S,3S)) and 1.41 (s, (2R,3S)) (total 9H), 0.96 (2d, J = 3.6 Hz, 6H), 0.90 (d, J 
= 6.4 Hz, 6H); ESI-MS cald for C22H39N2O6S [M+H]+ 459.3, found 458.8; Rf 0.22 
(Hexane/ethyl acetate 4:1) 
 
(2RS,3S)-Boc-Ala-sulfonamide (25d). The compound was prepared from the above 
procedure and afforded as a colorless oil, 0.17 g (75 % yield): 1H NMR (300 MHz, 
CD3OD) δ 7.75-7.69 (m, 2H), 6.99-6.94 (m, 2H), 4.83 (m, 1H), 3.86 (s, (2R,3S)) and 
3.86 (s, (2S,3S)) (total 3H), 3.80-3.58 (m, 2H), 2.89-2.75 (m, 2H), 1.92-1.78 (m, 1H), 
1.43 (s, 9H), 1.24 (d, J = 7.2 Hz, (2S,3S)) and 1.14 (d, J = 6.8 Hz, (2R,3S)) (total 3H), 
0.96-0.87 (m, 6H); ESI-MS cald for C20HN2NaO6S [M+Na]+ 453.2, found 453.1; Rf 
0.11 (hexane/ethyl acetate 4:1). 
 
General procedure for the synthesis of (2RS,3S)-N3-X-sulfonamide (26). To a 
solution of the Boc-protected sulfonamide 25 (1.00 mmol) in 1,4-dioxane (1.5 mL) 
was added dropwise 10 M HCl (1 mL, 10.00 mmol) with stirring. The reaction was 
stirred at room temperature for 1 h, following which the solution was concentrated in 
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vacuo. Repeated cycles of dioxane addition and concentration afford the deprotected 
product, which was used immediately in subsequent steps without further purification.  
Preparation of triflyl azide TfN3. To a solution of sodium azide (1.78 g, 27.45 
mmol) in water/DCM (12 mL, 5:3) at 0 oC was added trifluoromethane sulfonic 
anhydride (0.93 mL, 5.55 mmol). The reaction was maintained at 0 oC and stirred for 
2 h. After which, the organic layer was separated and the aqueous layer was extracted 
with DCM (2 x 3.75 mL). The combined organic extracts (15 mL) were washed with 
sat. Na2CO3 and the triflyl azide was used directly without further isolation. 
Diazo transfer reaction. To a solution of the crude deprotected product (1.00 mmol) 
in water (3.2 mL) was added K2CO3 (0.21 g, 1.50 mmol) and CuSO4 (2.5 mg, 0.01 
mmol). After which, MeOH (6.4 mL) and the TfN3 solution in DCM (5.4 mL, 2.00 
mmol) were added. More MeOH was added such that the biphasic mixture reached 
homogeneity and the reaction was allowed to stir at room temperature overnight. The 
solvents were removed in vacuo and concentrated mixture was redissolved in ethyl 
acetate. The organic layer was washed with water, brine, dried over MgSO4 and 
finally, concentrated in vacuo. Purification by flash chromatography using 
hexane/ethyl acetate afforded the title compound as a mixture of diastereomers. 
 
 
(2RS,3S)-N3-Phe-sulfonamide (26a). The compound was prepared from the above 
procedure and afforded as a colorless oil, 0.14 g (89 % yield): 1H NMR (300 MHz, 
CD3OD) δ 7.74-7.71 (m, 2H), 7.35-7.26 (m, 5H), 7.02-6.97 (m, 2H), 3.88-3.87 (m, 
4H) including 3.88 (s, (2R,3S)) and 3.87 (s, (2S,3S)) (total 3H), 3.50-3.45 (m, 1H), 
3.24 (dd, J = 8.0 Hz, J = 15.1 Hz, 1H), 3.14-2.76 (m, 6H), 1.75-1.66 (m, 1H), 0.83 
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(2d, J = 6.8 Hz, 6H); ESI-MS cald for C21H29N4O4S [M+H]+ 433.2, found 433.1; Rf 
0.24 (hexane/ethyl acetate 4:1). 
 
(2RS,3S)-N3-Leu-sulfonamide (26b). The compound was prepared from the above 
procedure and afforded as a colorless oil, 99 mg (72 % yield): 1H NMR (300 MHz, 
CD3OD) δ 7.78-7.73 (m, 2H), 7.03-6.98 (m, 2H), 3.88 (m, 4H) including 3.88 (s, 3H), 
3.30-3.20 (m, 2H), 3.05-2.94 (m, 3H), 2.88-2.79 (m, 1H), 1.92-1.64 (m, 3H), 1.51-
1.37 (m, 1H), 0.99-0.89 (m, 12H); ESI-MS cald for C18H31N4O4S [M+H]+ 399.2, 
found 399.0; Rf 0.21 (Hexane/ethyl acetate 4:1). 
 
(2RS,3S)-N3-Val-sulfonamide (26c). The compound was prepared from the above 
procedure and afforded as a colorless oil, 1.15 g (95 % yield): 1H NMR (300 MHz, 
CD3OD) δ 7.77-7.73 (m, 2H), 7.02-6.98 (m, 2H), 4.04 (m, 1H), 3.88 (s, 3H), 3.21 (dd, 
J = 14.9 Hz, 1H), 3.06-2.77 (m, 5H), 2.18-2.07 (m, 1H), 1.91-1.82 (m, 1H), 1.05 (2d, 
J = 6.8 Hz, 6H), 0.92 (2d, J = 6.4 Hz, 6H); ESI-MS cald for C17H29N4O4S [M+H]+ 
385.2, found 385.0; Rf 0.21 (hexane/ethyl acetate 4:1). 
 
(2RS,3S)-N3-Ala-sulfonamide (26d). The compound was prepared from the above 
procedure and afforded as a colorless oil, 0.14 g (89 % yield): 1H NMR (300 MHz, 
CD3OD) δ 7.78-7.73 (m, 2H), 7.02-6.97 (m, 2H), 3.88 (s, 3H), 3.81-3.64 (m, 1H), 
3.54-3.37 (m, 1H), 3.22 (dd, J = 8.4 Hz, J = 15.0 Hz, 1H), 3.13-2.92 (m, 3H), 2.88-
2.79 (m, 1H), 1.94-1.81 (m 1H), 1.38 (d, J = 6.8 Hz, (2S,3S)) and 1.34 (d, J = 6.8 Hz, 
(2R,3S)) (total 3H), 0.98-0.88 (m, 6H); ESI-MS cald for C15H25N4O4S [M+H]+ 357.2, 
found 357.0; Rf 0.19 (Hexane/ethyl acetate 4:1). 
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4.4.3 Chemical Synthesis of Alkyne Cores 
 
Boc-4-(aminomethyl)-benzoic acid (27). To a solution of 4-aminomethyl benzoic 
acid (0.20 g, 1.32 mmol) in dioxane/water (3.9 mL, 2:1) and 1 M NaOH (1.35 mL, 
1.35 mmol) at 0 oC was added di(t-butoxylcarbonyl) carbonate (0.33 mL, 1. 46 mmol) 
dropwise. The reaction was stirred at 0 oC for 40 min. The solution was then 
concentrated in vacuo to reduce the volume by half. Ethyl acetate was added and the 
mixture was acidified with 1M KHSO4 to pH 4. The organic layer was subsequently 
dried and concentrated in vacuo. The product 27 was afforded as a white crystalline 
solid following recrystallization from ethyl acetate, 0.93 g (45 % yield): 1H NMR 
(300 MHz, CD3OD) δ 8.07 (d, J = 8.4 Hz, 2H), 7.38 (d, J = 8.0 Hz, 2H), 4.94 (br s, 
1H), 4.39 (d, J = 5.6 Hz, 2H), 1.47 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 170.7, 
155.8, 145.1, 130.4, 128.2, 127.1, 79.8, 44.3, 28.3; ESI-MS cald for C13H17NNaO4 
[M+Na]+ 274.1, found 274.1. 
 
 
General procedure for the synthesis of the alkyne cores (28-31). To a solution of 
the carboxylic acid (1.00 mmol) in DMF (3 mL) was added DCC (0.21 g, 1.00 mmol) 
and HOBt (0.15 g, 1.00 mmol). The reaction was stirred at room temperature for 30 
min, after which the solution was filtered to remove the DCU formed. Propargyl 
amide (69 µL, 1.00 mmol) was added and the reaction was stirred overnight. The 
reaction mixture was concentrated in vacuo and subsequently dissolved in ethyl 
acetate (75 mL). The organic layer was extracted with saturated NaHCO3 (2 x 50 
mL), 0.5 M HCl (2 x 50 mL) and brine (2 x 50 mL). Subsequently, the organic layer 
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was dried over MgSO4 and concentrated in vacuo. The alkyne core was afforded from 
purification by flash chromatography using DCM/MeOH as the eluent. 
 
(3-Prop-2-ynylcarbamoyl-benzyl)-carbamic acid tert-butyl ester (28). The title 
compound was prepared from the above described method and afforded as a white 
solid, 69 mg (70 % yield): 1H NMR (300 MHz, CD3OD) δ 7.74 (d, J = 8.0 Hz, 2H), 
7.35 (d, J = 8.0 Hz, 2H), 6.26 (br s, 1H), 4.90 (br s, 1H), 4.35 (d, J = 6.0 Hz, 2H), 4.25 
(dd, J = 2.4 Hz, J = 5.2 Hz, 2H), 2.28 (t, J = 2.4 Hz, 1H), 1.46 (s, 9H); 13C NMR (75 
MHz, CDCl3) δ 166.6, 155.8, 143.0, 132.6, 130.7, 128.7, 79.7, 79.3, 71.8, 49.1, 28.3; 
ESI-MS cald for C16H20N2NaO3 [M+Na]+ 311.1; found 311.1; Rf 0.51 (DCM/MeOH 
8:1). 
 
(2-Phenyl-1-prop-2-ynylcarbamoyl-ethyl)-carbamic acid tert-butyl ester (29). The 
title compound was prepared from the above described method and afforded as a 
white solid, 0.24 g (78 % yield): 1H NMR (300 MHz, CD3OD) δ 7.33-7.18 (m, 5H), 
6,16 (br s, 1H), 5.02 (br s, 1H), 4.34-4.32 (m, 1H), 3.99-3.97 (m, 2H), 3.06 (d, J = 6.8 
Hz, 2H), 2.18 (t, J – 2.4 Hz, 1H), 1.40 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 170.9, 
155.3, 136.4, 129.2, 128.6, 126.9, 80.3, 78.9, 71.5, 55.7, 38.3, 29.0, 28.2; ESI-MS 
cald for C17H22N2NaO3 [M+Na]+ 325.2; found 325.0; Rf 0.64 (DCM/MeOH 8:1). 
 
N-Prop-2-ynyl-isonicotinamide (30). The title compound was prepared from the 
above described method and afforded as a yellow solid, 71 mg (44 % yield): 1H NMR 
(300 MHz, CD3OD) δ 8.76 (d, J = 5.2 Hz, 2H), 7.63 (dd, J = 1.6 Hz, J = 4.4 Hz, 2H), 
4.27 (dd, J = 2.4 Hz, J = 5.2 Hz, 2H), 2.31 (t, J = 2.8 Hz, 1H); 13C NMR (75 MHz, 
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CDCl3) δ 165.0 150.5, 140.8, 120.8, 78.6, 72.3, 29.8; ESI-MS cald for C9H9N2O 
[M+H]+ 161.1, found 161.1; Rf 0.51 (DCM/MeOH 8:1). 
 
N-Prop-2-ynyl-benzamide (31). The title compound was prepared from the above 
described method and afforded as a white solid, 0.12 (75 % yield): 1H NMR (300 
MHz, CD3OD) δ 7.80-7.77 (m, 2H), 7.55-7.41 (m, 3H), 6.26 (br s, 1H), 4.26 (dd, J = 
2.8 Hz, J = 5.2 Hz, 2H), 2.29 (t, J = 2.4 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 167.0, 
133.6, 131.7, 128.6, 126.9, 79.3, 71.8, 29.7; ESI-MS cald for C10H10NO [M+H]+ 
160.1, found 160.1; Rf 0.67 (DCM/MeOH 8:1). 
 
4.4.4 Experimental Set-up for Self-Assembly of HIV-1 Protease Inhibitors 
  
 1 µL of the azide core 26 (10 mM, t-BuOH) and 1 µL each of the alkyne cores 
28-31 (10 mM, t-BuOH) were dissolved in Tris.HCl buffer (2 mM, pH 6.4). 10 µL of 
HIV-1 protease stock solution (1 mg/mL) and Cu(I) catalyst, in the form of 1 µL of 
30 nM CuSO4 and copper powder, were added where required. Additional buffer was 
added such that the total reaction volume reached 100 µL. The reaction vials were 
gently agitated at room temperature for the required periods of time. Following 
which, the reactions were centrifuged and 25 µL of solution from each reaction vial 
was removed and analyzed by RP-HPLC using the elution gradient of 30-100 % 






CHAPTER 5 CONCLUSIONS 
 
5.1 Developing Affinity-based Probes for Proteomic Profiling 
 
 Activity-based profiling is an emerging small molecule approach to 
proteomics that provides a functional means of categorizing enzymes on the basis of 
catalytic activity rather than levels of natural abundance. Nevertheless, the existing 
limitations to activity-based profiling is that the reactive units are designed from 
mechanism-based inhibitors that are covalently modified through the enzymatic 
pathway. Herein, a complementary strategy is described where the reactive units are 
evolved into affinity-binding units that act as “Trojan horses” by ferrying the affinity-
based probes into the active site, thereby resulting in the formation of a tight-binding 
enzyme-substrate adduct. Covalent modification is conferred by a photolabile group, 
which upon UV irradiation, generates reactive intermediates that insert irreversibly 
into any C-H bonds within the vicinity of the active site. The inclusion of a 
fluorophore allows for in-gel fluorescence analysis of enzymatic labeling. 
 
 Using the above described approach, a series of affinity-based probes 
comprising of a diazirine moiety and a Cy3 fluorescent reporter unit, were developed 
using solid phase synthetic methods. The affinity-binding groups were designed from 
zinc-chelators, such as hydroxamates, and transition state analogs, like statine, and the 
resultant trifunctional probes were used to profile metalloproteases and aspartic 
proteases, respectively. Through a broad spectrum of affinity-based enzymatic 
studies, optimal labeling conditions were established. Using a repertoire of tripeptidyl 
hydroxamates with varied P1 positions, fingerprintings of the specificity profiles of 
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metalloproteases were generated, akin to the structure activity relationship. 
Mechanistic studies were carried out whereby enzymatic labeling of target proteins 
were suppressed in the presence of competitive inhibitors and irreversible inactivating 
agents, demonstrating the activity-dependent concept of the approach, which enables 
catalytically functional enzymes to be distinguished from their inactive counterparts. 
The affinity-based probes have also been shown to selectively profile desired 
enzymes spiked in crude cell extracts, laying the framework for large-scale proteomic 
experiments. In summary, the success of the affinity-based concept for the proteomic 
profiling has been validated independently through studies of the two classes of 
proteases. We bring chemical proteomics to a higher notch with our complementary 
approach to activity-based profiling, with eventual realization of the complete 
functional mapping of the enzymes in the human proteome using small molecule 
chemical ligands. 
 
5.2 Target-driven Selective Self-assembly of Inhibitors 
 
 Drug discovery processes have been accelerated through the dynamic 
combinatorial approach, which utilizes the “lock-and-key” relationship in the target-
driven self-assembly of a potent chemical ligand from a pool of precursors, reversibly 
linked via thermodynamically-stabilized chemical reactions. An alternative strategy 
has been reported where the active sites of enzymes function as reaction vessels for 
the assembly of femtomolar inhibitors from pairs of starting components ligated 
through kinetically-driven click chemistry. We describe an analogous concept where 
the biological target is used to selectively amplify it own potent inhibitorz from a 
library of precursors constructed through irreversible 1,2,3-triazole linkages. 
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  A series of four azide cores, bearing various large hydrophobic amino acid 
side chains at the P1 positions, as well as four aryl rings-containing alkyne cores, 
were prepared. Using recombinant HIV-1 protease as a host, the sequestering of the 
azide and alkyne cores in the active site of the enzyme causes the catalysis of the 1,3-
dipolar cycloaddition reaction due to proximity effects. The preliminary results 
obtained at this stage sets the groundwork for further studies, with potential for 
extension to more complex systems involving multiple chemical components. With 
drug discovery invariably tied to chemical proteomics, the target-driven approach 
paves the way for greater exploitation of affinity-binding units of greater potency in 
affinity-based proteomic profiling.  
 126
CHAPTER 6 REFERENCES 
 
 
1. Venter, J.C. et al. Science 2001, 291, 1304-1351. 
2. Wilkins, M.R., Sanchez, J.-C., Gooley, A.A., Appel, R.D., Humphrey-Smith, I., 
Hochstrasser, D.F., Williams, K.L. Biotech. Genetic Engg. Rev. 1996, 13, 19-50. 
3. Gygi, S.P.; Rochon, Y.; Franza, B.R.; Aebersold, R. Mol. Cell. Biol. 1999, 19, 
1720-1730. 
4. Tyers, M.; Mann, M. Nature 2003, 422, 193-197. 
5. (a) Aebersold, R.; Mann, M. Nature 2003, 422, 198-207.  (b) Huang, X.; Tan, 
E.L.P.; Chen, G.Y.J.; Yao, S.Q. Appl. Genomics Proteomics 2003, 2, 225-238.  
(c) Patton, W.F. Electrophoresis 2000, 21, 1123-1144.  (d) Gygi, S.P.; Rist, B.; 
Gerber, S.A; Turecek, F.; Gelb, M.H.; Aebersold, R. Nat. Biotechnol. 1999, 17, 
994-999.  (e) Monribot-Espagne, C.; Boucherie, H. Proteomics 2002, 2, 229-240.  
(f) Unlu, M.; Morgan, M.E.; Minden, J.S.  Electrophoresis 1997, 18, 2071-2077. 
6. For reviews, see: (a) MacBeath, G. Nat. Genet. 2002, 32, 526-532.  (b) Chen, 
G.Y.J.; Uttamchandani, M.; Lue, R.Y.P.; Lesaicherre, M.L.; Yao, S.Q. Curr. Top. 
Med. Chem. 2003, 3, 705-724.  (c) Braun, P.; LaBaer, J. Drug Disc. Today 2004, 
9, s1-s7.  (d) Schweitzer, B.; Predki, P.; Snyder, M. Proteomics 2003, 3, 2190-
2199.  
7. (a) Huh, W.K.; Falvo, J.V.; Gerke, L.C.; Carroll, A.S.; Howson, R.W.; Weissman, 
J.S.; O'Shea, E.K. Nature 2003, 425, 686-691.  (b) Ghaemmaghami, S.; Huh, W.; 
Bower, K.; Howson, R.W.; Belle, A.; Dephoure, N.; O'Shea, E.K.; Weissman, 
J.S. Nature 2003, 425, 737-741.  (c) Ho, Y. et al. Nature 2002, 415, 180-183.  (d) 
 127
Gavin, A. et al. Nature 2002, 415, 141-147.  (e) Uetz, P. et al. Nature 2000, 403, 
623-627. 
8. For reviews, see: (a) Cravatt, B.F.; Sorensen, E.J. Curr. Opin. Chem. Biol. 2000, 
4, 663. (b) Adam, G.C.; Sorensen, E.J.; Cravatt, B.J. Mol. Cell Proteomics, 2002, 
1, 781-90. (c) D. A. Jeffery and M. Bogyo, Curr. Opin. Biotechnol. 2003, 14, 87. 
(d) Speers, A.E.; Cravatt, B.F. ChemBioChem 2004, 5, 41-47.  (e) Jessani, N.; 
Cravatt, B.F. Curr. Opin. Chem. Biol. 2004, 8, 54-59.  
9. For recent reviews, see: (a) Thorpe, D.S. Comb. Chem. High Throughput 
Screening 2003, 6, 623-47. (b) Lokey, R.S. Curr. Opin. Chem. Biol. 2003, 7, 91-
96. (c) Strausberg, R.L.; Schreiber, S.L. Science, 2003, 300, 294-295. 
10. (a) Liu, Y.S.; Patricelli, M.P.; Cravatt, B.F. Proc. Natl. Acad. Sci. USA 1999, 96, 
14694-14699.  (b) Kidd, D.; Liu, Y.S.; Cravatt, B.F. Biochemistry 2001, 40, 4005-
4015. (c) Faleiro, L.; Kobayashi, R.; Fearnhead, H.; Lazebnik, Y. EMBO J. 1997, 
16, 2271-2281.  (d) Liau, M.L.; Panicker, R.C.; Yao, S.Q. Tetrahedron Lett. 2003, 
44, 1043-1046.  (e) Greenbaum, D.; Medzihradszky, K.F.; Burlingame, A.; 
Bogyo, M. Chem. Biol. 2000, 7, 569-581.  (f) Nizif, T.; Bogyo, M. Proc. Natl. 
Acad. Sci. USA 2001, 98, 2967-2972.   (g) Wang, G.; Uttamchandani, M.; Chen, 
G.Y.J.; Yao, S.Q. Org. Lett. 2003, 5, 737-740. (h) van Swietan, P.F.; Maehr, R.; 
van den Nieuwendijk, A.M.C.H.; Kessler, B.M.; Reich, M.; Wong, C.-S.; 
Kalbacher, H.; Leeuwenburgh, M.A.; Driessen, C.; ven der Marel, G.A.; Ploegh, 
H.L.; Overkleeft, H.S. Bioorg. Med. Chem. Lett. 2004, 14, 3131-3134. (i) Adam, 
G.C.; Sorensen, E.J.; Cravatt, B.F. Nat. Biotechnol. 2002, 20, 805-809. (j) Lo, 
L.C.; Pang, T.L.; Kuo, C.H.; Chiang, Y.L.; Wang, H.Y.; Lin, J.J. J. Proteome Res. 
 128
2002, 1, 35-40.  (k) Zhu, Q.; Huang, X.; Chen, G.Y.J.; Yao, S.Q. Tetrahedron 
Lett. 2003, 44, 2669-2672.  
11. For reviews, see: (a) Dorman, G. Top. Curr. Chem. 2000, 211, 169. (b) Dorman, 
G.; Prestwich, G.D. Trends Biotechnol. 2000, 18, 64-77. (c) Kotzyba-Hibert, F.; 
Kapfer, I.; Goeldner, M. Angew. Chem. Int. Ed. 1995, 34, 1296-1312. (d) 
Fleming, S.A. Tetrahedron, 1995, 51, 12479-12520. (e) Brunner, J. Annu. Rev. 
Biochem. 1993, 62, 483-514. (f) Dorman, G.; Prestwich, G.D. Biochemistry 1994, 
33, 5661-5673. 
12. Hagenstein, M.C.; Mussgnug, J.H.; Lotte, K.; Plessow, R.; Brockhinke, A.; 
Kruse, O.; Sewald, N. Angew. Chem. Int. Engl. 2003, 42, 5635-5638. 
13. For reviews, see: (a) Geysen, H.M.; Schoenen, F.; Wagner, D.; Wagner, R. Nat. 
Rev. Drug Disc. 2003, 2, 222-30. (b) Walters, W.P.; Namchuk, M. Nat. Rev. Drug 
Disc. 2003, 2, 259-66. (c) Bleicher, K.H.; Bohm, H.J.; Muller, K.; Alanine, A.I. 
Nat. Rev. Drug Disc. 2003, 2, 369-78. (d) Blundell, T.L.; Jhoti, H.; Abell, C. Nat. 
Rev. Drug Disc. 2002, 1, 45-54. (e) van de Waterbeemd, H.; Gifford, E. Nat. Rev. 
Drug Disc. 2003, 2, 192-204. (f) Bajorath, J. Nat. Rev. Drug Disc. 2002, 1, 882-
94. (g) Reichert, R.M. Nat. Rev. Drug Disc. 2003, 2, 695-702. 
14. (a) Houghten, R.A.; Phillac, C.; Blondelle, S.E.; Appel J.R.; Dooley, C.T.; 
Cuervo, S.H. Nature 1991, 354, 84. (b) Lam, S.K. et al. Nature 1991, 354, 82. (c) 
Tan, D.S.; Foley, M.A.; Shair, M.D.; Schreiber, S.L. J. Am. Chem. Soc. 1998, 
120, 8565-8566. 
15. For reviews, see: (a) Ramstrom, O.; Lehn, J.-M. Nat. Rev. Drug Disc. 2001, 1, 26-
36. (b) Otto, S.; Furlan, R.L.; Sanders, J.K. Drug Disc. Today 2002, 7, 117-25. 
 129
16. (a) Huc, I. Lehn, J.-M. Proc. Natl. Acad. Sci. USA 1997, 94, 2106-2110. (b) 
Bunyapaiboonsri, T.; Ramstrom, O.; Lohmann, S.; Lehn, J.-M.; Peng, L.; 
Goeldner, M. ChemBioChem 2001, 2, 438-444. (c) Nguyen, R.; Huc, I. Angew. 
Chem. Int. Ed. 2001, 40, 1774-1776. (d) Larsson, R.; Pei, Z.; Ramstrom, O. 
Angew. Chem. Int. Ed. 2004, 43, 3716-1718. 
17. Eliseev, A.V. Drug Disc. Today 2004, 9, 348-349. 
18. (a) Kolb, H.C.; Sharpless, K.B. Drug Disc. Today 2003, 8, 1128-1137. (b) Kolb, 
H.C.; Finn, M.G.; Sharpless, K.B. Angew. Chem. Int. Ed. 2001, 40, 2004-2021. 
19. (a) Lewis, W.G.; Green, L.G.; Grynszpan, F.; Radic, Z.; Carlier, P.R.; Taylor, P.; 
Finn, M.G.; Sharpless, K.B. Angew. Chem. Int. Ed. 2002, 41, 1053-1057. (b) 
Bourne, Y.; Kolb, H.C.; Radic, Z.; Sharpless, K.B.; Taylor, P.; Marchot, P. Proc. 
Natl. Acad. Sci. USA 2004, 101, 1449-1454. 
20. (a) Yu, Y.; Ye, L.; Haupt, K.; Mosbach, K. Angew. Chem. Int. Ed. 2002, 41, 
4459-4463. (b) Nicolaou, K.C.; Hughes, R.; Cho, S.Y.; Winssinger, N.; 
Smethurst, C.; Labischinski, H.; Endermann, R. Angew. Chem. Int. Ed. 2000, 39, 
3823-3828. 
21. (a) Saxon, E.; Bertozzi, C.R. Science 2000, 287, 2007-2010. (b) Kiick, K.L.; 
Saxon, E.; Tirrell, D.A.; Bertozzi, C.R. Proc. Natl. Acad. Sci. USA 2002, 199, 19-
24. 
22. (a) Domling, A. Curr. Opin. Chem. Biol. 2002, 6, 306-313. (b) Domling, A.; Ugi, 
I. Angew. Chem. Int. Ed. 2000, 39, 3168-3210. 
23. Lee, D.; Sello, J.K.; Schreiber, S.L. Org. Lett. 2000, 2, 709-712. 
 130
24. (a) Kanan, M.W.; Rozenman, M.M.; Sakurai, K.; Snyder, T.M.; Liu, D.R. Nature, 
2004, 431, 545-549. (b) Gartner, Z.J.; Tse, B.N.; Grubina, R.; Doyon, J.B.; 
Snyder, T.M.; Liu, D.R. Science, 2004, 306, 1601-1605.  
25. Handbook of Proteolytic Enzymes. Barrett, A.J.; Rawlings, N.D.; Woessner, J.F. 
Eds. Academic Press, San Diego, 1998. 
26. For reviews, see: (a) Powers, J.C.; Agian, J.L.; Ekici, O.D.; James, K.E. Chem. 
Rev. 2002, 102, 4639-4750. (b) Otto, H.-H.; Schirmeister, T. Chem. Rev. 1997, 
97, 133-171. 
27. For reviews, see: (a) Babine, R.E.; Bender, S.L. Chem. Rev. 1997, 97, 1359-1472. 
(b) Cooper, J.B. Curr. Drug Targets 2002, 3, 155-173. (c) Dash, C.; Kulkarni, A.; 
Dunn, B.; Rao, M. Crit. Rev. Biochem. Mol. Biol. 2003, 38, 89-119. (d) Kim, 
D.H.; Mobashery, S. Curr. Med. Chem. 2001, 8, 959-965. 
28. Lopez-Otin, C.; Overall, C.M. Nat. Rev. Mol. Cell. Biol. 2002, 3, 509-519. 
29. For reviews, see: (a) Christianson, D.W.; Lipbscomb, W.N. Acc. Chem. Res. 
1989, 22, 62-69. (b) Matthews, B.W. Acc. Chem. Res. 1988, 21, 333-340. 
30. (a) Bode, W.; Maskos, K. Biol. Chem. 2003, 384, 863-872. (b) Turner, A.J. 
Biochem. Soc. Trans. 2003, 31 (Pt 3), 723-727. 
31. (a) Martel-Pelletier, J.; Welsch, D.J.; Pelletier, J.P. Best Pract. Res. Clin. 
Rheumatol. 2001, 15, 805-829. (b) Hooper, N.M.; Turner, A.J. Curr. Med. Chem. 
2002, 9, 1107-1119. (c) Vihinen, P.; Kahari, V.M. Int. J. Cancer, 2002, 99, 157-
166. (d) Sierevogel, M.J.; Pasterkamp, G.; de Kleijn, D.P.; Strauss, B.H. Curr. 
Pharm. Des. 2003, 9, 1033-1040. 
32. Hooper, N.M.  FEBS Lett. 1994, 354, 1-6. 
 131
33.  (a) Whittaker, M.; Floyd, C.D.; Brown, P.; Gearing, A.J.H. Chem. Rev. 1999, 99, 
2735-2776. (b) Skiles, J.W.; Gonnella, N.C.; Jeng, A.Y. Curr. Med. Chem. 2001, 
8, 425-474. (c) Muri, E.M.; Neito, M.J.; Sindelar, R.D.; Williamson, J.S. Curr. 
Med. Chem. 2002, 9, 1631-1653. (d) Beckett, R.P.; Davidson, A.H.; Drummond, 
A.H.; Huxley, P.; Whittaker, M. Drug Disc. Today 1996, 1, 16-26. 
34. Korbel, G.A., Lalic, G., Shair, M.D. J. Am. Chem. Soc. 2001, 123, 361-362. 
35. Uttamchandani, M.; Chan, E.W.S.; Chen, G.Y.J.; Yao, S.Q. Bioorg. Med. Chem. 
Lett. 2003, 13, 2997-3000. 
36. (a) Mellor, S.L.; McGuire, C.; Chan, W.C. Tetrahedron Lett. 1997, 38, 3311-
3314.  (b) Chan, W.C.; Mellor, S.L.; Atkinson, G.E. N-Fmoc-aminooxy-2-
chlorotrityl polystyrene resin for High Throughput Synthesis of Hydroxamic 
Acids. In: Solid-Phase Organic Syntheses: Volume One (Czarnik, A.W. ed), 2001, 
John Wiley & Sons. 
37. Novabiochem 2003/2004 catalog. 
38. Colman, P.M.; Jansonius, J.N.; Matthews, B.W. J. Mol. Biol. 1972, 70, 701-720. 
39. (a) Fontana, A. Biophys. Chem. 1988, 29, 181-193. (b) Imanaka, T.; Shibazaki, 
M.; Takagi, M. Nature 1986, 324, 695-697. 
40. (a) Feder, J.; Schuck, J.M. Biochemistry 1970, 9, 2784-2791. (b) Pangburn, M.K.; 
Walsh, K.A. Biochemistry 1978, 21, 4363—4369. (c) Holmquist, B.; Vallee, B.L. 
Biochemistry 1976, 15, 101-107. (d) Kunigi, S.; Hirohara, H.; Ise, N. Eur. J. 
Biochem. 1982, 124, 157-163. 
 132
41. (a) Hersh, L.; Morihara, K. J. Biol. Chem. 1986, 261, 6433-6437. (b) Pozsgay, 
M.; Michaud, C.; Liebman, M.; Orlowski, M. Biochemistry 1986, 25, 1292-1299. 
(c) Morihara, K.; Tsuzuki, H. Arch. Biochem. Biophys. 1971, 146, 291-296. 
42. Heinrikson, R. Methods Enzymol. 1977, 47, 175-189. 
43. Holmes, M.A.; Matthews, B.W.; Biochemistry 1981, 20, 6912-6920. 
44. (a) Nishino, N.; Powers, J. Biochemistry 1978, 17, 2846-2850. (b) Nishino, N.; 
Powers, J. Biochemistry 1979, 18, 4340-4347. 
45. Roche, R.; Voorduow, G. CRC Crit. Rev. Biochem. 1978, 5, 1-23. 
46. Farkas, E.; Enyedy, E.A.; Csoka, H. J. Inorg. Biochem. 2000, 79, 205-211. 
47. Auld, D.S.; Vallee, B.L. Carboxypeptidase A. In: Hydrolytic Enzymes 
(Neuberger, A.; Brocklehurst, K. eds), 1987, Amsterdam: Elsevier, 201-255. 
48. Chan, E.W.S.; Chattopadhaya, S.; Panicker, R.C.; Huang, X.; Yao, S.Q. 
(Manuscript submitted to J. Am. Chem. Soc.) 
49. Fusek, M.; Vetvicka, V. Aspartic Proteinases: Physiology and Pathology. CRC 
Press, Florida, 1995. 
50. Tang, J.; James, M.N.G.; Hsu, I.N.; Jenkins, J.A.; Blundell, T.L. Nature 1978, 
271, 618-621. 
51. Davies, D.R. Annu. Rev. Biophys. Biophys. Chem. 1990, 19, 189-215. 
52. Umezawa, H.; Aoyagi, T.; Morishima, H.; Matzusaki, M.; Hamada, H.; Takeuchi, 
T. J. Antibiot. 1970, 23, 259-262. 
53. Boger, J.; Lohr, N.S.; Ulm, E.H.; Poe, M.; Blaine, E.H.; Fanelli, G.M.; Lin, T.Y.; 
Payne, L.S.; Schorn, T.W.; LaMont, B.I.; Vassil, T.C.; Stabilito, I.I.; Veber, D.F.; 
Rich, D.H.; Bopari, A.S. Nature 1983, 303, 81-84. 
 133
54. Marciniszyn, J.; Huang, J.S.; Hartsuck, J.A.; Tang, J. J. Biol. Chem. 1976, 251, 
7095-7102. 
55. Rich, D.H.; Bernatowicz, M.S.; Agarwal, N.S.; Kawai, M.; Salituro, F.G. 
Biochemistry 1985, 24, 3165-3173. 
56. McConnell, R.M.; Frizzell, D.; Camp, A.; Evans, A.; Jones, W.; Cagle, C. J. Med. 
Chem. 1991, 34, 2298-2300. 
57. Fehrentz, J.-A., Castro, B. Synthesis 1983, 676. 
58. Rich, D.H.; Sun, E.T.; Boparai, A.S. J. Org. Chem. 1978, 43, 3624-3626. 
59. Kaestle, K.L., Anwer, M.K., Audhya, T.K., Goldstein, G. Tetrahedron Lett. 1991, 
32, 327-330. 
60. Lin, Y.; Fusek, M.; Lin, X.; Hartsuck, J.A.; Kezdy, F.J.; Tang, J. J. Biol. Chem. 
1992, 267, 18413-18418. 
61. Tang, J.; Sepulveda, P.; Marciniszyn, J.; Jr, Chen, K.C.S.; Huang, W.-Y.; Liu, D.; 
Lanier, J.P. Proc. Natl. Acad. Sci. USA 1973, 70, 3437-3439. 
62. (a) Abad-Zapatero, C.; Rydel, T.J.; Erickson, J. Proteins 1990, 8, 62-71. (b) 
Cooper, J.B.; Khan, G.; Taylor, G.; Tickle, I.J.; Blundell, T.L. J. Mol. Biol. 1990, 
214, 199-222. (c) Sielecki, A.R.; Fujinaga, M.; Read, R.J.; James, M.N.G. J. Mol. 
Biol. 1990, 214, 143-170. 
63. (a) Tang, J. Nature 1963, 199, 1094-1095. (b) Fruton, J.S. Adv. Enzymol. 1976, 
44, 1-36. 
64. (a) Dunn, B.M.; Jimenez, M.; Parten, B.F.; Valler, M.J.; Rolph, C.E.; Kay, J. 
Biochem. J. 1986, 237, 899-906. (b) Rao, C.; Dunn, B.M. Adv. Exp. Med. Biol. 
1995, 362, 91-94. 
 134
65. Lin, X.L.; Loy, J.A.; Sussman, F.; Tang, J. Protein Sci. 1993, 2, 1383-1390. 
66. Herriott, R.M.; Desreux, V.; Northrop, J.H. J. Gen. Physiol. 1940, 23, 439-447. 
67. Barrett, A.J. Cathepsin D and other carboxyl peptidases. In: Proteinases in 
Mammalian Cells and Tissues (Barret, A.J. ed.), 1977, Amsterdam: North-
Holland Biomed. Press, 209-248. 
68. Martin, P. Raymond, M.N.; Bricas, E.; Ribadeau Ducas, B. Biochim. Biophys. 
Acta 1980, 612, 410-420. 
69. (a) Offermann, M.K.; Chlebowski, J.F.; Bond, J.S. Biochem. J. 1983, 211, 529-
534. (b) van Noort, J.M.; Van der Drift, A.C. J. Biol. Chem. 1989, 264, 12159-
12164. 
70. Oka, T.; Ishino, K.; Tsuzuki, H.; Morihara, K. Arima, K. Agric. Biol. Chem. 1973, 
37, 1177-1184. 
71. Huisgen, R. 1,3-Dipolar cycloaddition – introduction, survey, mechanism. In: 1,3-
Dipolar Cycloaddtion Chemistry (Vol. 1) (Padwa, A.; ed.), 1984, Wiley, 1-176. 
72. Wang, Q.; Chan, T.R.; Hilgraf, R.; Fokin, V.V.; Sharpless, K.B.; McFinn, M.G. J. 
Am. Chem. Soc. 2003, 125, 3192-3193. 
73. Speers, A.E.; Adam, G.C.; Cravatt, B.F. J. Am. Chem. Soc. 2003, 125, 4686-4687. 
74. (a) Fazio, F; Bryan, C.M.; Blixt, O.; Paulson, C.J.; Wong, C.-H. J. Am. Chem. 
Soc. 2002, 124, 14397-14402. (b) Brik, A.; Muldoon, J.; Lin, Y.-C.; Elder, J.H.; 
Goodsell, D.S.; Olson, A.J.; Fokin, V.V.; Sharpless, K.B.; Wong, C.-H. 
ChemBioChem 2003, 4, 1246-1248. 
75. www.unaids.org 
76. Wlodawer, A.; Gustchina, A. Biochim. Biophys. Acta, 2000, 1477, 16-34. 
 135
77. Brik, A.; Wong, C.-H. Org. Biomol. Chem. 2003, 1, 5-14. 
78. Kohl, N.E.; Emini, W.A.; Schleif, L.J.; Davis, J.C.; Heimbach, R.A.F.; Dixon, 
E.M.; Scolnick, E.M.; Sigal, I.S. Proc. Natl. Acad. Sci. USA 1988, 85, 4688-4690. 
79. (a) Toh, H.; Ono, M,; Saigo, K.; Miyata, T. Nature, 1985, 315, 691. (b) Power, 
M.D.; Marx, P.A.; Bryant, M.L.; Bardner, M.B.; Barr, P.J.; Luciw, P.A. Science 
1986, 231, 1567-1572. 
80. Pearl, L.H.; Taylor, W.R. Nature 1987, 329, 351-354. 
81. Tomasselli, A.G.; Heinrikson, R.L. Biochim. Biophys. Acta, 2000, 1477, 189-214. 
82. Seelmeier, S.; Schmidt, H.; Turk, V.; von der Helm, K. Proc. Natl. Acad. Sci. 
USA 1988, 85, 6612-6616. 
83. (a) Roberts, N.A.; Martin, J.A.; Kinchington, D.; Broadhurst, A.V.; Craig, J.C.; 
Duncan, I.B.; Galpin, S.A.; Handa, B.K.; Kay, J.; Krohn, A.; Lambert, R.W., 
Merrett, J.H.; Mills, J.S.; Parkes, K.E.B.; Redshaw, S.; Ritchie, A.J.; Taylor, D.L.; 
Thomas, G.J.; Machin, P.J. Science 1990, 248, 358-361. (b), Rich, D.H.; Green, 
J.; Toth, M.W.; Marshall, G.R.; Kent, S.B. J. Med. Chem. 1990, 33, 1285-1288. 
(c) Rich, D.H.; Sun, C.Q.; Vara-Prasad, J.V.; Pathiasseril, A.; Tohn, M.V.; 
Marshall. G.R.; Clare, M.; Mueller, R.A.; Houseman, K. J. Med. Chem. 1991, 34, 
1222-1225. 
84. Kim, E.E.; Baker, C.T.; Dwyer, M.D.; Murcko, M.A.; Rao, B.G.; Tung, R.D.; 
Navia, M.A. J. Am. Chem. Soc. 1995, 117, 1181-1182. 
85. (a) Cheng, Y.S.E.; McGowan, M.H.; Kettner, C.A.; Schloss, J.V.; Erickson-
Viitanen, S.; Yin, F.H. Gene 1990, 87, 243-248. (b) Goobar, L.; Danielson, U.H.; 
Brodin, P.; Grundstrom, T.; Oberg, B.; Norrby, E. Protein Exp. Purif. 1991, 2, 15-
 136
23. (c) Hui, J.O.; Tomasselli, A.G.; Reardon, I.M.; Lull, J.M.; Brunner, D.P.; 
Tomich, C.S.; Heinrikson, R.L. J. Protein. Chem. 1993, 12, 323-327. (d) 
Stebbins, J.; Debouck, C. Methods Enzymol. 1994, 241, 13-16. 
86. Luly, J.R.; Dellaria, J.F.; Plattner, J.J.; Soderquist, J.L.; Yi, N. J. Med. Chem. 
1987, 52, 1487-1492. 
87. Luly, J.R.; Yi, N.; Soderquist, J.; Stein, H.; Cohen, J.; Perun, T.J.; Plattner, J.J. J. 
Med. Chem. 1987, 30, 1609-1616. 
88. Kim, B.M.; Bae, S.J.; So, S.M.; Yoo, H.T.; Chang, S.K.; Lee, J.H.; Kang, J. J. 
Org. Lett. 2001, 3, 2349-2351. 
89. Alper, P.B.; Hung, S.-C.; Wong, C.-H. Tetrahedron Lett. 1996, 37, 6029-6032. 
90. Rostovtsev, V.V.; Green, L.G.; Fokin, V.V.; Sharpless, K.B. Angew. Chem. Int. 
Ed. 2002, 41, 2596-2599. 
 
 137
CHAPTER 7 APPENDIX 
 
 












Figure 1. Affinity-based labeling of control enzymes using hydroxamate-based probes 
8a-i: trypsin and proteinase K (serine proteases), papain (cysteine protease), pepsin 
(aspartic protease), alkaline phosphatase and lipase. 
 
7.2 Developing Affinity-based Probes for Proteomic Profiling of Aspartic 
Proteases 
 








Figure 2. Affinity-based labeling of control enzymes (0.1 – 1.0 mg/mL) using statine-
based probe 21 (500 nM). Lanes (1) bromelain; (2) chymopapain; (3) α-chymotrypsin; 
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(4) β-chymotrypsin; (5) γ-chymotrypsin; (6) chymotrypsinogen; (7) papain; (8) 
proteinase K; (9) subtilisin; (10) trypsin inhibitor; (11) trypsinogen; (12) trypsin; (13) 
thrombin; (14) lysozyme; (15) acid phosphatase P-3627. 
 
7.3 Target-driven Selective Self-Assembly of Inhibitors 
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